{"doc_id": 0, "doc": {"person_id": 115967197, "visit_occurrence_id": 118782908, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2018-04-25 00:00:00", "visit_end_datetime": "2018-04-25 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Neuraxial labor analgesia/anesthesia for planned vaginal delivery (this includes any repeat subarachnoid needle placement and drug injection and/or any necessary replacement of an epidural catheter during labor)\n\n### Condition\n- Finding related to pregnancy\n- Obstructed labor due to incomplete rotation of fetal head\n- First degree perineal laceration\n- Post-term pregnancy\n- Gestation period, 40 weeks\n- Single live birth\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 175, "patient_first_visit_date": "2012-10-05 14:12:00", "patient_last_visit_date": "2021-03-30 16:05:00", "end_obs_date": "2019-04-25", "readmission_30d": 1, "visit_sequence_number": 23, "cumulated_visit_num": 23, "cumulated_approximate_token_count": 8877, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-10-05 14:12:00, ended at 2012-10-07 09:35:00\nThe patient in this visit was 31 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.51 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.29 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Prothrombin time (PT): 14.1 (second)\n- Body height: 5' 2\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.40 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.0 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n- Laparoscopic cholecystectomy\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Laparoscopy, surgical; cholecystectomy\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Cholelithiasis AND cholecystitis without obstruction\n- Gallbladder calculus with acute cholecystitis and no obstruction\n- Right upper quadrant pain\n- Epigastric pain\n- Primary diagnosis: Acute cholecystitis\n- Leukocytosis\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2012-10-06, presumably until 2012-10-06\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2012-10-05, presumably until 2012-10-06\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2012-10-05, presumably until 2012-10-05\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2012-10-06, presumably until 2012-10-06\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-10-07, presumably until 2013-10-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2012-10-06, presumably until 2012-10-07\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2012-10-05, presumably until 2012-10-05\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2012-10-05, presumably until 2012-10-06\n- 2 ML ondansetron 2 MG/ML Injection, started on 2012-10-05, presumably until 2012-10-05\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2012-10-05, presumably until 2012-10-06\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2012-10-07, presumably until 2013-04-05, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2012-10-05, presumably until 2012-10-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2012-10-06 00:00:00, ended at 2012-10-06 00:00:00\nThe patient in this visit was 31 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2012-10-06, presumably until 2012-10-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-11-12 00:00:00, ended at 2016-11-12 00:00:00\nThe patient in this visit was 35 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Choriogonadotropin.intact+Beta subunit [Units/volume] in Serum or Plasma: 34192 (milli-international unit per milliliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.44 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.85 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.9 (percent)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-11-12 13:39:00, ended at 2016-11-12 16:12:00\nThe patient in this visit was 35 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.3 (percent)\n- MCV [Entitic volume] by Automated count: 85.9 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.85 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.44 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Choriogonadotropin.intact+Beta subunit [Units/volume] in Serum or Plasma: 34192 (milli-international unit per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation\n- Collection of venous blood by venipuncture\n- Ultrasound, pregnant uterus, real time with image documentation, transvaginal\n\n### Condition\n- Primary diagnosis: Threatened miscarriage\n- First trimester pregnancy\n- Genitourinary tract hemorrhage\n- Gestation period, 8 weeks\n- Spotting per vagina in pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-15 00:00:00, ended at 2017-09-15 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.5 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 307 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.49 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.4 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-15 20:29:00, ended at 2017-09-15 22:41:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.49 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 307 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n\n### Condition\n- Gestation less than 9 weeks\n- Primary diagnosis: Mild hyperemesis gravidarum\n- Vomiting\n- Nausea\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2017-09-15, presumably until 2018-09-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea (nausea or vomiting)\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-15, presumably until 2017-09-15\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-09-15, presumably until 2017-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- First trimester pregnancy\n- High risk pregnancy\n- Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- First trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-09 14:52:00, ended at 2017-10-09 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation\n\n### Condition\n- First trimester pregnancy\n- High risk pregnancy\n- Gestation period, 12 weeks\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-10-24 00:00:00, ended at 2017-10-24 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.73 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.7 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.45 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.21 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.0 (percent)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 252 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-10-24 19:03:00, ended at 2017-10-24 22:10:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- MCV [Entitic volume] by Automated count: 83.7 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.21 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.73 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.45 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 252 (unit per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Gestation period, 14 weeks\n- Second trimester pregnancy\n- Finding related to pregnancy\n- Primary diagnosis: Gastritis\n- Complication occurring during pregnancy\n- Complication of pregnancy, childbirth and/or puerperium\n- Vomiting\n- Epigastric pain\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-10-24, presumably until 2017-11-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-10-24, presumably until 2017-10-24\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-10-24, presumably until 2017-10-24\n- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2017-10-24, presumably until 2017-10-24\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2017-10-24, presumably until 2017-10-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-22 10:30:00, ended at 2018-03-22 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n- Fetal non-stress test\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Finding of length of gestation\n- Primary diagnosis: Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-29 00:00:00, ended at 2018-03-29 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- High risk pregnancy\n- Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-29 08:33:00, ended at 2018-03-29 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fetal non-stress test\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n\n### Condition\n- Finding of length of gestation\n- Primary diagnosis: High risk pregnancy\n- Primary diagnosis: Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-05 00:00:00, ended at 2018-04-05 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-05 09:00:00, ended at 2018-04-05 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n- Fetal non-stress test\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Primary diagnosis: Third trimester pregnancy\n- Gestation period, 38 weeks\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-14 00:00:00, ended at 2018-04-14 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-14 08:30:00, ended at 2018-04-14 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n- Fetal non-stress test\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Primary diagnosis: Third trimester pregnancy\n- Finding of length of gestation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-21 00:00:00, ended at 2018-04-21 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-term pregnancy\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-21 08:40:00, ended at 2018-04-21 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fetal non-stress test\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Finding of length of gestation\n- Post-term pregnancy\n- Primary diagnosis: Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 13.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.04 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 216 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.52 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.41 (million per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Neuraxial labor analgesia/anesthesia for planned vaginal delivery (this includes any repeat subarachnoid needle placement and drug injection and/or any necessary replacement of an epidural catheter during labor)\n\n### Condition\n- Finding related to pregnancy\n- Obstructed labor due to incomplete rotation of fetal head\n- First degree perineal laceration\n- Post-term pregnancy\n- Gestation period, 40 weeks\n- Single live birth\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-10-05 14:12:00, ended at 2012-10-07 09:35:00\nThe patient in this visit was 31 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.51 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.29 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Prothrombin time (PT): 14.1 (second)\n- Body height: 5' 2\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.40 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.0 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n- Laparoscopic cholecystectomy\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Laparoscopy, surgical; cholecystectomy\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Cholelithiasis AND cholecystitis without obstruction\n- Gallbladder calculus with acute cholecystitis and no obstruction\n- Right upper quadrant pain\n- Epigastric pain\n- Primary diagnosis: Acute cholecystitis\n- Leukocytosis\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2012-10-06, presumably until 2012-10-06\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2012-10-05, presumably until 2012-10-06\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2012-10-05, presumably until 2012-10-05\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2012-10-06, presumably until 2012-10-06\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-10-07, presumably until 2013-10-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2012-10-06, presumably until 2012-10-07\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2012-10-05, presumably until 2012-10-05\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2012-10-05, presumably until 2012-10-06\n- 2 ML ondansetron 2 MG/ML Injection, started on 2012-10-05, presumably until 2012-10-05\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2012-10-05, presumably until 2012-10-06\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2012-10-07, presumably until 2013-04-05, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2012-10-05, presumably until 2012-10-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2012-10-06 00:00:00, ended at 2012-10-06 00:00:00\nThe patient in this visit was 31 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2012-10-06, presumably until 2012-10-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-11-12 00:00:00, ended at 2016-11-12 00:00:00\nThe patient in this visit was 35 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Choriogonadotropin.intact+Beta subunit [Units/volume] in Serum or Plasma: 34192 (milli-international unit per milliliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.44 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.85 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.9 (percent)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-11-12 13:39:00, ended at 2016-11-12 16:12:00\nThe patient in this visit was 35 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.3 (percent)\n- MCV [Entitic volume] by Automated count: 85.9 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.85 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.44 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Choriogonadotropin.intact+Beta subunit [Units/volume] in Serum or Plasma: 34192 (milli-international unit per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation\n- Collection of venous blood by venipuncture\n- Ultrasound, pregnant uterus, real time with image documentation, transvaginal\n\n### Condition\n- Primary diagnosis: Threatened miscarriage\n- First trimester pregnancy\n- Genitourinary tract hemorrhage\n- Gestation period, 8 weeks\n- Spotting per vagina in pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-15 00:00:00, ended at 2017-09-15 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.5 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 307 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.49 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.4 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-09-15 20:29:00, ended at 2017-09-15 22:41:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.49 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 307 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n\n### Condition\n- Gestation less than 9 weeks\n- Primary diagnosis: Mild hyperemesis gravidarum\n- Vomiting\n- Nausea\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2017-09-15, presumably until 2018-09-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea (nausea or vomiting)\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-15, presumably until 2017-09-15\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-09-15, presumably until 2017-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- First trimester pregnancy\n- High risk pregnancy\n- Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- First trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-09 14:52:00, ended at 2017-10-09 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation\n\n### Condition\n- First trimester pregnancy\n- High risk pregnancy\n- Gestation period, 12 weeks\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-10-24 00:00:00, ended at 2017-10-24 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.73 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.7 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.45 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.21 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.0 (percent)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 252 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-10-24 19:03:00, ended at 2017-10-24 22:10:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- MCV [Entitic volume] by Automated count: 83.7 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.21 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.73 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.45 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 252 (unit per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Gestation period, 14 weeks\n- Second trimester pregnancy\n- Finding related to pregnancy\n- Primary diagnosis: Gastritis\n- Complication occurring during pregnancy\n- Complication of pregnancy, childbirth and/or puerperium\n- Vomiting\n- Epigastric pain\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-10-24, presumably until 2017-11-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-10-24, presumably until 2017-10-24\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-10-24, presumably until 2017-10-24\n- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2017-10-24, presumably until 2017-10-24\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2017-10-24, presumably until 2017-10-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-22 10:30:00, ended at 2018-03-22 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n- Fetal non-stress test\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Finding of length of gestation\n- Primary diagnosis: Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-29 00:00:00, ended at 2018-03-29 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- High risk pregnancy\n- Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-29 08:33:00, ended at 2018-03-29 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fetal non-stress test\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n\n### Condition\n- Finding of length of gestation\n- Primary diagnosis: High risk pregnancy\n- Primary diagnosis: Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-05 00:00:00, ended at 2018-04-05 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-05 09:00:00, ended at 2018-04-05 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n- Fetal non-stress test\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Primary diagnosis: Third trimester pregnancy\n- Gestation period, 38 weeks\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-14 00:00:00, ended at 2018-04-14 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-14 08:30:00, ended at 2018-04-14 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n- Fetal non-stress test\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Primary diagnosis: Third trimester pregnancy\n- Finding of length of gestation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-21 00:00:00, ended at 2018-04-21 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-term pregnancy\n- Third trimester pregnancy\n- High risk pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-21 08:40:00, ended at 2018-04-21 23:59:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fetal non-stress test\n- Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses\n\n### Condition\n- Primary diagnosis: High risk pregnancy\n- Finding of length of gestation\n- Post-term pregnancy\n- Primary diagnosis: Third trimester pregnancy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 13.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.04 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 216 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.52 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.41 (million per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 36 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Neuraxial labor analgesia/anesthesia for planned vaginal delivery (this includes any repeat subarachnoid needle placement and drug injection and/or any necessary replacement of an epidural catheter during labor)\n\n### Condition\n- Finding related to pregnancy\n- Obstructed labor due to incomplete rotation of fetal head\n- First degree perineal laceration\n- Post-term pregnancy\n- Gestation period, 40 weeks\n- Single live birth\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2018-04-25 00:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "55180acc4926dfdb6d1809646f987a64053f89d6143b04b15b2395ea02cdbf5e", "prompt_hash": "c10abdc9342e6a3da4b21a7a967f526b270dddb4d1d2e8b2184ebb485112a534", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 1, "doc": {"person_id": 115967648, "visit_occurrence_id": 184843708, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2021-08-18 05:10:00", "visit_end_datetime": "2021-08-21 12:16:00", "visit_length_in_hours": 79.1, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2021-08-18 05:10:00, ended at 2021-08-21 12:16:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 44 (percent)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.42 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Activated clotting time (ACT) of Blood by Coagulation assay: 372 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Aldosterone [Mass/volume] in Serum or Plasma: 6.8 (nanogram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 15.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 169 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.00 (micro-international unit per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Potassium [Moles/volume] in Blood: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 139 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separatel\n- Collection of venous blood by venipuncture\n- Destruction of Conduction Mechanism, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary\n- Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Left heart catheterization by transseptal puncture through intact septum or by transapical puncture (List separately in addition to code for primary procedure)\n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n\n### Condition\n- Ventricular premature complex\n- Hypothyroidism\n- Hypothyroidism caused by drug\n- Atrial fibrillation\n- Coronary atherosclerosis\n- Persistent atrial fibrillation\n- Primary diagnosis: Postoperative state\n- Metabolic syndrome X\n- Prediabetes\n- Atrial flutter\n- Essential hypertension\n- Typical atrial flutter\n- Electrocardiogram abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorders of both mitral and tricuspid valves\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Paroxysmal atrial fibrillation\n- Rheumatic disease of heart valve\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-21\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-21\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-21\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-21\n- 10 ML furosemide 10 MG/ML Injection, started on 2021-08-19, presumably until 2021-08-19\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2021-08-21, presumably until 2021-10-20, with intended 1 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth as needed PRN BID for sustained ( 3-4 hours) of HR >110 bpm.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- dofetilide 0.25 MG Oral Capsule, through Oral route, started on 2021-08-18, presumably until 2021-08-22, with intended 1 refill(s). Instructions: take 1 Capsule (250 mcg total) by mouth 2 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2021-08-19, presumably until 2021-08-19\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-20\n- benazepril hydrochloride 10 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-20\n\n", "approximate_token_count": 1613, "patient_first_visit_date": "2019-12-21 00:00:00", "patient_last_visit_date": "2023-01-16 00:00:00", "end_obs_date": "2022-08-21", "readmission_30d": 0, "visit_sequence_number": 94, "cumulated_visit_num": 94, "cumulated_approximate_token_count": 16626, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 11:43:13, ended at 2019-12-21 13:57:21\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2019-03-04, presumably until 2020-12-16, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:00:00, ended at 2019-12-21 14:42:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Persistent atrial fibrillation\n- Chronic atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:43:00, ended at 2019-12-21 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-29 07:00:00, ended at 2020-01-29 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Ventricular tachycardia\n- Atrial flutter\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily Start on 05/10 and continue until prescription is completed.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (1 g total) by mouth 4 times a day Start medication on 05/22/2020 and continue until completed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-18 10:42:00, ended at 2020-05-18 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 12:43:14, ended at 2020-05-19 13:10:48\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-20, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 75 mg by mouth 4 times a day \n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, started on 2020-03-27, presumably until 2021-06-05, with intended 0 refill(s). Instructions: INHALE 2 PUFFS BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-21 10:02:38, ended at 2020-05-21 10:02:53\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- mepivacaine hydrochloride 20 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hypothyroidism\n- Chronic kidney disease stage 2\n- Persistent atrial fibrillation\n- Chronic kidney disease due to hypertension\n- Prediabetes\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- midazolam 1 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 05:31:00, ended at 2020-05-25 11:37:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Activated clotting time (ACT) of Blood by Coagulation assay: 392 (second)\n- Body height: 5' 10.276\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 79.5 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.38 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 14.50 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Prothrombin time (PT): 17.6 (second)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Collection of venous blood by venipuncture\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac \n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Disorder of cardiovascular system\n- Lumbar radiculopathy\n- Metabolic syndrome X\n- Essential hypertension\n- Hypothyroidism\n- Postoperative state\n- Chronic kidney disease due to hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial fibrillation\n- Paroxysmal atrial fibrillation\n- Primary diagnosis: Persistent atrial fibrillation\n- Abnormal results of cardiovascular function studies\n- Chronic kidney disease stage 2\n- Prediabetes\n- Electrocardiogram abnormal\n- Polyp of colon\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-05-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- benazepril hydrochloride 40 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-08-31, with intended 0 refill(s). Instructions: inject 1 mg/kg subcutaneous (under the skin) daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n- amiodarone hydrochloride 400 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-06-08, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day for 7 days, THEN 200 mg 2 times a day for 7 days, THEN 200 mg daily.\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.91 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-05-27, presumably until 2020-09-22, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-28 00:00:00, ended at 2020-05-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-29, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-05-29, presumably until 2020-05-29, with intended 0 refill(s). Instructions: take 1 Packet (17 g total) by mouth One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-07 00:00:00, ended at 2020-06-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-08-15, with intended 11 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Electrocardiogram abnormal\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-09 11:25:00, ended at 2020-06-09 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-10 00:00:00, ended at 2020-06-10 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-11 00:00:00, ended at 2020-06-11 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH ONCE DAILY START ON 05/10 AND CONTINUE UNTIL PRESCRIPTION IS COMPLETED.\n- sucralfate 1000 MG Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH 4 TIMES A DAY START MEDICATION ON 05/22/2020 AND CONTINUE UNTIL COMPLETED.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-13 06:00:00, ended at 2020-06-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 08:52:48, ended at 2020-06-16 10:12:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: 2.6 (international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 160 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 255 (picogram per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 7 (international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.6 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32.6 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation: 24 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L: 12.770 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.11 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Body height: 5' 10.25\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 1.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (international unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 95 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Hyperlipidemia\n- Vitamin B deficiency\n- Vitamin D deficiency\n- Atrial fibrillation\n- Proteinuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-20 11:30:00, ended at 2020-06-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Respiratory flow volume loop\n\n### Condition\n- Pulmonary function studies abnormal\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-01 00:00:00, ended at 2020-07-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-04 00:00:00, ended at 2020-07-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-07 00:00:00, ended at 2020-07-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-20 14:35:26, ended at 2020-07-20 14:50:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Prediabetes\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-08-15, presumably until 2020-12-05, with intended 0 refill(s). Instructions: take 0.5 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-29 00:00:00, ended at 2020-08-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-30 10:00:00, ended at 2020-08-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-31 10:18:59, ended at 2020-08-31 11:01:03\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2020-08-31, presumably until 2021-09-05, with intended 12 refill(s). Instructions: take 1 Tab (5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-22 09:31:38, ended at 2020-09-22 09:59:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-09-22, presumably until 2021-03-30, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-30 07:30:00, ended at 2020-09-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n- Persistent atrial fibrillation\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 12:57:09, ended at 2020-11-16 13:31:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Long QT syndrome\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 11:00:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 09:02:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-05 00:00:00, ended at 2020-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-16 00:00:00, ended at 2020-12-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-12-16, presumably until 2021-03-09, with intended 0 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-19 10:19:56, ended at 2020-12-19 10:30:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism caused by drug\n- Prediabetes\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-09 00:00:00, ended at 2021-01-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-17 09:59:16, ended at 2021-01-17 11:01:22\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n- Coronary atherosclerosis\n- Blood glucose abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-17, presumably until 2021-03-09, with intended 11 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-20 06:45:00, ended at 2021-01-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-09 00:00:00, ended at 2021-02-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-02-09, presumably until 2021-03-03, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-13 00:00:00, ended at 2021-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Complete atrioventricular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-15 08:30:00, ended at 2021-02-15 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-22 08:32:00, ended at 2021-02-22 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-03, presumably until 2021-03-10, with intended 1 refill(s). Instructions: take 1 Tab (1 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-03-03 15:11:00, ended at 2021-03-03 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, started on 2021-03-09, presumably until 2021-08-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-10 00:00:00, ended at 2021-03-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-03-10, presumably until 2021-03-20, with intended 1 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-20 00:00:00, ended at 2021-03-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-20, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth as directed (Take 1mg in the morning and 2mg at night)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-30 00:00:00, ended at 2021-03-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-03-30, presumably until 2021-11-20, with intended 3 refill(s). Instructions: TAKE 1 TAB (50 MCG TOTAL) BY MOUTH EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-04, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-19, presumably until 2021-06-05, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every morning AND 1.5 Tabs (3 mg total) Daily at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-19 11:34:11, ended at 2021-04-19 12:12:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-20 06:15:00, ended at 2021-04-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-25 10:16:13, ended at 2021-04-25 11:00:40\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-04-25, presumably until 2021-08-21, with intended 11 refill(s). Instructions: take 12.5 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-26 16:08:55, ended at 2021-04-26 16:09:05\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 00:00:00, ended at 2021-04-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Prediabetes\n- Paroxysmal atrial fibrillation\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-04-28, presumably until 2021-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 07:16:00, ended at 2021-04-28 11:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.1 (millimole per liter)\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardioversion, elective, electrical conversion of arrhythmia; external\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hypothyroidism\n- Rheumatic tricuspid valve regurgitation\n- Atrial fibrillation\n- Typical atrial flutter\n- Atrial flutter\n- Atrial premature complex\n- Persistent atrial fibrillation\n- Lumbar radiculopathy\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Ventricular premature complex\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Essential hypertension\n- Prediabetes\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-14 14:29:00, ended at 2021-05-14 18:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.6 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.28 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Tachycardia\n- Essential hypertension\n- Hypothyroidism\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-14\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-15 00:00:00, ended at 2021-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-16 00:00:00, ended at 2021-05-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-16, presumably until 2021-06-29, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed For AFib episodes\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-23 00:00:00, ended at 2021-05-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Atrial fibrillation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-06-13, presumably until 2021-11-28, with intended 0 refill(s). Instructions: take 1 Tablet (40 mg total) by mouth daily Start 4 days pre-procedure, and continue 30 days after, no refills. First dose 08/14/2021\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-31 13:29:00, ended at 2021-05-31 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-02 00:00:00, ended at 2021-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-06-29 00:00:00, ended at 2021-06-29 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-06-29, presumably until 2021-08-04, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed (breakthrough arrhythmias if HR are sustained above 110-120 bpm, for at least 3-4 hours)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-31 00:00:00, ended at 2021-07-31 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-08-03 00:00:00, ended at 2021-08-03 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-08-04, presumably until 2021-08-21, with intended 2 refill(s). Instructions: TAKE 0.5 TABLETS (12.5 MG TOTAL) BY MOUTH 2 TIMES A DAY AS NEEDED (BREAKTHROUGH ARRHYTHMIAS IF HR ARE SUSTAINED ABOVE 110-120 BPM, FOR AT LEAST 3-4 HOURS)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-08-08 11:07:18, ended at 2021-08-08 16:05:47\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Hypothyroidism caused by drug\n- Essential hypertension\n- Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-08-15 14:49:38, ended at 2021-08-15 15:24:18\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, presumably until 2021-08-22, with intended 0 refill(s). Instructions: take 1 mg by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-16 00:00:00, ended at 2021-08-16 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-08-17 00:00:00, ended at 2021-08-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-17 08:11:00, ended at 2021-08-17 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2021-08-18 00:00:00, ended at 2021-08-18 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2021-08-18, presumably until 2021-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-18 00:00:00, ended at 2021-08-18 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n\n### Condition\n- Essential hypertension\n- Atrial fibrillation\n- Hypothyroidism\n\n### Drug\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- 10 ML furosemide 10 MG/ML Injection, started on 2021-08-18, presumably until 2021-08-18\n- remifentanil 2 MG Injection, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-08-18, presumably until 2021-08-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2021-08-18, presumably until 2021-08-18\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2021-08-18, presumably until 2021-08-18\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2021-08-18, presumably until 2021-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2021-08-18 05:10:00, ended at 2021-08-21 12:16:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 44 (percent)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.42 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Activated clotting time (ACT) of Blood by Coagulation assay: 372 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Aldosterone [Mass/volume] in Serum or Plasma: 6.8 (nanogram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 15.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 169 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.00 (micro-international unit per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Potassium [Moles/volume] in Blood: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 139 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separatel\n- Collection of venous blood by venipuncture\n- Destruction of Conduction Mechanism, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary\n- Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Left heart catheterization by transseptal puncture through intact septum or by transapical puncture (List separately in addition to code for primary procedure)\n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n\n### Condition\n- Ventricular premature complex\n- Hypothyroidism\n- Hypothyroidism caused by drug\n- Atrial fibrillation\n- Coronary atherosclerosis\n- Persistent atrial fibrillation\n- Primary diagnosis: Postoperative state\n- Metabolic syndrome X\n- Prediabetes\n- Atrial flutter\n- Essential hypertension\n- Typical atrial flutter\n- Electrocardiogram abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorders of both mitral and tricuspid valves\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Paroxysmal atrial fibrillation\n- Rheumatic disease of heart valve\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-21\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-21\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-21\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-21\n- 10 ML furosemide 10 MG/ML Injection, started on 2021-08-19, presumably until 2021-08-19\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2021-08-21, presumably until 2021-10-20, with intended 1 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth as needed PRN BID for sustained ( 3-4 hours) of HR >110 bpm.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- dofetilide 0.25 MG Oral Capsule, through Oral route, started on 2021-08-18, presumably until 2021-08-22, with intended 1 refill(s). Instructions: take 1 Capsule (250 mcg total) by mouth 2 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2021-08-19, presumably until 2021-08-19\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-20\n- benazepril hydrochloride 10 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-20\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 11:43:13, ended at 2019-12-21 13:57:21\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2019-03-04, presumably until 2020-12-16, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:00:00, ended at 2019-12-21 14:42:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Persistent atrial fibrillation\n- Chronic atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:43:00, ended at 2019-12-21 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-29 07:00:00, ended at 2020-01-29 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Ventricular tachycardia\n- Atrial flutter\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily Start on 05/10 and continue until prescription is completed.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (1 g total) by mouth 4 times a day Start medication on 05/22/2020 and continue until completed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-18 10:42:00, ended at 2020-05-18 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 12:43:14, ended at 2020-05-19 13:10:48\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-20, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 75 mg by mouth 4 times a day \n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, started on 2020-03-27, presumably until 2021-06-05, with intended 0 refill(s). Instructions: INHALE 2 PUFFS BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-21 10:02:38, ended at 2020-05-21 10:02:53\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- mepivacaine hydrochloride 20 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hypothyroidism\n- Chronic kidney disease stage 2\n- Persistent atrial fibrillation\n- Chronic kidney disease due to hypertension\n- Prediabetes\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- midazolam 1 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 05:31:00, ended at 2020-05-25 11:37:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Activated clotting time (ACT) of Blood by Coagulation assay: 392 (second)\n- Body height: 5' 10.276\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 79.5 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.38 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 14.50 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Prothrombin time (PT): 17.6 (second)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Collection of venous blood by venipuncture\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac \n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Disorder of cardiovascular system\n- Lumbar radiculopathy\n- Metabolic syndrome X\n- Essential hypertension\n- Hypothyroidism\n- Postoperative state\n- Chronic kidney disease due to hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial fibrillation\n- Paroxysmal atrial fibrillation\n- Primary diagnosis: Persistent atrial fibrillation\n- Abnormal results of cardiovascular function studies\n- Chronic kidney disease stage 2\n- Prediabetes\n- Electrocardiogram abnormal\n- Polyp of colon\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-05-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- benazepril hydrochloride 40 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-08-31, with intended 0 refill(s). Instructions: inject 1 mg/kg subcutaneous (under the skin) daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n- amiodarone hydrochloride 400 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-06-08, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day for 7 days, THEN 200 mg 2 times a day for 7 days, THEN 200 mg daily.\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.91 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-05-27, presumably until 2020-09-22, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-28 00:00:00, ended at 2020-05-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-29, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-05-29, presumably until 2020-05-29, with intended 0 refill(s). Instructions: take 1 Packet (17 g total) by mouth One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-07 00:00:00, ended at 2020-06-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-08-15, with intended 11 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Electrocardiogram abnormal\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-09 11:25:00, ended at 2020-06-09 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-10 00:00:00, ended at 2020-06-10 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-11 00:00:00, ended at 2020-06-11 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH ONCE DAILY START ON 05/10 AND CONTINUE UNTIL PRESCRIPTION IS COMPLETED.\n- sucralfate 1000 MG Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH 4 TIMES A DAY START MEDICATION ON 05/22/2020 AND CONTINUE UNTIL COMPLETED.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-13 06:00:00, ended at 2020-06-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 08:52:48, ended at 2020-06-16 10:12:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: 2.6 (international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 160 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 255 (picogram per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 7 (international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.6 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32.6 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation: 24 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L: 12.770 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.11 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Body height: 5' 10.25\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 1.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (international unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 95 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Hyperlipidemia\n- Vitamin B deficiency\n- Vitamin D deficiency\n- Atrial fibrillation\n- Proteinuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-20 11:30:00, ended at 2020-06-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Respiratory flow volume loop\n\n### Condition\n- Pulmonary function studies abnormal\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-01 00:00:00, ended at 2020-07-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-04 00:00:00, ended at 2020-07-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-07 00:00:00, ended at 2020-07-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-20 14:35:26, ended at 2020-07-20 14:50:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Prediabetes\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-08-15, presumably until 2020-12-05, with intended 0 refill(s). Instructions: take 0.5 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-29 00:00:00, ended at 2020-08-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-30 10:00:00, ended at 2020-08-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-31 10:18:59, ended at 2020-08-31 11:01:03\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2020-08-31, presumably until 2021-09-05, with intended 12 refill(s). Instructions: take 1 Tab (5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-22 09:31:38, ended at 2020-09-22 09:59:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-09-22, presumably until 2021-03-30, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-30 07:30:00, ended at 2020-09-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n- Persistent atrial fibrillation\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 12:57:09, ended at 2020-11-16 13:31:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Long QT syndrome\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 11:00:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 09:02:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-05 00:00:00, ended at 2020-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-16 00:00:00, ended at 2020-12-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-12-16, presumably until 2021-03-09, with intended 0 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-19 10:19:56, ended at 2020-12-19 10:30:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism caused by drug\n- Prediabetes\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-09 00:00:00, ended at 2021-01-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-17 09:59:16, ended at 2021-01-17 11:01:22\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n- Coronary atherosclerosis\n- Blood glucose abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-17, presumably until 2021-03-09, with intended 11 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-20 06:45:00, ended at 2021-01-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-09 00:00:00, ended at 2021-02-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-02-09, presumably until 2021-03-03, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-13 00:00:00, ended at 2021-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Complete atrioventricular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-15 08:30:00, ended at 2021-02-15 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-22 08:32:00, ended at 2021-02-22 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-03, presumably until 2021-03-10, with intended 1 refill(s). Instructions: take 1 Tab (1 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-03-03 15:11:00, ended at 2021-03-03 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, started on 2021-03-09, presumably until 2021-08-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-10 00:00:00, ended at 2021-03-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-03-10, presumably until 2021-03-20, with intended 1 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-20 00:00:00, ended at 2021-03-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-20, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth as directed (Take 1mg in the morning and 2mg at night)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-30 00:00:00, ended at 2021-03-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-03-30, presumably until 2021-11-20, with intended 3 refill(s). Instructions: TAKE 1 TAB (50 MCG TOTAL) BY MOUTH EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-04, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-19, presumably until 2021-06-05, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every morning AND 1.5 Tabs (3 mg total) Daily at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-19 11:34:11, ended at 2021-04-19 12:12:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-20 06:15:00, ended at 2021-04-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-25 10:16:13, ended at 2021-04-25 11:00:40\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-04-25, presumably until 2021-08-21, with intended 11 refill(s). Instructions: take 12.5 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-26 16:08:55, ended at 2021-04-26 16:09:05\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 00:00:00, ended at 2021-04-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Prediabetes\n- Paroxysmal atrial fibrillation\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-04-28, presumably until 2021-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 07:16:00, ended at 2021-04-28 11:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.1 (millimole per liter)\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardioversion, elective, electrical conversion of arrhythmia; external\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hypothyroidism\n- Rheumatic tricuspid valve regurgitation\n- Atrial fibrillation\n- Typical atrial flutter\n- Atrial flutter\n- Atrial premature complex\n- Persistent atrial fibrillation\n- Lumbar radiculopathy\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Ventricular premature complex\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Essential hypertension\n- Prediabetes\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-14 14:29:00, ended at 2021-05-14 18:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.6 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.28 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Tachycardia\n- Essential hypertension\n- Hypothyroidism\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-14\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-15 00:00:00, ended at 2021-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-16 00:00:00, ended at 2021-05-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-16, presumably until 2021-06-29, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed For AFib episodes\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-23 00:00:00, ended at 2021-05-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Atrial fibrillation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-06-13, presumably until 2021-11-28, with intended 0 refill(s). Instructions: take 1 Tablet (40 mg total) by mouth daily Start 4 days pre-procedure, and continue 30 days after, no refills. First dose 08/14/2021\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-31 13:29:00, ended at 2021-05-31 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-02 00:00:00, ended at 2021-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-06-29 00:00:00, ended at 2021-06-29 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-06-29, presumably until 2021-08-04, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed (breakthrough arrhythmias if HR are sustained above 110-120 bpm, for at least 3-4 hours)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-31 00:00:00, ended at 2021-07-31 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-08-03 00:00:00, ended at 2021-08-03 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-08-04, presumably until 2021-08-21, with intended 2 refill(s). Instructions: TAKE 0.5 TABLETS (12.5 MG TOTAL) BY MOUTH 2 TIMES A DAY AS NEEDED (BREAKTHROUGH ARRHYTHMIAS IF HR ARE SUSTAINED ABOVE 110-120 BPM, FOR AT LEAST 3-4 HOURS)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-08-08 11:07:18, ended at 2021-08-08 16:05:47\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Hypothyroidism caused by drug\n- Essential hypertension\n- Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-08-15 14:49:38, ended at 2021-08-15 15:24:18\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, presumably until 2021-08-22, with intended 0 refill(s). Instructions: take 1 mg by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-16 00:00:00, ended at 2021-08-16 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-08-17 00:00:00, ended at 2021-08-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-17 08:11:00, ended at 2021-08-17 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2021-08-18 00:00:00, ended at 2021-08-18 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2021-08-18, presumably until 2021-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-18 00:00:00, ended at 2021-08-18 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n\n### Condition\n- Essential hypertension\n- Atrial fibrillation\n- Hypothyroidism\n\n### Drug\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- 10 ML furosemide 10 MG/ML Injection, started on 2021-08-18, presumably until 2021-08-18\n- remifentanil 2 MG Injection, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2021-08-18, presumably until 2021-08-18\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-08-18, presumably until 2021-08-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2021-08-18, presumably until 2021-08-18\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2021-08-18, presumably until 2021-08-18\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2021-08-18, presumably until 2021-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2021-08-18 05:10:00, ended at 2021-08-21 12:16:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 44 (percent)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.42 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Activated clotting time (ACT) of Blood by Coagulation assay: 372 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Aldosterone [Mass/volume] in Serum or Plasma: 6.8 (nanogram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 15.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 169 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.00 (micro-international unit per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Potassium [Moles/volume] in Blood: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 139 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separatel\n- Collection of venous blood by venipuncture\n- Destruction of Conduction Mechanism, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary\n- Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Left heart catheterization by transseptal puncture through intact septum or by transapical puncture (List separately in addition to code for primary procedure)\n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n\n### Condition\n- Ventricular premature complex\n- Hypothyroidism\n- Hypothyroidism caused by drug\n- Atrial fibrillation\n- Coronary atherosclerosis\n- Persistent atrial fibrillation\n- Primary diagnosis: Postoperative state\n- Metabolic syndrome X\n- Prediabetes\n- Atrial flutter\n- Essential hypertension\n- Typical atrial flutter\n- Electrocardiogram abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorders of both mitral and tricuspid valves\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Paroxysmal atrial fibrillation\n- Rheumatic disease of heart valve\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-21\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-21\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-21\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-21\n- 10 ML furosemide 10 MG/ML Injection, started on 2021-08-19, presumably until 2021-08-19\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2021-08-21, presumably until 2021-10-20, with intended 1 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth as needed PRN BID for sustained ( 3-4 hours) of HR >110 bpm.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- dofetilide 0.25 MG Oral Capsule, through Oral route, started on 2021-08-18, presumably until 2021-08-22, with intended 1 refill(s). Instructions: take 1 Capsule (250 mcg total) by mouth 2 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2021-08-19, presumably until 2021-08-19\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2021-08-19, presumably until 2021-08-19\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-08-18, presumably until 2021-08-20\n- benazepril hydrochloride 10 MG Oral Tablet, through Oral route, started on 2021-08-19, presumably until 2021-08-20\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2021-08-21 12:16:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "6c7cc26c923b9e0595cf66c74e52cf3b121978008e1048a62b7a2c25cdbb1318", "prompt_hash": "4009c7fd15883fe8aba97be22b5ba9f24870ca6e6dcdbe80f0a229bd1dcd3611", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 0.0, "f1_gu_yn": [0, 1], "recall_gu_yn": [0, 1]}
{"doc_id": 2, "doc": {"person_id": 115967699, "visit_occurrence_id": 170664272, "death_date": null, "visit_concept_name": "Hospital", "visit_start_datetime": "2020-12-31 00:00:00", "visit_end_datetime": "2020-12-31 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Hospital, started at 2020-12-31 00:00:00, ended at 2020-12-31 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2020-12-31, presumably until 2020-12-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-12-31, presumably until 2020-12-31\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2020-12-31, presumably until 2020-12-31\n\n", "approximate_token_count": 163, "patient_first_visit_date": "2018-07-27 08:09:53", "patient_last_visit_date": "2022-11-11 10:16:14", "end_obs_date": "2021-12-31", "readmission_30d": 0, "visit_sequence_number": 36, "cumulated_visit_num": 36, "cumulated_approximate_token_count": 4963, "visit_cumulated": "## Visit\nThis visit record, was from Office Visit, started at 2018-07-27 08:09:53, ended at 2018-07-27 09:18:56\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low grade squamous intraepithelial lesion on cervical Papanicolaou smear\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 2 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-27, presumably until 2019-02-15, with intended 1 refill(s). Instructions: inject 10 Units subcutaneous (under the skin) every bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-22 00:00:00, ended at 2018-12-22 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 15.6 (milligram per gram of creatinine)\n- Creatinine [Mass/volume] in Urine: 265.5 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 41.3 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-31 00:00:00, ended at 2018-12-31 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-15 15:14:21, ended at 2019-02-15 15:46:51\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-15, presumably until 2019-02-20, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-20 00:00:00, ended at 2019-02-20 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-20, presumably until 2019-03-01, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-28 00:00:00, ended at 2019-02-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin degludec 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-01, presumably until 2019-03-07, with intended 1 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-30 00:00:00, ended at 2019-05-30 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-05-30, presumably until 2019-10-18, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER SKIN EVERY EVENING.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-28 00:00:00, ended at 2019-08-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-04 00:00:00, ended at 2019-09-04 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-06 11:31:00, ended at 2019-09-06 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Mammographic calcification of breast\n- Mammographic microcalcification of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-12 12:25:00, ended at 2019-09-12 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in upper inner quadrant of right breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-09-12, presumably until 2019-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-23 00:00:00, ended at 2019-09-23 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-09-24, presumably until 2019-11-06, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-26 00:00:00, ended at 2019-09-26 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-06 00:00:00, ended at 2019-11-06 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-11-07, presumably until 2020-01-08, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-01-08, presumably until 2020-02-28, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-07, presumably until 2020-01-21, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER THE SKIN EVERY EVENING\n- atorvastatin 40 MG Oral Tablet, started on 2020-01-07, presumably until 2020-07-13, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-21 15:09:17, ended at 2020-01-21 15:59:07\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.0 (percent)\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Hyperlipidemia\n- Secondary diabetes mellitus\n- Type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Mild nonproliferative retinopathy of left eye due to diabetes mellitus\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2020-01-21, presumably until 2020-05-20, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-21, presumably until 2020-01-28, with intended 3 refill(s). Instructions: 24 Units by abdominal subcutaneous route AM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-04 00:00:00, ended at 2020-02-04 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-02-04, presumably until 2020-02-04, with intended 1 refill(s). Instructions: inject 100 Units subcutaneous (under the skin) daily in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-02-28, presumably until 2020-04-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-11 00:00:00, ended at 2020-04-11 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-04-13, presumably until 2020-05-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-12 00:00:00, ended at 2020-07-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-07-13, presumably until 2021-01-16, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-21 00:00:00, ended at 2020-09-21 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-06 20:40:00, ended at 2020-10-06 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-08 00:00:00, ended at 2020-10-08 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-30 11:10:00, ended at 2020-10-30 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-12 00:00:00, ended at 2020-11-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Lump in upper inner quadrant of right breast\n- Lump in upper outer quadrant of right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-11-12, presumably until 2020-11-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-13 12:00:00, ended at 2020-11-13 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 07:03:00, ended at 2020-12-02 09:27:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 09:28:00, ended at 2020-12-02 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Disorder of breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-09 15:16:28, ended at 2020-12-09 15:58:22\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance\n\n### Condition\n- Benign neoplasm of right breast\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-31 00:00:00, ended at 2020-12-31 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2020-12-31, presumably until 2020-12-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-12-31, presumably until 2020-12-31\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2020-12-31, presumably until 2020-12-31\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-27 08:09:53, ended at 2018-07-27 09:18:56\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low grade squamous intraepithelial lesion on cervical Papanicolaou smear\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 2 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-27, presumably until 2019-02-15, with intended 1 refill(s). Instructions: inject 10 Units subcutaneous (under the skin) every bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-22 00:00:00, ended at 2018-12-22 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 15.6 (milligram per gram of creatinine)\n- Creatinine [Mass/volume] in Urine: 265.5 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 41.3 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-31 00:00:00, ended at 2018-12-31 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-15 15:14:21, ended at 2019-02-15 15:46:51\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-15, presumably until 2019-02-20, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-20 00:00:00, ended at 2019-02-20 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-20, presumably until 2019-03-01, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-28 00:00:00, ended at 2019-02-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin degludec 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-01, presumably until 2019-03-07, with intended 1 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-30 00:00:00, ended at 2019-05-30 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-05-30, presumably until 2019-10-18, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER SKIN EVERY EVENING.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-28 00:00:00, ended at 2019-08-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-04 00:00:00, ended at 2019-09-04 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-06 11:31:00, ended at 2019-09-06 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Mammographic calcification of breast\n- Mammographic microcalcification of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-12 12:25:00, ended at 2019-09-12 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in upper inner quadrant of right breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-09-12, presumably until 2019-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-23 00:00:00, ended at 2019-09-23 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-09-24, presumably until 2019-11-06, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-26 00:00:00, ended at 2019-09-26 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-06 00:00:00, ended at 2019-11-06 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-11-07, presumably until 2020-01-08, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-01-08, presumably until 2020-02-28, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-07, presumably until 2020-01-21, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER THE SKIN EVERY EVENING\n- atorvastatin 40 MG Oral Tablet, started on 2020-01-07, presumably until 2020-07-13, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-21 15:09:17, ended at 2020-01-21 15:59:07\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.0 (percent)\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Hyperlipidemia\n- Secondary diabetes mellitus\n- Type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Mild nonproliferative retinopathy of left eye due to diabetes mellitus\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2020-01-21, presumably until 2020-05-20, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-21, presumably until 2020-01-28, with intended 3 refill(s). Instructions: 24 Units by abdominal subcutaneous route AM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-04 00:00:00, ended at 2020-02-04 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-02-04, presumably until 2020-02-04, with intended 1 refill(s). Instructions: inject 100 Units subcutaneous (under the skin) daily in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-02-28, presumably until 2020-04-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-11 00:00:00, ended at 2020-04-11 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-04-13, presumably until 2020-05-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-12 00:00:00, ended at 2020-07-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-07-13, presumably until 2021-01-16, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-21 00:00:00, ended at 2020-09-21 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-06 20:40:00, ended at 2020-10-06 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-08 00:00:00, ended at 2020-10-08 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-30 11:10:00, ended at 2020-10-30 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-12 00:00:00, ended at 2020-11-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Lump in upper inner quadrant of right breast\n- Lump in upper outer quadrant of right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-11-12, presumably until 2020-11-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-13 12:00:00, ended at 2020-11-13 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 07:03:00, ended at 2020-12-02 09:27:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 09:28:00, ended at 2020-12-02 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Disorder of breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-09 15:16:28, ended at 2020-12-09 15:58:22\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance\n\n### Condition\n- Benign neoplasm of right breast\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-31 00:00:00, ended at 2020-12-31 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2020-12-31, presumably until 2020-12-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-12-31, presumably until 2020-12-31\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2020-12-31, presumably until 2020-12-31\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2020-12-31 00:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "ee2a7794e4d8d4e63af1b3a0853a1de2eda57ec312e528f50c7fce05b9f6ff27", "prompt_hash": "3a837fb0f8cee6b055b733c4a5217020881fcc7f41127d2f641bc297e22b6aae", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 3, "doc": {"person_id": 115967769, "visit_occurrence_id": 171772496, "death_date": null, "visit_concept_name": "Emergency Room and Inpatient Visit", "visit_start_datetime": "2021-01-02 14:36:00", "visit_end_datetime": "2021-01-08 22:00:00", "visit_length_in_hours": 151.4, "integrated_visit_record": "## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2021-01-02 14:36:00, ended at 2021-01-08 22:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.42 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 18.6 (picogram per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.020 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.29 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 265 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 276 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 300 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Body height: 5' 10\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, pelvis; 1 or 2 views\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Replacement of Left Hip Joint, Femoral Surface with Synthetic Substitute, Cemented, Open Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Radiologic examination, hip, unilateral, with pelvis when performed; 2-3 views\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Open treatment of femoral fracture, proximal end, neck, internal fixation or prosthetic replacement\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n\n### Condition\n- Essential hypertension\n- Mononeuropathy of lower limb\n- Chronic kidney disease\n- Chronic kidney disease due to hypertension\n- Complication due to diabetes mellitus\n- Nausea and vomiting\n- End-stage renal disease\n- Hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic pain\n- Disorder of bone\n- Illness\n- Polyneuropathy due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Tachycardia\n- Acute posthemorrhagic anemia\n- Anemia in chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Bipolar disorder\n- Disorder of eye due to type 1 diabetes mellitus\n- Hip pain\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Polyneuropathy\n- Acute myocardial infarction\n- Primary diagnosis: Closed fracture of neck of femur\n- Disorder of upper gastrointestinal tract\n- Gastroesophageal reflux disease without esophagitis\n- Macular edema due to diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Hypertensive heart and chronic kidney disease\n- Persistent pain following procedure\n- Sarcoidosis\n- Chronic obstructive lung disease\n- Coronary artery graft present\n- Finding of urine output\n- Hypoglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 1 diabetes mellitus\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2021-01-04, presumably until 2021-01-05\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2021-01-06, presumably until 2021-01-08\n- 24 HR nicotine 0.875 MG/HR Transdermal System, through Transdermal route, started on 2021-01-02, presumably until 2021-01-07\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth every 8 hours\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2021-01-03, presumably until 2021-01-03\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2021-01-03, presumably until 2021-01-08\n- cefazolin 1000 MG Injection, started on 2021-01-04, presumably until 2021-01-05\n- 24 HR nicotine 0.292 MG/HR Transdermal System, through Transdermal route, started on 2021-01-05, presumably until 2021-01-07\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2021-01-03, presumably until 2021-01-06\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-08\n- sodium chloride 9 MG/ML Injection, started on 2021-01-04, presumably until 2021-01-05\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Prefilled Syringe, through Subcutaneous route, started on 2021-01-02, presumably until 2021-01-18, with intended 0 refill(s). Instructions: inject 0.5 mL (5,000 Units total) subcutaneous (under the skin) every 8 hours\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2021-01-05, presumably until 2021-01-08\n- 30 ML ropivacaine hydrochloride 5 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-05\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-05\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2021-01-03, presumably until 2021-01-04\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2021-01-04, presumably until 2021-01-15, with intended 0 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every 4 hours as needed (2mg moderate pain, 4mg severe pain) G89.18\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 650 mg by mouth every 4 to 6 hours as needed\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-08\n- 2 ML ondansetron 2 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2021-01-02, presumably until 2021-01-06\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet, through Sublingual route, started on 2021-01-04, presumably until 2021-01-08\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2021-01-02, presumably until 2021-01-07\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2021-01-04, presumably until 2021-01-08\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-03\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2021-01-07, presumably until 2021-01-07\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-07\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2021-01-05, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 1 Tab (81 mg total) by mouth every morning with breakfast Resuming home medication.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-02\n\n", "approximate_token_count": 3286, "patient_first_visit_date": "2012-03-31 14:46:00", "patient_last_visit_date": "2023-02-06 10:56:09", "end_obs_date": "2022-01-08", "readmission_30d": 1, "visit_sequence_number": 198, "cumulated_visit_num": 198, "cumulated_approximate_token_count": 41657, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-03-31 14:46:00, ended at 2012-03-31 16:19:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 236 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.34 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Chronic pain\n- Dysuria\n- Abdominal pain\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus without complication\n- Congestive heart failure\n- Type 1 diabetes mellitus uncontrolled\n- Chronic kidney disease\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Nausea\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2012-03-31, presumably until 2012-04-30, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-20 00:00:00, ended at 2018-10-20 00:00:00\nThe patient in this visit was 45 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-05 12:36:05, ended at 2019-01-05 15:56:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary artery graft present\n- Mixed hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Pulmonary emphysema\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Anemia in chronic kidney disease\n- Chronic nephritic syndrome\n- End-stage renal disease\n- Essential hypertension\n- Vitamin D deficiency\n- Hyperparathyroidism due to renal insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-05 15:58:00, ended at 2019-01-05 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: <0.02 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-12 00:00:00, ended at 2019-01-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 00:00:00, ended at 2019-02-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 08:37:00, ended at 2019-02-23 13:35:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Primary diagnosis: Hearing loss of right ear\n- Atelectasis\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic pain\n- Obesity\n- Type 2 diabetes mellitus\n- Bilateral hearing loss\n- Heart failure\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic obstructive lung disease\n- Sudden hearing loss\n- Disorder of bronchus\n- Hypertensive heart and chronic kidney disease\n- Disorder of nervous system due to type 2 diabetes mellitus\n- End-stage renal disease\n- Hearing loss of left ear\n\n### Drug\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-03-05, with intended 0 refill(s). Instructions: take 1.5 Tabs (600 mg total) by mouth daily for 10 days\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-04-15, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily for 60 doses Take 6 tabs (60mg) daily for 3 days, then 5 tabs daily for 3 days, then 4 tabs daily for 3 days, then 3 tabs daily for 2 days, then 2 tabs daily for 2 days, then 1 tab daily for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-24 07:30:51, ended at 2019-02-24 12:44:18\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 200 mg by mouth\n- atorvastatin 10 MG Oral Tablet, started on 2018-12-19, presumably until 2019-04-15, with intended 0 refill(s)\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-01-14, presumably until 2019-04-15, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2018-12-12, presumably until 2019-04-15, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2019-02-19, presumably until 2019-04-15, with intended 0 refill(s)\n- losartan potassium 100 MG Oral Tablet, started on 2019-02-17, presumably until 2019-04-15, with intended 0 refill(s)\n- furosemide 80 MG Oral Tablet, started on 2018-12-21, presumably until 2019-04-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-24 07:31:03, ended at 2019-02-24 08:47:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sudden hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-03 09:57:52, ended at 2019-03-03 11:50:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-03 09:58:03, ended at 2019-03-03 11:50:40\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-08 07:24:30, ended at 2019-03-08 09:43:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-08 07:24:41, ended at 2019-03-08 08:42:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-09 07:17:57, ended at 2019-03-09 09:04:26\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-12 00:00:00, ended at 2019-03-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-23 08:42:00, ended at 2019-03-23 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Abnormal findings on diagnostic imaging of lung\n- Fibrosis of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-24 07:21:38, ended at 2019-03-24 10:09:25\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pure tone audiometry (threshold); air only\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-24 07:21:55, ended at 2019-03-24 12:22:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 12:57:53, ended at 2019-03-26 15:17:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 16:52:00, ended at 2019-03-26 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Atherosclerosis of aorta\n- Sensorineural hearing loss, bilateral\n- Opioid dependence in remission\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 11:55:31, ended at 2019-04-15 16:21:50\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication due to diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Retinal disorder\n- Type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Mixed conductive AND sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Chronic obstructive lung disease\n- Disorder of upper gastrointestinal tract\n- Heart failure\n- End-stage renal disease\n- Illness\n- Bipolar disorder in remission\n- Chronic pain\n- Pure hypercholesterolemia\n- Dependence on supplemental oxygen\n- Mechanical complication of peritoneal dialysis catheter\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-15 16:14:08, ended at 2019-04-15 17:19:35\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: End-stage renal disease\n- Retinal disorder\n- Complication due to diabetes mellitus\n- Pure hypercholesterolemia\n- Chronic pain\n- Mechanical complication of peritoneal dialysis catheter\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder in remission\n- Dependence on supplemental oxygen\n- Chronic obstructive lung disease\n- Heart failure\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Disorder of upper gastrointestinal tract\n- Type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2019-11-22, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n- vitamin E, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- selenomethionine, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n- cholecalciferol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- folic acid, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- wheat germ oil, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- alpha tocopherol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2019-07-07, with intended 1 refill(s). Instructions: place 1.5 Tabs under the tongue and let dissolve every day\n- zinc oxide, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-04-15, presumably until 2020-02-28, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-06, with intended 11 refill(s). Instructions: take 1 Tab (81 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 18 units under the skin at bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-26, with intended 11 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2020-04-14, with intended 11 refill(s). Instructions: place 1 Tab (0.4 mg total) under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-19 14:07:51, ended at 2019-04-19 17:41:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 19 (millimeter mercury column)\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Retinal neovascularization\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-20 12:25:18, ended at 2019-04-20 13:25:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Pulmonary hypertension\n- Severe nonproliferative retinopathy due to diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-04-20, presumably until 2019-05-04, with intended 5 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 14 days\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-20, presumably until 2019-04-26, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1-2 Tabs (4-8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-05-04, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-29 13:05:19, ended at 2019-04-29 15:15:57\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hearing loss\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2019-04-29, presumably until 2019-06-22, with intended 2 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 11:05:35, ended at 2019-05-04 13:44:21\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 13:34:13, ended at 2019-05-04 14:57:46\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- esomeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take by mouth every day\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2019-12-06, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every 6 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-05 13:45:06, ended at 2019-05-05 15:08:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Pulmonary emphysema\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 00:00:00, ended at 2019-05-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on lower anterior abdominal wall; not otherwise specified\n\n### Condition\n- Mechanical complication of peritoneal dialysis catheter\n- End-stage renal disease\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cefazolin 1000 MG Injection, started on 2019-05-07, presumably until 2019-05-07\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 07:10:00, ended at 2019-05-07 12:08:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.14 (millimole per liter)\n- Base excess in Arterial blood by calculation: 7.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.5 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Glucose [Mass/volume] in Blood: 320 (milligram per deciliter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 23.7 (millimeter mercury column)\n\n### Procedure\n- Removal of tunneled intraperitoneal catheter\n- Collection of venous blood by venipuncture\n- Removal of Infusion Device from Peritoneal Cavity, Open Approach\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: End-stage renal disease\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Mechanical complication of peritoneal dialysis catheter\n- Hyperlipidemia\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-05-07, presumably until 2019-05-11, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-07, presumably until 2019-05-11, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-11 09:13:38, ended at 2019-05-11 13:20:07\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2019-05-11, presumably until 2019-05-16, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2019-05-11, presumably until 2019-05-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-11 12:31:00, ended at 2019-05-11 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Disorder of brain\n- Hearing loss\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-18 10:33:23, ended at 2019-05-18 14:44:56\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 14:03:22, ended at 2019-05-21 15:43:17\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary hypertension\n- End-stage renal disease\n- Essential hypertension\n- Sensorineural hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for procedures on external, middle, and inner ear including biopsy; not otherwise specified\n\n### Condition\n- Chronic kidney disease\n- Essential hypertension\n- Sensorineural hearing loss, bilateral\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2019-05-27, presumably until 2019-05-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- ketamine 100 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium hyaluronate 10 MG/ML Prefilled Syringe, through Intraocular route, started on 2019-05-27, presumably until 2019-05-27\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 05:58:00, ended at 2019-05-27 12:20:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 5.5 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 63.1 (millimeter mercury column)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood: 27.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Oxygen [Partial pressure] in Arterial blood: 93.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Blood: 87 (milligram per deciliter)\n\n### Procedure\n- Cochlear device implantation, with or without mastoidectomy\n- Radiologic examination, skull; less than 4 views\n- Insertion of Single Channel Cochlear Prosthesis into Left Inner Ear, Open Approach\n\n### Condition\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Sarcoidosis\n- Heart failure\n- Old myocardial infarction\n- Retinopathy due to type 1 diabetes mellitus\n- Sensorineural hearing loss, bilateral\n- End-stage renal disease\n- Hypertensive heart and chronic kidney disease\n- Renal disorder due to type 1 diabetes mellitus\n- Uncomplicated asthma\n- Sensorineural hearing loss\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-05-27, presumably until 2019-06-26, with intended 0 refill(s). Instructions: take 1 Boley (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-05-27, presumably until 2019-05-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-05-22, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-15 08:37:55, ended at 2019-06-15 10:25:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-15 08:38:27, ended at 2019-06-15 11:04:42\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; with programming\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 15:18:47, ended at 2019-06-17 16:25:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Dependence on supplemental oxygen\n- Leukocytosis\n- Sarcoidosis\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperglycemia due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Sensorineural hearing loss\n- End-stage renal disease\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-06-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n- oxycodone hydrochloride 5 MG Oral Tablet, started on 2019-05-26, presumably until 2019-07-29, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-18 00:00:00, ended at 2019-06-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.41 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.57 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Leukocytosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-22 09:47:01, ended at 2019-06-22 10:28:28\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, presumably until 2019-07-29, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-06-22, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-22 13:45:04, ended at 2019-06-22 16:45:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-24 13:32:00, ended at 2019-06-24 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-06 00:00:00, ended at 2019-07-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-07-06, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily 15 mg (3 x 5 mg) for 1 mo, 10 mg (2 x 5 mg) for 1 mo, 5 mg (1 x 5 mg) for 1 mo then STOP.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-07 00:00:00, ended at 2019-07-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-07-07, presumably until 2019-08-05, with intended 0 refill(s). Instructions: DISSOLVE 1&1/2 TABLETS UNDER TONGUE ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-12 11:41:00, ended at 2019-07-12 12:03:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n\n### Condition\n- Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-13 11:35:08, ended at 2019-07-13 12:28:27\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-13 11:36:03, ended at 2019-07-13 15:03:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-23 00:00:00, ended at 2019-07-23 12:10:45\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin E, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol 0.05 MG Oral Tablet, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 1 tablet by oral route once daily\n- selenomethionine, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cefdinir 300 MG Oral Capsule, presumably until 2019-07-29, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- folic acid, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- ergocalciferol 1.25 MG Oral Capsule, started on 2014-03-15, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Take 1 capsule by mouth once a week for 10 weeks\n- wheat germ oil, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- alpha tocopherol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- sucroferric oxyhydroxide 500 MG Chewable Tablet, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Velphoro 500 mg chewable tablet\n- zinc oxide, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- lidocaine 0.05 MG/MG Medicated Patch, started on 2012-08-06, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Apply 1/2 patch to right foot, 1/2 patch to left foot once a day, may wear up to 12 hours.\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-09-28, presumably until 2019-11-23, with intended 11 refill(s). Instructions: inject 8 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-29 12:02:28, ended at 2019-07-29 12:55:15\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Chronic ulcer of foot\n- End-stage renal disease\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-07-29, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Kravitz (10,000 Units total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-05, presumably until 2019-08-06, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-06, presumably until 2019-09-17, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2019-08-23, presumably until 2019-10-06, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- folic acid, through Oral route, started on 2019-08-24, presumably until 2019-10-06, with intended 3 refill(s). Instructions: take 1 Tab (0.8 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:44:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:59:48\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2019-09-09, presumably until 2019-09-21, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-24, presumably until 2019-09-24, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-09-17, presumably until 2021-10-13, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2019-09-17, presumably until 2019-10-17, with intended 0 refill(s). Instructions: place 2 Tabs under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-22 00:00:00, ended at 2019-09-22 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-23, presumably until 2019-09-23, with intended 0 refill(s). Instructions: Dissolve one and one half under the tongue daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-28 11:52:23, ended at 2019-09-28 18:06:19\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.583\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Atherosclerosis of coronary artery without angina pectoris\n- End-stage renal disease\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Essential hypertension\n- Nicotine dependence\n- Nondependent opioid abuse in remission\n- Primary diagnosis: Type 1 diabetes mellitus\n- Opioid abuse\n- Chronic ulcer of foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-09-28, presumably until 2019-09-28, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- varenicline 1 MG Oral Tablet, through Oral route, started on 2019-09-28, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 0.5 Tabs (0.5 mg total) by mouth 2 times a day Take daily for first 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-30 15:21:18, ended at 2019-09-30 16:33:16\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n- Intraocular pressure of right eye: 18 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Primary diagnosis: Retinal neovascularization\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-04 13:40:14, ended at 2019-10-04 14:40:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n- Hypercalcemia\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2019-10-19, presumably until 2020-03-09, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-18 00:00:00, ended at 2019-10-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- biotin, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbate manganese, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbyl tetraisopalmitate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- folic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- zinc ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- potassium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- 6-O-palmitoylascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- magnesium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- calcium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- sodium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-20 12:25:42, ended at 2019-10-20 14:05:54\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-21 13:37:15, ended at 2019-10-21 15:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypersomnia\n- Gastroesophageal reflux disease without esophagitis\n- Nicotine dependence\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n- Cough\n\n### Drug\n- nicotine 2 MG Oral Lozenge, through Buccal route, started on 2019-10-21, presumably until 2021-05-16, with intended 6 refill(s). Instructions: place 2 mg inside cheek or to gum every 4 hours as needed\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2019-10-21, presumably until 2020-01-03, with intended 3 refill(s). Instructions: take 2 Tabs (40 mg total) by mouth daily\n- nicotine bitartrate, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n- nicotine, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 12:36:49, ended at 2019-10-28 14:38:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-10-29, presumably until 2022-07-30, with intended 0 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 7 days\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-08 00:00:00, ended at 2019-11-08 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-09 10:05:00, ended at 2019-11-09 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-09 10:05:06, ended at 2019-11-09 16:40:03\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-22 11:58:27, ended at 2019-11-22 15:11:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Opioid abuse\n- Pulmonary hypertension\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-23 00:00:00, ended at 2019-11-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Opioid abuse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 13:07:20, ended at 2019-11-26 13:47:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Determination of refractive state\n\n### Condition\n- Presbyopia\n- Primary diagnosis: Regular astigmatism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-06, presumably until 2019-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-09 12:11:19, ended at 2019-12-09 14:09:17\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-14 08:08:46, ended at 2019-12-14 09:14:42\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-15 00:00:00, ended at 2019-12-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-16, presumably until 2020-03-06, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 12:32:47, ended at 2019-12-21 15:44:55\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n- Retinal disorder\n- End-stage renal disease\n- Type 1 diabetes mellitus\n- Complication due to diabetes mellitus\n- Nicotine dependence\n- Polyneuropathy due to diabetes mellitus\n- Secondary diabetes mellitus\n- Primary diagnosis: Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 00:00:00, ended at 2019-12-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Pulmonary hypertension\n- Lymph node sarcoidosis\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Type 1 diabetes mellitus without complication\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-12-29, presumably until 2019-12-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 07:10:00, ended at 2019-12-29 10:09:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n- Radiologic examination, chest; single view\n\n### Condition\n- Chronic obstructive lung disease\n- Lymph node sarcoidosis\n- Old myocardial infarction\n- Primary diagnosis: Pulmonary hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Nicotine dependence\n- Essential hypertension\n- Heart failure\n- Post-inflammatory pulmonary fibrosis\n- Abnormal findings on diagnostic imaging of lung\n- Hyperlipidemia\n- Interstitial lung disease\n- Disorder of lung\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Pulmonary sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-31 00:00:00, ended at 2019-12-31 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-03 14:07:08, ended at 2020-01-03 15:25:08\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Primary diagnosis: Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-01-04 00:00:00, ended at 2020-01-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-04, presumably until 2020-01-05, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-05 00:00:00, ended at 2020-01-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-05, presumably until 2020-06-08, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:10:00, ended at 2020-01-06 12:24:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 29.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.52 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 102.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 326 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperosmolarity\n- Hypercalcemia\n- Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:25:00, ended at 2020-01-06 13:06:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Sarcoidosis\n- Closed fracture of second metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of first metatarsal bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:07:00, ended at 2020-01-06 13:19:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Closed fracture of first metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of second metatarsal bone\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Interstitial lung disease\n- Sarcoidosis\n- Dyspnea\n- Hyperosmolarity\n- Secondary diabetes mellitus\n- Hypercalcemia\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-06 14:09:28, ended at 2020-01-06 16:00:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-11 09:30:59, ended at 2020-01-11 10:16:22\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-12 10:30:00, ended at 2020-01-12 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Type 2 diabetes mellitus\n- Type 1 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-18 11:42:19, ended at 2020-01-18 12:43:33\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-30 00:00:00, ended at 2020-01-30 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n\n### Drug\n- 24 HR nicotine 0.875 MG/HR Transdermal System, started on 2020-02-01, presumably until 2021-05-16, with intended 2 refill(s). Instructions: APPLY ONE PATCH EXTERNALLY ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-06 00:00:00, ended at 2020-02-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium acetate 667 MG Oral Capsule, started on 2020-02-07, presumably until 2020-04-10, with intended 4 refill(s). Instructions: TAKE TWO CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-02-10, with intended 0 refill(s). Instructions: Take 1 capsule now and then 1 after next 3 dialysis sessions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-11 00:00:00, ended at 2020-02-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-11, presumably until 2020-02-24, with intended 0 refill(s). Instructions: APPLY TOPICALLY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-15 10:15:00, ended at 2020-02-15 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Closed fracture of first metatarsal bone\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-15 10:38:28, ended at 2020-02-15 11:17:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-23 00:00:00, ended at 2020-02-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-24, presumably until 2020-05-08, with intended 3 refill(s). Instructions: apply to affected area topically as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- ascorbate manganese, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbyl tetraisopalmitate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- folic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- zinc ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- potassium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- 6-O-palmitoylascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- magnesium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- calcium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- sodium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- biotin, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2020-02-28, presumably until 2021-02-27, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-05 00:00:00, ended at 2020-03-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2020-03-06, presumably until 2021-03-14, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE A DAY AS NEEDED FOR NAUSEA \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-03-09, presumably until 2020-08-04, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-09 12:18:40, ended at 2020-03-09 12:48:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Hyperglycemia due to type 1 diabetes mellitus\n- Nicotine dependence\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Anemia\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-04-06, with intended 0 refill(s)\n- 3 ML insulin lispro 200 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-09, presumably until 2021-03-15, with intended 11 refill(s). Instructions: inject 6-10 Units subcutaneous (under the skin) before meals\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-03-09, presumably until 2021-03-19, with intended 11 refill(s). Instructions: Inject 30 units under the skin at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-22 00:00:00, ended at 2020-03-22 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-24 13:41:40, ended at 2020-03-24 13:51:46\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-28 09:16:21, ended at 2020-03-28 09:27:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-06 14:27:38, ended at 2020-04-06 15:01:14\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Type 2 diabetes mellitus\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-04-06, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-13 14:48:23, ended at 2020-04-13 15:32:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-20 10:33:00, ended at 2020-04-20 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Sarcoidosis\n- Primary diagnosis: Interstitial lung disease\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-26 00:00:00, ended at 2020-04-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-04-26, presumably until 2021-06-14, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-02 00:00:00, ended at 2020-05-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-04 08:28:00, ended at 2020-05-04 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Type 2 diabetes mellitus\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-07 00:00:00, ended at 2020-05-07 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-05-08, presumably until 2020-10-10, with intended 11 refill(s). Instructions: APPLY TOPICALLY TO THE AFFECTED AREA AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-20 00:00:00, ended at 2020-05-20 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, started on 2020-05-22, presumably until 2021-03-12, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-23 16:51:43, ended at 2020-05-23 17:08:13\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-05-30 09:22:08, ended at 2020-05-30 10:18:31\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Primary diagnosis: Sciatica\n\n### Drug\n- Twice-Daily diclofenac epolamine 0.013 MG/MG Medicated Patch, through Transdermal route, started on 2020-05-30, presumably until 2020-09-28, with intended 3 refill(s). Instructions: apply 1 Patch to skin 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-30 09:59:00, ended at 2020-05-30 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Sciatica\n- Fracture of phalanx of foot\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-05 12:18:16, ended at 2020-06-05 12:49:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pain\n- Disorder of sacrum\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-06 09:50:00, ended at 2020-06-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of bone\n- Disorder of thigh\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-08 15:23:12, ended at 2020-06-08 16:01:32\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-15 13:24:08, ended at 2020-06-15 14:45:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-16 16:50:15, ended at 2020-06-16 17:19:24\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n- Chronic pain\n- Type 2 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Primary diagnosis: Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-28 09:19:30, ended at 2020-06-28 10:51:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Intervertebral disc disorder of lumbar region with myelopathy\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2020-06-28, presumably until 2020-08-15, with intended 2 refill(s). Instructions: Apply a small amount, up to 2 grams, 2-3 times per day if needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-03 00:00:00, ended at 2020-07-03 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dependence on enabling machine or device\n- Primary diagnosis: Obstructive sleep apnea syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-01 09:39:00, ended at 2020-08-01 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Obstructive sleep apnea syndrome\n- Dyspnea\n- Hyperglycemia due to type 1 diabetes mellitus\n- Localized enlarged lymph nodes\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Chronic pulmonary edema\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-01 14:21:03, ended at 2020-08-01 14:44:49\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Obstructive sleep apnea syndrome\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-03 00:00:00, ended at 2020-08-03 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-08-04, presumably until 2020-09-05, with intended 0 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-03 16:21:24, ended at 2020-08-03 16:57:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Seronegative rheumatoid arthritis\n- Rheumatoid arthritis - hand joint\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- 0.4 ML adalimumab 100 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-08-04, presumably until 2020-11-22, with intended 6 refill(s). Instructions: inject 40 mg subcutaneous (under the skin) every 2 weeks\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-05 00:00:00, ended at 2020-08-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-08-07, presumably until 2020-08-07, with intended 0 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-07 13:08:56, ended at 2020-08-07 13:51:02\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of right eye: 20 (millimeter mercury column)\n- Intraocular pressure of left eye: 21 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal neovascularization\n- Primary diagnosis: Proliferative retinopathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-09 10:01:12, ended at 2020-08-09 11:29:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2020-08-15, presumably until 2020-09-07, with intended 0 refill(s). Instructions: Apply a small amount, up to 2 grams, 2-3 times per day if needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 10:09:54, ended at 2020-08-15 10:26:45\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Primary central sleep apnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-16 11:17:48, ended at 2020-08-16 11:53:16\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Seronegative rheumatoid arthritis\n- Rheumatoid arthritis - hand joint\n- Sarcoidosis\n- Primary diagnosis: Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-17 00:00:00, ended at 2020-08-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-29 13:11:03, ended at 2020-08-29 15:19:32\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-05 00:00:00, ended at 2020-09-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2020-09-07, presumably until 2020-09-28, with intended 0 refill(s). Instructions: Apply UP TO 2 GRAMS to affected area twice TO 3 TIMES daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-05 00:00:00, ended at 2020-09-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-09-05, presumably until 2020-10-03, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-06 00:00:00, ended at 2020-09-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-07 09:19:00, ended at 2020-09-07 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Metatarsal bone fracture\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in right foot\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-15 00:00:00, ended at 2020-09-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-19 08:00:00, ended at 2020-09-19 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Neuropathic arthropathy due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in right foot\n- Pain in left foot\n- Onychomycosis due to dermatophyte\n- Secondary diabetes mellitus\n- Sciatica\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2020-09-26 00:00:00, ended at 2020-09-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 268 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.16 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 39 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 311 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Prothrombin time (PT): 13.4 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- MCV [Entitic volume] by Automated count: 100.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.50 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 227 (unit per liter)\n- Base excess in Blood by calculation: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2020-09-26 12:11:00, ended at 2020-09-28 20:31:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Left ventricular Ejection fraction: 57.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.57 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Body height: 5' 9\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.50 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 311 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.9 (percent)\n- Prothrombin time (PT): 13.4 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 227 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Glucose [Mass/volume] in Blood: 491 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Base excess in Blood by calculation: 4 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.28 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 101.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 235 (thousand per microliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Radiologic examination, hip, unilateral, with pelvis when performed; 2-3 views\n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, pelvis; 1 or 2 views\n- Collection of venous blood by venipuncture\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Radiologic examination, femur; minimum 2 views\n\n### Condition\n- Bilateral hearing loss\n- Chest pain\n- Chronic pain\n- Pain provoked by trauma\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Gastroesophageal reflux disease without esophagitis\n- Hyperparathyroidism due to renal insufficiency\n- Pulmonary sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Retinopathy due to type 1 diabetes mellitus\n- Chronic obstructive lung disease\n- Primary diagnosis: Closed fracture of neck of femur\n- Fibrosis of lung\n- Hip pain\n- Polyneuropathy due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Coronary artery graft present\n- Falls\n- Pulmonary hypertension\n- Pure hypercholesterolemia\n- Anemia in chronic kidney disease\n- Hypertensive heart and chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Macular edema due to diabetes mellitus\n- Hyperlipidemia\n- Nicotine dependence\n- Bipolar disorder\n- End-stage renal disease\n- Sarcoidosis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2021-01-02, with intended 0 refill(s). Instructions: take 2 Tabs (650 mg total) by mouth every 6 hours\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2020-09-28, presumably until 2020-09-28\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-09-26, presumably until 2020-09-26\n- 24 HR nicotine 0.292 MG/HR Transdermal System, through Transdermal route, started on 2020-09-27, presumably until 2020-09-27\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-09-26\n- metoclopramide 5 MG Oral Tablet, through Oral route, started on 2020-09-28, presumably until 2020-09-28\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2021-03-12, with intended 0 refill(s). Instructions: take 3 Tabs (3 mg total) by mouth daily\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-09-26, presumably until 2020-09-26\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2020-09-26, presumably until 2020-10-12, with intended 0 refill(s). Instructions: inject 0.5 mL (5,000 Units total) subcutaneous (under the skin) every 8 hours\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-09-28\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-09-28, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-09-27, presumably until 2020-09-27\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-09-28, presumably until 2020-09-28\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2020-09-28, presumably until 2020-09-28\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-09-26, presumably until 2020-09-27\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2020-09-26, presumably until 2021-01-10, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-10-03, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed G89.18\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-09-27\n- calcium carbonate 1000 MG Chewable Tablet, through Oral route, started on 2020-09-28, presumably until 2020-09-28\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- promethazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-27\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-03 17:46:37, ended at 2020-10-03 18:15:37\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Closed fracture of neck of femur\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet, through Sublingual route, started on 2020-10-03, presumably until 2020-12-11, with intended 2 refill(s). Instructions: place 1 Tab under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-04 00:00:00, ended at 2020-10-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture proximal phalanx, toe\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-05 10:12:00, ended at 2020-10-05 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Closed fracture proximal phalanx, toe\n- Closed fracture of neck of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-05 10:12:40, ended at 2020-10-05 11:36:23\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Closed treatment of femoral fracture, proximal end, neck; without manipulation\n\n### Condition\n- Closed fracture of neck of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-09 11:20:33, ended at 2020-10-09 11:57:37\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-09 13:37:26, ended at 2020-10-09 14:27:16\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n- Intraocular pressure of left eye: 22 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n\n### Condition\n- Interstitial lung disease\n- Primary diagnosis: Proliferative retinopathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-10-10, presumably until 2021-01-16, with intended 6 refill(s). Instructions: Apply to affected area  every day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-11 00:00:00, ended at 2020-10-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-23 00:00:00, ended at 2020-10-23 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture proximal phalanx, toe\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-31 13:55:47, ended at 2020-10-31 15:02:49\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-31 13:55:47, ended at 2020-10-31 15:40:24\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-09 09:38:00, ended at 2020-11-09 09:56:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Closed fracture proximal phalanx, toe\n- Closed fracture of neck of femur\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-09 09:38:11, ended at 2020-11-09 11:43:48\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of neck of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-09 09:57:00, ended at 2020-11-09 23:59:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, skull; complete, minimum of 4 views\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-14 00:00:00, ended at 2020-11-14 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2020-11-14, presumably until 2020-11-14, with intended 11 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-14 13:27:18, ended at 2020-11-14 13:56:43\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Primary diagnosis: Nausea and vomiting\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-14 15:04:09, ended at 2020-11-14 16:20:52\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-15 00:00:00, ended at 2020-11-15 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-19 00:00:00, ended at 2020-11-19 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2020-11-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, presumably until 2020-11-19, with intended 0 refill(s). Instructions: place 1 Tab under the tongue and let dissolve Q5 MIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-19 10:09:59, ended at 2020-11-19 10:35:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2020-11-21, presumably until 2021-10-13, with intended 11 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-11-22 00:00:00, ended at 2020-11-22 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-11-22, presumably until 2020-11-22\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-11-22, presumably until 2020-11-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-11-22, presumably until 2020-11-22\n- midazolam 1 MG/ML Injectable Solution, started on 2020-11-22, presumably until 2020-11-22\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-11-22, presumably until 2020-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-22 05:50:00, ended at 2020-11-22 09:44:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.9 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 4.5 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 138 (millimole per liter)\n- INR in Blood by Coagulation assay: 1.2 (ratio)\n- Hematocrit [Volume Fraction] of Blood: 32 (percent)\n\n### Procedure\n- Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis \n- Collection of venous blood by venipuncture\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n\n### Condition\n- Hyperlipidemia\n- Hypoglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Anemia in chronic kidney disease\n- Complication of surgical procedure\n- Pulmonary hypertension\n- Sarcoidosis\n- Stenosis due to any device, implant AND/OR graft\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Adverse effect of prosthetic device\n- End-stage renal disease\n- Polyneuropathy due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Disorder of soft tissue\n- Obstructive sleep apnea syndrome\n\n### Drug\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2020-11-22, presumably until 2020-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-27 13:04:51, ended at 2020-11-27 14:49:05\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Primary diagnosis: Sudden hearing loss\n- Mechanical complication of device\n- Sarcoidosis\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2020-11-27, presumably until 2020-12-02, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-27 15:07:59, ended at 2020-11-27 17:12:34\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2021-06-06, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) 4 times a day before meals and bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-29 00:00:00, ended at 2020-11-29 14:59:01\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sleep apnea\n- Obstructive sleep apnea syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-06 00:00:00, ended at 2020-12-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on nose and accessory sinuses; not otherwise specified\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication of internal device\n- Essential hypertension\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- hydrocortisone 100 MG Injection, started on 2020-12-06, presumably until 2020-12-06\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-12-06, presumably until 2020-12-06\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- cefazolin 1000 MG Injection, started on 2020-12-06, presumably until 2020-12-06\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- ketamine 100 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- midazolam 1 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-06 00:00:00, ended at 2020-12-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2020-12-06, presumably until 2020-12-06\n- potassium nitrate 250 MG/ML / silver nitrate 750 MG/ML Medicated Pad, through Topical route, started on 2020-12-06, presumably until 2020-12-06\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2020-12-06 07:44:00, ended at 2020-12-06 17:10:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 64 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 238 (unit per liter)\n- Base excess in Arterial blood by calculation: 2.6 (milliequivalent per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 381 (milligram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 6.7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 27.5 (milliequivalent per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 27.8 (millimeter mercury column)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n\n### Procedure\n- Removal of implant; superficial (eg, buried wire, pin or rod) (separate procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n- Renal disorder due to type 1 diabetes mellitus\n- Gastroesophageal reflux disease without esophagitis\n- Hypertensive heart and chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Sarcoidosis\n- Acute myocardial infarction\n- Anemia\n- Mechanical complication of device\n- Neurogenic bladder\n- Late effect of medical and surgical care complication\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2020-12-06, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 1 Putnam (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-12-06, presumably until 2020-12-06\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, started on 2020-12-06, presumably until 2021-01-02, with intended 0 refill(s). Instructions: take 1 Tab (650 mg total) by mouth every 4 to 6 hours as needed\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2020-12-06, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2020-12-06, presumably until 2020-12-06\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-12-06, presumably until 2020-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-11 13:51:43, ended at 2020-12-11 14:14:49\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Closed fracture of neck of femur\n- Primary diagnosis: Type 1 diabetes mellitus\n- Anemia\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Hearing loss\n- Obstructive sleep apnea syndrome\n\n### Drug\n- buprenorphine 5.7 MG / naloxone 1.4 MG Sublingual Tablet, through Sublingual route, started on 2020-12-11, presumably until 2021-01-02, with intended 0 refill(s). Instructions: place 1 Tab under the tongue and let dissolve every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-18 00:00:00, ended at 2020-12-18 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sleep apnea\n- Primary diagnosis: Primary central sleep apnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-18 11:07:51, ended at 2020-12-18 12:06:02\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-18 11:07:51, ended at 2020-12-18 14:11:26\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-27 00:00:00, ended at 2020-12-27 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstructive sleep apnea syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-29 11:21:09, ended at 2020-12-29 12:15:18\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Chronic pain\n- Primary diagnosis: Cataract\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-01-02 00:00:00, ended at 2021-01-02 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 265 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 245 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 8.11 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.78 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Prothrombin time (PT): 13.3 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.7 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 229 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 100.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2021-01-02 14:36:00, ended at 2021-01-08 22:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.42 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 18.6 (picogram per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.020 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.29 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 265 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 276 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 300 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Body height: 5' 10\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, pelvis; 1 or 2 views\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Replacement of Left Hip Joint, Femoral Surface with Synthetic Substitute, Cemented, Open Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Radiologic examination, hip, unilateral, with pelvis when performed; 2-3 views\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Open treatment of femoral fracture, proximal end, neck, internal fixation or prosthetic replacement\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n\n### Condition\n- Essential hypertension\n- Mononeuropathy of lower limb\n- Chronic kidney disease\n- Chronic kidney disease due to hypertension\n- Complication due to diabetes mellitus\n- Nausea and vomiting\n- End-stage renal disease\n- Hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic pain\n- Disorder of bone\n- Illness\n- Polyneuropathy due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Tachycardia\n- Acute posthemorrhagic anemia\n- Anemia in chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Bipolar disorder\n- Disorder of eye due to type 1 diabetes mellitus\n- Hip pain\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Polyneuropathy\n- Acute myocardial infarction\n- Primary diagnosis: Closed fracture of neck of femur\n- Disorder of upper gastrointestinal tract\n- Gastroesophageal reflux disease without esophagitis\n- Macular edema due to diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Hypertensive heart and chronic kidney disease\n- Persistent pain following procedure\n- Sarcoidosis\n- Chronic obstructive lung disease\n- Coronary artery graft present\n- Finding of urine output\n- Hypoglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 1 diabetes mellitus\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2021-01-04, presumably until 2021-01-05\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2021-01-06, presumably until 2021-01-08\n- 24 HR nicotine 0.875 MG/HR Transdermal System, through Transdermal route, started on 2021-01-02, presumably until 2021-01-07\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth every 8 hours\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2021-01-03, presumably until 2021-01-03\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2021-01-03, presumably until 2021-01-08\n- cefazolin 1000 MG Injection, started on 2021-01-04, presumably until 2021-01-05\n- 24 HR nicotine 0.292 MG/HR Transdermal System, through Transdermal route, started on 2021-01-05, presumably until 2021-01-07\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2021-01-03, presumably until 2021-01-06\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-08\n- sodium chloride 9 MG/ML Injection, started on 2021-01-04, presumably until 2021-01-05\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Prefilled Syringe, through Subcutaneous route, started on 2021-01-02, presumably until 2021-01-18, with intended 0 refill(s). Instructions: inject 0.5 mL (5,000 Units total) subcutaneous (under the skin) every 8 hours\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2021-01-05, presumably until 2021-01-08\n- 30 ML ropivacaine hydrochloride 5 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-05\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-05\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2021-01-03, presumably until 2021-01-04\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2021-01-04, presumably until 2021-01-15, with intended 0 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every 4 hours as needed (2mg moderate pain, 4mg severe pain) G89.18\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 650 mg by mouth every 4 to 6 hours as needed\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-08\n- 2 ML ondansetron 2 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2021-01-02, presumably until 2021-01-06\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet, through Sublingual route, started on 2021-01-04, presumably until 2021-01-08\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2021-01-02, presumably until 2021-01-07\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2021-01-04, presumably until 2021-01-08\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-03\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2021-01-07, presumably until 2021-01-07\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-07\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2021-01-05, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 1 Tab (81 mg total) by mouth every morning with breakfast Resuming home medication.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-02\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-03-31 14:46:00, ended at 2012-03-31 16:19:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 236 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.34 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Chronic pain\n- Dysuria\n- Abdominal pain\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus without complication\n- Congestive heart failure\n- Type 1 diabetes mellitus uncontrolled\n- Chronic kidney disease\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Nausea\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2012-03-31, presumably until 2012-04-30, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-20 00:00:00, ended at 2018-10-20 00:00:00\nThe patient in this visit was 45 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-05 12:36:05, ended at 2019-01-05 15:56:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary artery graft present\n- Mixed hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Pulmonary emphysema\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Anemia in chronic kidney disease\n- Chronic nephritic syndrome\n- End-stage renal disease\n- Essential hypertension\n- Vitamin D deficiency\n- Hyperparathyroidism due to renal insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-05 15:58:00, ended at 2019-01-05 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: <0.02 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-12 00:00:00, ended at 2019-01-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 00:00:00, ended at 2019-02-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 08:37:00, ended at 2019-02-23 13:35:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Primary diagnosis: Hearing loss of right ear\n- Atelectasis\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic pain\n- Obesity\n- Type 2 diabetes mellitus\n- Bilateral hearing loss\n- Heart failure\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic obstructive lung disease\n- Sudden hearing loss\n- Disorder of bronchus\n- Hypertensive heart and chronic kidney disease\n- Disorder of nervous system due to type 2 diabetes mellitus\n- End-stage renal disease\n- Hearing loss of left ear\n\n### Drug\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-03-05, with intended 0 refill(s). Instructions: take 1.5 Tabs (600 mg total) by mouth daily for 10 days\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-04-15, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily for 60 doses Take 6 tabs (60mg) daily for 3 days, then 5 tabs daily for 3 days, then 4 tabs daily for 3 days, then 3 tabs daily for 2 days, then 2 tabs daily for 2 days, then 1 tab daily for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-24 07:30:51, ended at 2019-02-24 12:44:18\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 200 mg by mouth\n- atorvastatin 10 MG Oral Tablet, started on 2018-12-19, presumably until 2019-04-15, with intended 0 refill(s)\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-01-14, presumably until 2019-04-15, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2018-12-12, presumably until 2019-04-15, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2019-02-19, presumably until 2019-04-15, with intended 0 refill(s)\n- losartan potassium 100 MG Oral Tablet, started on 2019-02-17, presumably until 2019-04-15, with intended 0 refill(s)\n- furosemide 80 MG Oral Tablet, started on 2018-12-21, presumably until 2019-04-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-24 07:31:03, ended at 2019-02-24 08:47:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sudden hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-03 09:57:52, ended at 2019-03-03 11:50:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-03 09:58:03, ended at 2019-03-03 11:50:40\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-08 07:24:30, ended at 2019-03-08 09:43:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-08 07:24:41, ended at 2019-03-08 08:42:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-09 07:17:57, ended at 2019-03-09 09:04:26\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-12 00:00:00, ended at 2019-03-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-23 08:42:00, ended at 2019-03-23 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Abnormal findings on diagnostic imaging of lung\n- Fibrosis of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-24 07:21:38, ended at 2019-03-24 10:09:25\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pure tone audiometry (threshold); air only\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-24 07:21:55, ended at 2019-03-24 12:22:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 12:57:53, ended at 2019-03-26 15:17:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 16:52:00, ended at 2019-03-26 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Atherosclerosis of aorta\n- Sensorineural hearing loss, bilateral\n- Opioid dependence in remission\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 11:55:31, ended at 2019-04-15 16:21:50\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication due to diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Retinal disorder\n- Type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Mixed conductive AND sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Chronic obstructive lung disease\n- Disorder of upper gastrointestinal tract\n- Heart failure\n- End-stage renal disease\n- Illness\n- Bipolar disorder in remission\n- Chronic pain\n- Pure hypercholesterolemia\n- Dependence on supplemental oxygen\n- Mechanical complication of peritoneal dialysis catheter\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-15 16:14:08, ended at 2019-04-15 17:19:35\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: End-stage renal disease\n- Retinal disorder\n- Complication due to diabetes mellitus\n- Pure hypercholesterolemia\n- Chronic pain\n- Mechanical complication of peritoneal dialysis catheter\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder in remission\n- Dependence on supplemental oxygen\n- Chronic obstructive lung disease\n- Heart failure\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Disorder of upper gastrointestinal tract\n- Type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2019-11-22, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n- vitamin E, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- selenomethionine, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n- cholecalciferol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- folic acid, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- wheat germ oil, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- alpha tocopherol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2019-07-07, with intended 1 refill(s). Instructions: place 1.5 Tabs under the tongue and let dissolve every day\n- zinc oxide, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-04-15, presumably until 2020-02-28, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-06, with intended 11 refill(s). Instructions: take 1 Tab (81 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 18 units under the skin at bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-26, with intended 11 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2020-04-14, with intended 11 refill(s). Instructions: place 1 Tab (0.4 mg total) under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-19 14:07:51, ended at 2019-04-19 17:41:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 19 (millimeter mercury column)\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Retinal neovascularization\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-20 12:25:18, ended at 2019-04-20 13:25:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Pulmonary hypertension\n- Severe nonproliferative retinopathy due to diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-04-20, presumably until 2019-05-04, with intended 5 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 14 days\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-20, presumably until 2019-04-26, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1-2 Tabs (4-8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-05-04, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-29 13:05:19, ended at 2019-04-29 15:15:57\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hearing loss\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2019-04-29, presumably until 2019-06-22, with intended 2 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 11:05:35, ended at 2019-05-04 13:44:21\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 13:34:13, ended at 2019-05-04 14:57:46\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- esomeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take by mouth every day\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2019-12-06, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every 6 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-05 13:45:06, ended at 2019-05-05 15:08:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Pulmonary emphysema\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 00:00:00, ended at 2019-05-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on lower anterior abdominal wall; not otherwise specified\n\n### Condition\n- Mechanical complication of peritoneal dialysis catheter\n- End-stage renal disease\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cefazolin 1000 MG Injection, started on 2019-05-07, presumably until 2019-05-07\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 07:10:00, ended at 2019-05-07 12:08:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.14 (millimole per liter)\n- Base excess in Arterial blood by calculation: 7.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.5 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Glucose [Mass/volume] in Blood: 320 (milligram per deciliter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 23.7 (millimeter mercury column)\n\n### Procedure\n- Removal of tunneled intraperitoneal catheter\n- Collection of venous blood by venipuncture\n- Removal of Infusion Device from Peritoneal Cavity, Open Approach\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: End-stage renal disease\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Mechanical complication of peritoneal dialysis catheter\n- Hyperlipidemia\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-05-07, presumably until 2019-05-11, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-07, presumably until 2019-05-11, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-11 09:13:38, ended at 2019-05-11 13:20:07\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2019-05-11, presumably until 2019-05-16, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2019-05-11, presumably until 2019-05-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-11 12:31:00, ended at 2019-05-11 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Disorder of brain\n- Hearing loss\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-18 10:33:23, ended at 2019-05-18 14:44:56\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 14:03:22, ended at 2019-05-21 15:43:17\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary hypertension\n- End-stage renal disease\n- Essential hypertension\n- Sensorineural hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for procedures on external, middle, and inner ear including biopsy; not otherwise specified\n\n### Condition\n- Chronic kidney disease\n- Essential hypertension\n- Sensorineural hearing loss, bilateral\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2019-05-27, presumably until 2019-05-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- ketamine 100 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium hyaluronate 10 MG/ML Prefilled Syringe, through Intraocular route, started on 2019-05-27, presumably until 2019-05-27\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 05:58:00, ended at 2019-05-27 12:20:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 5.5 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 63.1 (millimeter mercury column)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood: 27.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Oxygen [Partial pressure] in Arterial blood: 93.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Blood: 87 (milligram per deciliter)\n\n### Procedure\n- Cochlear device implantation, with or without mastoidectomy\n- Radiologic examination, skull; less than 4 views\n- Insertion of Single Channel Cochlear Prosthesis into Left Inner Ear, Open Approach\n\n### Condition\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Sarcoidosis\n- Heart failure\n- Old myocardial infarction\n- Retinopathy due to type 1 diabetes mellitus\n- Sensorineural hearing loss, bilateral\n- End-stage renal disease\n- Hypertensive heart and chronic kidney disease\n- Renal disorder due to type 1 diabetes mellitus\n- Uncomplicated asthma\n- Sensorineural hearing loss\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-05-27, presumably until 2019-06-26, with intended 0 refill(s). Instructions: take 1 Boley (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-05-27, presumably until 2019-05-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-05-22, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-15 08:37:55, ended at 2019-06-15 10:25:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-15 08:38:27, ended at 2019-06-15 11:04:42\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; with programming\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 15:18:47, ended at 2019-06-17 16:25:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Dependence on supplemental oxygen\n- Leukocytosis\n- Sarcoidosis\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperglycemia due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Sensorineural hearing loss\n- End-stage renal disease\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-06-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n- oxycodone hydrochloride 5 MG Oral Tablet, started on 2019-05-26, presumably until 2019-07-29, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-18 00:00:00, ended at 2019-06-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.41 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.57 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Leukocytosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-22 09:47:01, ended at 2019-06-22 10:28:28\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, presumably until 2019-07-29, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-06-22, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-22 13:45:04, ended at 2019-06-22 16:45:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-24 13:32:00, ended at 2019-06-24 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-06 00:00:00, ended at 2019-07-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-07-06, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily 15 mg (3 x 5 mg) for 1 mo, 10 mg (2 x 5 mg) for 1 mo, 5 mg (1 x 5 mg) for 1 mo then STOP.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-07 00:00:00, ended at 2019-07-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-07-07, presumably until 2019-08-05, with intended 0 refill(s). Instructions: DISSOLVE 1&1/2 TABLETS UNDER TONGUE ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-12 11:41:00, ended at 2019-07-12 12:03:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n\n### Condition\n- Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-13 11:35:08, ended at 2019-07-13 12:28:27\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-13 11:36:03, ended at 2019-07-13 15:03:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-23 00:00:00, ended at 2019-07-23 12:10:45\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin E, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol 0.05 MG Oral Tablet, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 1 tablet by oral route once daily\n- selenomethionine, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cefdinir 300 MG Oral Capsule, presumably until 2019-07-29, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- folic acid, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- ergocalciferol 1.25 MG Oral Capsule, started on 2014-03-15, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Take 1 capsule by mouth once a week for 10 weeks\n- wheat germ oil, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- alpha tocopherol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- sucroferric oxyhydroxide 500 MG Chewable Tablet, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Velphoro 500 mg chewable tablet\n- zinc oxide, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- lidocaine 0.05 MG/MG Medicated Patch, started on 2012-08-06, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Apply 1/2 patch to right foot, 1/2 patch to left foot once a day, may wear up to 12 hours.\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-09-28, presumably until 2019-11-23, with intended 11 refill(s). Instructions: inject 8 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-29 12:02:28, ended at 2019-07-29 12:55:15\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Chronic ulcer of foot\n- End-stage renal disease\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-07-29, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Kravitz (10,000 Units total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-05, presumably until 2019-08-06, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-06, presumably until 2019-09-17, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2019-08-23, presumably until 2019-10-06, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- folic acid, through Oral route, started on 2019-08-24, presumably until 2019-10-06, with intended 3 refill(s). Instructions: take 1 Tab (0.8 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:44:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:59:48\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2019-09-09, presumably until 2019-09-21, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-24, presumably until 2019-09-24, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-09-17, presumably until 2021-10-13, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2019-09-17, presumably until 2019-10-17, with intended 0 refill(s). Instructions: place 2 Tabs under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-22 00:00:00, ended at 2019-09-22 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-23, presumably until 2019-09-23, with intended 0 refill(s). Instructions: Dissolve one and one half under the tongue daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-28 11:52:23, ended at 2019-09-28 18:06:19\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.583\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Atherosclerosis of coronary artery without angina pectoris\n- End-stage renal disease\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Essential hypertension\n- Nicotine dependence\n- Nondependent opioid abuse in remission\n- Primary diagnosis: Type 1 diabetes mellitus\n- Opioid abuse\n- Chronic ulcer of foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-09-28, presumably until 2019-09-28, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- varenicline 1 MG Oral Tablet, through Oral route, started on 2019-09-28, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 0.5 Tabs (0.5 mg total) by mouth 2 times a day Take daily for first 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-30 15:21:18, ended at 2019-09-30 16:33:16\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n- Intraocular pressure of right eye: 18 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Primary diagnosis: Retinal neovascularization\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-04 13:40:14, ended at 2019-10-04 14:40:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n- Hypercalcemia\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2019-10-19, presumably until 2020-03-09, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-18 00:00:00, ended at 2019-10-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- biotin, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbate manganese, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbyl tetraisopalmitate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- folic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- zinc ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- potassium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- 6-O-palmitoylascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- magnesium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- calcium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- sodium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-20 12:25:42, ended at 2019-10-20 14:05:54\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-21 13:37:15, ended at 2019-10-21 15:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypersomnia\n- Gastroesophageal reflux disease without esophagitis\n- Nicotine dependence\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n- Cough\n\n### Drug\n- nicotine 2 MG Oral Lozenge, through Buccal route, started on 2019-10-21, presumably until 2021-05-16, with intended 6 refill(s). Instructions: place 2 mg inside cheek or to gum every 4 hours as needed\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2019-10-21, presumably until 2020-01-03, with intended 3 refill(s). Instructions: take 2 Tabs (40 mg total) by mouth daily\n- nicotine bitartrate, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n- nicotine, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 12:36:49, ended at 2019-10-28 14:38:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-10-29, presumably until 2022-07-30, with intended 0 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 7 days\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-08 00:00:00, ended at 2019-11-08 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-09 10:05:00, ended at 2019-11-09 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-09 10:05:06, ended at 2019-11-09 16:40:03\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-22 11:58:27, ended at 2019-11-22 15:11:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Opioid abuse\n- Pulmonary hypertension\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-23 00:00:00, ended at 2019-11-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Opioid abuse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 13:07:20, ended at 2019-11-26 13:47:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Determination of refractive state\n\n### Condition\n- Presbyopia\n- Primary diagnosis: Regular astigmatism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-06, presumably until 2019-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-09 12:11:19, ended at 2019-12-09 14:09:17\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-14 08:08:46, ended at 2019-12-14 09:14:42\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-15 00:00:00, ended at 2019-12-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-16, presumably until 2020-03-06, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 12:32:47, ended at 2019-12-21 15:44:55\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n- Retinal disorder\n- End-stage renal disease\n- Type 1 diabetes mellitus\n- Complication due to diabetes mellitus\n- Nicotine dependence\n- Polyneuropathy due to diabetes mellitus\n- Secondary diabetes mellitus\n- Primary diagnosis: Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 00:00:00, ended at 2019-12-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Pulmonary hypertension\n- Lymph node sarcoidosis\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Type 1 diabetes mellitus without complication\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-12-29, presumably until 2019-12-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 07:10:00, ended at 2019-12-29 10:09:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n- Radiologic examination, chest; single view\n\n### Condition\n- Chronic obstructive lung disease\n- Lymph node sarcoidosis\n- Old myocardial infarction\n- Primary diagnosis: Pulmonary hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Nicotine dependence\n- Essential hypertension\n- Heart failure\n- Post-inflammatory pulmonary fibrosis\n- Abnormal findings on diagnostic imaging of lung\n- Hyperlipidemia\n- Interstitial lung disease\n- Disorder of lung\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Pulmonary sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-31 00:00:00, ended at 2019-12-31 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-03 14:07:08, ended at 2020-01-03 15:25:08\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Primary diagnosis: Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-01-04 00:00:00, ended at 2020-01-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-04, presumably until 2020-01-05, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-05 00:00:00, ended at 2020-01-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-05, presumably until 2020-06-08, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:10:00, ended at 2020-01-06 12:24:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 29.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.52 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 102.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 326 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperosmolarity\n- Hypercalcemia\n- Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:25:00, ended at 2020-01-06 13:06:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Sarcoidosis\n- Closed fracture of second metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of first metatarsal bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:07:00, ended at 2020-01-06 13:19:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Closed fracture of first metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of second metatarsal bone\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Interstitial lung disease\n- Sarcoidosis\n- Dyspnea\n- Hyperosmolarity\n- Secondary diabetes mellitus\n- Hypercalcemia\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-06 14:09:28, ended at 2020-01-06 16:00:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-11 09:30:59, ended at 2020-01-11 10:16:22\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-12 10:30:00, ended at 2020-01-12 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Type 2 diabetes mellitus\n- Type 1 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-18 11:42:19, ended at 2020-01-18 12:43:33\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-30 00:00:00, ended at 2020-01-30 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n\n### Drug\n- 24 HR nicotine 0.875 MG/HR Transdermal System, started on 2020-02-01, presumably until 2021-05-16, with intended 2 refill(s). Instructions: APPLY ONE PATCH EXTERNALLY ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-06 00:00:00, ended at 2020-02-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium acetate 667 MG Oral Capsule, started on 2020-02-07, presumably until 2020-04-10, with intended 4 refill(s). Instructions: TAKE TWO CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-02-10, with intended 0 refill(s). Instructions: Take 1 capsule now and then 1 after next 3 dialysis sessions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-11 00:00:00, ended at 2020-02-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-11, presumably until 2020-02-24, with intended 0 refill(s). Instructions: APPLY TOPICALLY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-15 10:15:00, ended at 2020-02-15 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Closed fracture of first metatarsal bone\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-15 10:38:28, ended at 2020-02-15 11:17:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-23 00:00:00, ended at 2020-02-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-24, presumably until 2020-05-08, with intended 3 refill(s). Instructions: apply to affected area topically as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- ascorbate manganese, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbyl tetraisopalmitate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- folic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- zinc ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- potassium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- 6-O-palmitoylascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- magnesium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- calcium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- sodium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- biotin, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2020-02-28, presumably until 2021-02-27, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-05 00:00:00, ended at 2020-03-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2020-03-06, presumably until 2021-03-14, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE A DAY AS NEEDED FOR NAUSEA \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-03-09, presumably until 2020-08-04, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-09 12:18:40, ended at 2020-03-09 12:48:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Hyperglycemia due to type 1 diabetes mellitus\n- Nicotine dependence\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Anemia\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-04-06, with intended 0 refill(s)\n- 3 ML insulin lispro 200 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-09, presumably until 2021-03-15, with intended 11 refill(s). Instructions: inject 6-10 Units subcutaneous (under the skin) before meals\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-03-09, presumably until 2021-03-19, with intended 11 refill(s). Instructions: Inject 30 units under the skin at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-22 00:00:00, ended at 2020-03-22 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-24 13:41:40, ended at 2020-03-24 13:51:46\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-28 09:16:21, ended at 2020-03-28 09:27:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-06 14:27:38, ended at 2020-04-06 15:01:14\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Type 2 diabetes mellitus\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-04-06, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-13 14:48:23, ended at 2020-04-13 15:32:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-20 10:33:00, ended at 2020-04-20 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Sarcoidosis\n- Primary diagnosis: Interstitial lung disease\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-26 00:00:00, ended at 2020-04-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-04-26, presumably until 2021-06-14, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-02 00:00:00, ended at 2020-05-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-04 08:28:00, ended at 2020-05-04 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Type 2 diabetes mellitus\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-07 00:00:00, ended at 2020-05-07 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-05-08, presumably until 2020-10-10, with intended 11 refill(s). Instructions: APPLY TOPICALLY TO THE AFFECTED AREA AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-20 00:00:00, ended at 2020-05-20 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, started on 2020-05-22, presumably until 2021-03-12, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-23 16:51:43, ended at 2020-05-23 17:08:13\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-05-30 09:22:08, ended at 2020-05-30 10:18:31\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Primary diagnosis: Sciatica\n\n### Drug\n- Twice-Daily diclofenac epolamine 0.013 MG/MG Medicated Patch, through Transdermal route, started on 2020-05-30, presumably until 2020-09-28, with intended 3 refill(s). Instructions: apply 1 Patch to skin 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-30 09:59:00, ended at 2020-05-30 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Sciatica\n- Fracture of phalanx of foot\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-05 12:18:16, ended at 2020-06-05 12:49:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pain\n- Disorder of sacrum\n- Primary diagnosis: Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-06 09:50:00, ended at 2020-06-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of bone\n- Disorder of thigh\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-08 15:23:12, ended at 2020-06-08 16:01:32\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-15 13:24:08, ended at 2020-06-15 14:45:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-16 16:50:15, ended at 2020-06-16 17:19:24\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n- Chronic pain\n- Type 2 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Primary diagnosis: Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-28 09:19:30, ended at 2020-06-28 10:51:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Intervertebral disc disorder of lumbar region with myelopathy\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2020-06-28, presumably until 2020-08-15, with intended 2 refill(s). Instructions: Apply a small amount, up to 2 grams, 2-3 times per day if needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-03 00:00:00, ended at 2020-07-03 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dependence on enabling machine or device\n- Primary diagnosis: Obstructive sleep apnea syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-01 09:39:00, ended at 2020-08-01 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Obstructive sleep apnea syndrome\n- Dyspnea\n- Hyperglycemia due to type 1 diabetes mellitus\n- Localized enlarged lymph nodes\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Chronic pulmonary edema\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-01 14:21:03, ended at 2020-08-01 14:44:49\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Obstructive sleep apnea syndrome\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-03 00:00:00, ended at 2020-08-03 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-08-04, presumably until 2020-09-05, with intended 0 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-03 16:21:24, ended at 2020-08-03 16:57:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Seronegative rheumatoid arthritis\n- Rheumatoid arthritis - hand joint\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- 0.4 ML adalimumab 100 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-08-04, presumably until 2020-11-22, with intended 6 refill(s). Instructions: inject 40 mg subcutaneous (under the skin) every 2 weeks\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-05 00:00:00, ended at 2020-08-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-08-07, presumably until 2020-08-07, with intended 0 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-07 13:08:56, ended at 2020-08-07 13:51:02\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of right eye: 20 (millimeter mercury column)\n- Intraocular pressure of left eye: 21 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal neovascularization\n- Primary diagnosis: Proliferative retinopathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-09 10:01:12, ended at 2020-08-09 11:29:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2020-08-15, presumably until 2020-09-07, with intended 0 refill(s). Instructions: Apply a small amount, up to 2 grams, 2-3 times per day if needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 10:09:54, ended at 2020-08-15 10:26:45\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstructive sleep apnea syndrome\n- Primary central sleep apnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-16 11:17:48, ended at 2020-08-16 11:53:16\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Seronegative rheumatoid arthritis\n- Rheumatoid arthritis - hand joint\n- Sarcoidosis\n- Primary diagnosis: Lumbar radiculopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-17 00:00:00, ended at 2020-08-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-29 13:11:03, ended at 2020-08-29 15:19:32\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-05 00:00:00, ended at 2020-09-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2020-09-07, presumably until 2020-09-28, with intended 0 refill(s). Instructions: Apply UP TO 2 GRAMS to affected area twice TO 3 TIMES daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-05 00:00:00, ended at 2020-09-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-09-05, presumably until 2020-10-03, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-06 00:00:00, ended at 2020-09-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-07 09:19:00, ended at 2020-09-07 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Metatarsal bone fracture\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in right foot\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-15 00:00:00, ended at 2020-09-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-19 08:00:00, ended at 2020-09-19 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Neuropathic arthropathy due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in right foot\n- Pain in left foot\n- Onychomycosis due to dermatophyte\n- Secondary diabetes mellitus\n- Sciatica\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2020-09-26 00:00:00, ended at 2020-09-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 268 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.16 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 39 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 311 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Prothrombin time (PT): 13.4 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- MCV [Entitic volume] by Automated count: 100.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.50 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 227 (unit per liter)\n- Base excess in Blood by calculation: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2020-09-26 12:11:00, ended at 2020-09-28 20:31:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Left ventricular Ejection fraction: 57.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.57 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Body height: 5' 9\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.50 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 311 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.9 (percent)\n- Prothrombin time (PT): 13.4 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 227 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Glucose [Mass/volume] in Blood: 491 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Base excess in Blood by calculation: 4 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.28 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 101.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 235 (thousand per microliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Radiologic examination, hip, unilateral, with pelvis when performed; 2-3 views\n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, pelvis; 1 or 2 views\n- Collection of venous blood by venipuncture\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Radiologic examination, femur; minimum 2 views\n\n### Condition\n- Bilateral hearing loss\n- Chest pain\n- Chronic pain\n- Pain provoked by trauma\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Gastroesophageal reflux disease without esophagitis\n- Hyperparathyroidism due to renal insufficiency\n- Pulmonary sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Retinopathy due to type 1 diabetes mellitus\n- Chronic obstructive lung disease\n- Primary diagnosis: Closed fracture of neck of femur\n- Fibrosis of lung\n- Hip pain\n- Polyneuropathy due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Coronary artery graft present\n- Falls\n- Pulmonary hypertension\n- Pure hypercholesterolemia\n- Anemia in chronic kidney disease\n- Hypertensive heart and chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Macular edema due to diabetes mellitus\n- Hyperlipidemia\n- Nicotine dependence\n- Bipolar disorder\n- End-stage renal disease\n- Sarcoidosis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2021-01-02, with intended 0 refill(s). Instructions: take 2 Tabs (650 mg total) by mouth every 6 hours\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2020-09-28, presumably until 2020-09-28\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-09-26, presumably until 2020-09-26\n- 24 HR nicotine 0.292 MG/HR Transdermal System, through Transdermal route, started on 2020-09-27, presumably until 2020-09-27\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-09-26\n- metoclopramide 5 MG Oral Tablet, through Oral route, started on 2020-09-28, presumably until 2020-09-28\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2021-03-12, with intended 0 refill(s). Instructions: take 3 Tabs (3 mg total) by mouth daily\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-09-26, presumably until 2020-09-26\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2020-09-26, presumably until 2020-10-12, with intended 0 refill(s). Instructions: inject 0.5 mL (5,000 Units total) subcutaneous (under the skin) every 8 hours\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-09-28\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-09-28, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-09-27, presumably until 2020-09-27\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-09-28, presumably until 2020-09-28\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2020-09-28, presumably until 2020-09-28\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-09-26, presumably until 2020-09-27\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2020-09-26, presumably until 2021-01-10, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-10-03, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed G89.18\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-09-27\n- calcium carbonate 1000 MG Chewable Tablet, through Oral route, started on 2020-09-28, presumably until 2020-09-28\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n- promethazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-27\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2020-09-27, presumably until 2020-09-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-03 17:46:37, ended at 2020-10-03 18:15:37\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Closed fracture of neck of femur\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet, through Sublingual route, started on 2020-10-03, presumably until 2020-12-11, with intended 2 refill(s). Instructions: place 1 Tab under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-04 00:00:00, ended at 2020-10-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture proximal phalanx, toe\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-05 10:12:00, ended at 2020-10-05 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Closed fracture proximal phalanx, toe\n- Closed fracture of neck of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-05 10:12:40, ended at 2020-10-05 11:36:23\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Closed treatment of femoral fracture, proximal end, neck; without manipulation\n\n### Condition\n- Closed fracture of neck of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-09 11:20:33, ended at 2020-10-09 11:57:37\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-09 13:37:26, ended at 2020-10-09 14:27:16\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n- Intraocular pressure of left eye: 22 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n\n### Condition\n- Interstitial lung disease\n- Primary diagnosis: Proliferative retinopathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-10-10, presumably until 2021-01-16, with intended 6 refill(s). Instructions: Apply to affected area  every day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-11 00:00:00, ended at 2020-10-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-23 00:00:00, ended at 2020-10-23 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture proximal phalanx, toe\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-31 13:55:47, ended at 2020-10-31 15:02:49\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-31 13:55:47, ended at 2020-10-31 15:40:24\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-09 09:38:00, ended at 2020-11-09 09:56:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hip, unilateral, with pelvis when performed; 1 view\n\n### Condition\n- Closed fracture proximal phalanx, toe\n- Closed fracture of neck of femur\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-09 09:38:11, ended at 2020-11-09 11:43:48\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture of neck of femur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-09 09:57:00, ended at 2020-11-09 23:59:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, skull; complete, minimum of 4 views\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-14 00:00:00, ended at 2020-11-14 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2020-11-14, presumably until 2020-11-14, with intended 11 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-14 13:27:18, ended at 2020-11-14 13:56:43\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Primary diagnosis: Nausea and vomiting\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-14 15:04:09, ended at 2020-11-14 16:20:52\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-15 00:00:00, ended at 2020-11-15 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-19 00:00:00, ended at 2020-11-19 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2020-11-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, presumably until 2020-11-19, with intended 0 refill(s). Instructions: place 1 Tab under the tongue and let dissolve Q5 MIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-19 10:09:59, ended at 2020-11-19 10:35:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2020-11-21, presumably until 2021-10-13, with intended 11 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-11-22 00:00:00, ended at 2020-11-22 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-11-22, presumably until 2020-11-22\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-11-22, presumably until 2020-11-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-11-22, presumably until 2020-11-22\n- midazolam 1 MG/ML Injectable Solution, started on 2020-11-22, presumably until 2020-11-22\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-11-22, presumably until 2020-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-22 05:50:00, ended at 2020-11-22 09:44:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.9 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 4.5 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 138 (millimole per liter)\n- INR in Blood by Coagulation assay: 1.2 (ratio)\n- Hematocrit [Volume Fraction] of Blood: 32 (percent)\n\n### Procedure\n- Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis \n- Collection of venous blood by venipuncture\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n\n### Condition\n- Hyperlipidemia\n- Hypoglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Anemia in chronic kidney disease\n- Complication of surgical procedure\n- Pulmonary hypertension\n- Sarcoidosis\n- Stenosis due to any device, implant AND/OR graft\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Adverse effect of prosthetic device\n- End-stage renal disease\n- Polyneuropathy due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Disorder of soft tissue\n- Obstructive sleep apnea syndrome\n\n### Drug\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2020-11-22, presumably until 2020-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-27 13:04:51, ended at 2020-11-27 14:49:05\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Primary diagnosis: Sudden hearing loss\n- Mechanical complication of device\n- Sarcoidosis\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2020-11-27, presumably until 2020-12-02, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-27 15:07:59, ended at 2020-11-27 17:12:34\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2021-06-06, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) 4 times a day before meals and bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-29 00:00:00, ended at 2020-11-29 14:59:01\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sleep apnea\n- Obstructive sleep apnea syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-06 00:00:00, ended at 2020-12-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on nose and accessory sinuses; not otherwise specified\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication of internal device\n- Essential hypertension\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- hydrocortisone 100 MG Injection, started on 2020-12-06, presumably until 2020-12-06\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-12-06, presumably until 2020-12-06\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- cefazolin 1000 MG Injection, started on 2020-12-06, presumably until 2020-12-06\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- ketamine 100 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- midazolam 1 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-06 00:00:00, ended at 2020-12-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2020-12-06, presumably until 2020-12-06\n- potassium nitrate 250 MG/ML / silver nitrate 750 MG/ML Medicated Pad, through Topical route, started on 2020-12-06, presumably until 2020-12-06\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-12-06, presumably until 2020-12-06\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2020-12-06 07:44:00, ended at 2020-12-06 17:10:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 64 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 238 (unit per liter)\n- Base excess in Arterial blood by calculation: 2.6 (milliequivalent per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 381 (milligram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 6.7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 27.5 (milliequivalent per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 27.8 (millimeter mercury column)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n\n### Procedure\n- Removal of implant; superficial (eg, buried wire, pin or rod) (separate procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n- Renal disorder due to type 1 diabetes mellitus\n- Gastroesophageal reflux disease without esophagitis\n- Hypertensive heart and chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Sarcoidosis\n- Acute myocardial infarction\n- Anemia\n- Mechanical complication of device\n- Neurogenic bladder\n- Late effect of medical and surgical care complication\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2020-12-06, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 1 Putnam (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-12-06, presumably until 2020-12-06\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, started on 2020-12-06, presumably until 2021-01-02, with intended 0 refill(s). Instructions: take 1 Tab (650 mg total) by mouth every 4 to 6 hours as needed\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2020-12-06, presumably until 2020-12-06\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2020-12-06, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2020-12-06, presumably until 2020-12-06\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-12-06, presumably until 2020-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-11 13:51:43, ended at 2020-12-11 14:14:49\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Closed fracture of neck of femur\n- Primary diagnosis: Type 1 diabetes mellitus\n- Anemia\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Hearing loss\n- Obstructive sleep apnea syndrome\n\n### Drug\n- buprenorphine 5.7 MG / naloxone 1.4 MG Sublingual Tablet, through Sublingual route, started on 2020-12-11, presumably until 2021-01-02, with intended 0 refill(s). Instructions: place 1 Tab under the tongue and let dissolve every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-18 00:00:00, ended at 2020-12-18 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sleep apnea\n- Primary diagnosis: Primary central sleep apnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-18 11:07:51, ended at 2020-12-18 12:06:02\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-18 11:07:51, ended at 2020-12-18 14:11:26\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-27 00:00:00, ended at 2020-12-27 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstructive sleep apnea syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-29 11:21:09, ended at 2020-12-29 12:15:18\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Chronic pain\n- Primary diagnosis: Cataract\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-01-02 00:00:00, ended at 2021-01-02 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 265 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 245 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 8.11 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.78 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Prothrombin time (PT): 13.3 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.7 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 229 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 100.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2021-01-02 14:36:00, ended at 2021-01-08 22:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.42 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 18.6 (picogram per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.020 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.29 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 265 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 276 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 300 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Body height: 5' 10\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An \n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, pelvis; 1 or 2 views\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Replacement of Left Hip Joint, Femoral Surface with Synthetic Substitute, Cemented, Open Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Radiologic examination, hip, unilateral, with pelvis when performed; 2-3 views\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Open treatment of femoral fracture, proximal end, neck, internal fixation or prosthetic replacement\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n\n### Condition\n- Essential hypertension\n- Mononeuropathy of lower limb\n- Chronic kidney disease\n- Chronic kidney disease due to hypertension\n- Complication due to diabetes mellitus\n- Nausea and vomiting\n- End-stage renal disease\n- Hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic pain\n- Disorder of bone\n- Illness\n- Polyneuropathy due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Tachycardia\n- Acute posthemorrhagic anemia\n- Anemia in chronic kidney disease\n- Obstructive sleep apnea syndrome\n- Type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Bipolar disorder\n- Disorder of eye due to type 1 diabetes mellitus\n- Hip pain\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Polyneuropathy\n- Acute myocardial infarction\n- Primary diagnosis: Closed fracture of neck of femur\n- Disorder of upper gastrointestinal tract\n- Gastroesophageal reflux disease without esophagitis\n- Macular edema due to diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Hypertensive heart and chronic kidney disease\n- Persistent pain following procedure\n- Sarcoidosis\n- Chronic obstructive lung disease\n- Coronary artery graft present\n- Finding of urine output\n- Hypoglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 1 diabetes mellitus\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2021-01-04, presumably until 2021-01-05\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2021-01-06, presumably until 2021-01-08\n- 24 HR nicotine 0.875 MG/HR Transdermal System, through Transdermal route, started on 2021-01-02, presumably until 2021-01-07\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth every 8 hours\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2021-01-03, presumably until 2021-01-03\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2021-01-03, presumably until 2021-01-08\n- cefazolin 1000 MG Injection, started on 2021-01-04, presumably until 2021-01-05\n- 24 HR nicotine 0.292 MG/HR Transdermal System, through Transdermal route, started on 2021-01-05, presumably until 2021-01-07\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2021-01-03, presumably until 2021-01-06\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-08\n- sodium chloride 9 MG/ML Injection, started on 2021-01-04, presumably until 2021-01-05\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Prefilled Syringe, through Subcutaneous route, started on 2021-01-02, presumably until 2021-01-18, with intended 0 refill(s). Instructions: inject 0.5 mL (5,000 Units total) subcutaneous (under the skin) every 8 hours\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2021-01-05, presumably until 2021-01-08\n- 30 ML ropivacaine hydrochloride 5 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-05\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-05\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2021-01-03, presumably until 2021-01-04\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2021-01-04, presumably until 2021-01-15, with intended 0 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every 4 hours as needed (2mg moderate pain, 4mg severe pain) G89.18\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, presumably until 2021-01-08, with intended 0 refill(s). Instructions: take 650 mg by mouth every 4 to 6 hours as needed\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-08\n- 2 ML ondansetron 2 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2021-01-02, presumably until 2021-01-06\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2021-01-03, presumably until 2021-01-08\n- buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet, through Sublingual route, started on 2021-01-04, presumably until 2021-01-08\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2021-01-02, presumably until 2021-01-07\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2021-01-04, presumably until 2021-01-08\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-03\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2021-01-07, presumably until 2021-01-07\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2021-01-02, presumably until 2021-01-07\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2021-01-05, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 1 Tab (81 mg total) by mouth every morning with breakfast Resuming home medication.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2021-01-02, presumably until 2021-01-02\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2021-01-08 22:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "f5040b8d3fee150fb98c5c6b31fb54c1e7fc7d1b1718b357931698a3766012b6", "prompt_hash": "4a235818df74066f4516659cb91f75ffca624cd523933b7608931d51293583af", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 1.0, "f1_gu_yn": [1, 1], "recall_gu_yn": [1, 1]}
{"doc_id": 4, "doc": {"person_id": 115967856, "visit_occurrence_id": 39493534, "death_date": "2020-06-30", "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2010-05-15 12:48:00", "visit_end_datetime": "2010-05-18 09:50:00", "visit_length_in_hours": 69.03333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2010-05-15 12:48:00, ended at 2010-05-18 09:50:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.09 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 175 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.81 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.40 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Bone graft\n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Revision of total hip replacement\n- Radiologic examination, pelvis; 1 or 2 views\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Chronic hepatitis C\n- Mitral valve disorder\n- Primary cardiomyopathy\n- Asthma\n- Essential hypertension\n- Joint derangement\n- Periprosthetic osteolysis\n- Prosthetic joint dislocation\n- Prosthetic joint loosening\n- Disorder of hip joint\n- Bone marrow transplant present\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous gluconate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous fumarate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous ascorbate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron,peptonized, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous succinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous bisglycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous cysteine glycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous aspartate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ammonium ferrous sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- soy protein-iron complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2010-05-15, presumably until 2010-05-15\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2010-05-17, presumably until 2010-05-17\n- ferrous carbonate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-17\n- ferrous glycine sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- folic acid, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-05-17, presumably until 2013-06-11, with quantity of 11.0, with intended 0 refill(s). Instructions: 40 mg by SUBCUTANEOUS route daily. \n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2010-05-15, presumably until 2010-05-16\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2010-05-15, presumably until 2010-05-16\n- iron succinyl milk protein complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron-dextran complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- teferrol, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-16\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-05-16, presumably until 2011-05-17, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- ferrous asparto glycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous cacodylate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-05-15, presumably until 2010-05-16\n- iron, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous oxalate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2010-05-17, presumably until 2010-05-17\n- iron sucrose, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron carbonyl, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous lactate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous chloride, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-16\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-05-16, presumably until 2010-05-18\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-11-13, with quantity of 90.0, with intended 0 refill(s). Instructions: take 2-4 Tabs by mouth every 4 hours as needed \n- iron sorbitex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous phosphate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2013-06-11. Instructions: take by mouth 2 times a day. \n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-05-15, presumably until 2010-05-15\n\n", "approximate_token_count": 2169, "patient_first_visit_date": "2008-02-17 00:00:00", "patient_last_visit_date": "2018-10-23 10:43:00", "end_obs_date": "2011-05-18", "readmission_30d": 0, "visit_sequence_number": 16, "cumulated_visit_num": 16, "cumulated_approximate_token_count": 6639, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2008-02-17 00:00:00, ended at 2008-02-17 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.89 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 267 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.19 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.67 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-03-10 00:00:00, ended at 2008-03-10 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 32 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.62 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.3 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.82 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.75 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-03-24 00:00:00, ended at 2008-03-24 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.60 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 45 (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.39 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 350 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Alpha-1-fetoprotein.tumor marker [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 79 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.30 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Prothrombin time (PT): 13.5 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- MCV [Entitic volume] by Automated count: 92.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-22 11:30:15, ended at 2009-09-22 13:22:26\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Joint pain of pelvic region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-22 12:07:00, ended at 2009-09-22 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hips, bilateral, minimum of 2 views of each hip, including anteroposterior view of pelvis\n\n### Condition\n- Joint pain of pelvic region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-23 15:01:05, ended at 2009-09-23 15:48:43\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-23 15:57:00, ended at 2009-09-23 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 87.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 144 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.78 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 328 (thousand per microliter)\n- Prothrombin time (PT): 13.1 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.5 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary cardiomyopathy\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-19 14:30:00, ended at 2009-10-19 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-11-19 00:00:00, ended at 2009-11-19 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint derangement\n- Primary diagnosis: Disorder of hip joint\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2009-11-19, presumably until 2010-05-18, with quantity of 8.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-06 12:42:36, ended at 2009-12-06 13:53:39\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mechanical complication of internal orthopedic device, implant AND/OR graft\n- Primary diagnosis: Disorder of hip joint\n- Primary diagnosis: Joint derangement\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-03-16 13:06:25, ended at 2010-03-16 15:37:46\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Prosthetic arthroplasty of hip\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-16 14:16:00, ended at 2010-03-16 16:16:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, pelvis; complete, minimum of 3 views\n- Radiologic examination, hip, unilateral; complete, minimum of 2 views\n\n### Condition\n- Aseptic necrosis of bone\n- Mechanical complication of internal joint prosthesis\n- Congenital subluxation of hip\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-03-20 00:00:00, ended at 2010-03-20 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of hip joint\n- Primary diagnosis: Joint derangement\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2010-03-20, presumably until 2010-09-16. Instructions: take 1 Tab by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-02 11:55:20, ended at 2010-05-02 14:14:25\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Pre-surgery evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-02 14:21:00, ended at 2010-05-02 23:59:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.28 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.81 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 10.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.3 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 258 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Prothrombin time (PT): 12.9 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Joint derangement\n- Disorder of hip joint\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-05-15 12:48:00, ended at 2010-05-18 09:50:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.09 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 175 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.81 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.40 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Bone graft\n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Revision of total hip replacement\n- Radiologic examination, pelvis; 1 or 2 views\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Chronic hepatitis C\n- Mitral valve disorder\n- Primary cardiomyopathy\n- Asthma\n- Essential hypertension\n- Joint derangement\n- Periprosthetic osteolysis\n- Prosthetic joint dislocation\n- Prosthetic joint loosening\n- Disorder of hip joint\n- Bone marrow transplant present\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous gluconate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous fumarate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous ascorbate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron,peptonized, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous succinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous bisglycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous cysteine glycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous aspartate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ammonium ferrous sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- soy protein-iron complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2010-05-15, presumably until 2010-05-15\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2010-05-17, presumably until 2010-05-17\n- ferrous carbonate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-17\n- ferrous glycine sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- folic acid, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-05-17, presumably until 2013-06-11, with quantity of 11.0, with intended 0 refill(s). Instructions: 40 mg by SUBCUTANEOUS route daily. \n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2010-05-15, presumably until 2010-05-16\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2010-05-15, presumably until 2010-05-16\n- iron succinyl milk protein complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron-dextran complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- teferrol, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-16\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-05-16, presumably until 2011-05-17, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- ferrous asparto glycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous cacodylate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-05-15, presumably until 2010-05-16\n- iron, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous oxalate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2010-05-17, presumably until 2010-05-17\n- iron sucrose, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron carbonyl, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous lactate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous chloride, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-16\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-05-16, presumably until 2010-05-18\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-11-13, with quantity of 90.0, with intended 0 refill(s). Instructions: take 2-4 Tabs by mouth every 4 hours as needed \n- iron sorbitex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous phosphate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2013-06-11. Instructions: take by mouth 2 times a day. \n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-05-15, presumably until 2010-05-15\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-02-17 00:00:00, ended at 2008-02-17 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.89 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 267 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.19 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.67 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-03-10 00:00:00, ended at 2008-03-10 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 32 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.62 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.3 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.82 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.75 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-03-24 00:00:00, ended at 2008-03-24 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.60 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 45 (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.39 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 350 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Alpha-1-fetoprotein.tumor marker [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 79 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.30 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Prothrombin time (PT): 13.5 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- MCV [Entitic volume] by Automated count: 92.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-22 11:30:15, ended at 2009-09-22 13:22:26\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Joint pain of pelvic region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-22 12:07:00, ended at 2009-09-22 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, hips, bilateral, minimum of 2 views of each hip, including anteroposterior view of pelvis\n\n### Condition\n- Joint pain of pelvic region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-23 15:01:05, ended at 2009-09-23 15:48:43\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-23 15:57:00, ended at 2009-09-23 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 87.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 144 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.78 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 328 (thousand per microliter)\n- Prothrombin time (PT): 13.1 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.5 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary cardiomyopathy\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-19 14:30:00, ended at 2009-10-19 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-11-19 00:00:00, ended at 2009-11-19 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint derangement\n- Primary diagnosis: Disorder of hip joint\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2009-11-19, presumably until 2010-05-18, with quantity of 8.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-06 12:42:36, ended at 2009-12-06 13:53:39\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mechanical complication of internal orthopedic device, implant AND/OR graft\n- Primary diagnosis: Disorder of hip joint\n- Primary diagnosis: Joint derangement\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-03-16 13:06:25, ended at 2010-03-16 15:37:46\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Prosthetic arthroplasty of hip\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-16 14:16:00, ended at 2010-03-16 16:16:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, pelvis; complete, minimum of 3 views\n- Radiologic examination, hip, unilateral; complete, minimum of 2 views\n\n### Condition\n- Aseptic necrosis of bone\n- Mechanical complication of internal joint prosthesis\n- Congenital subluxation of hip\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-03-20 00:00:00, ended at 2010-03-20 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of hip joint\n- Primary diagnosis: Joint derangement\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2010-03-20, presumably until 2010-09-16. Instructions: take 1 Tab by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-02 11:55:20, ended at 2010-05-02 14:14:25\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Pre-surgery evaluation\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-02 14:21:00, ended at 2010-05-02 23:59:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.28 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.81 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 10.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.3 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 258 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Prothrombin time (PT): 12.9 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Joint derangement\n- Disorder of hip joint\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-05-15 12:48:00, ended at 2010-05-18 09:50:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.09 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 175 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.81 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.40 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Bone graft\n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Revision of total hip replacement\n- Radiologic examination, pelvis; 1 or 2 views\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Chronic hepatitis C\n- Mitral valve disorder\n- Primary cardiomyopathy\n- Asthma\n- Essential hypertension\n- Joint derangement\n- Periprosthetic osteolysis\n- Prosthetic joint dislocation\n- Prosthetic joint loosening\n- Disorder of hip joint\n- Bone marrow transplant present\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous gluconate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous fumarate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous ascorbate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron,peptonized, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous succinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous bisglycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous cysteine glycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous aspartate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ammonium ferrous sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- soy protein-iron complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2010-05-15, presumably until 2010-05-15\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2010-05-17, presumably until 2010-05-17\n- ferrous carbonate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-17\n- ferrous glycine sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- folic acid, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-05-17, presumably until 2013-06-11, with quantity of 11.0, with intended 0 refill(s). Instructions: 40 mg by SUBCUTANEOUS route daily. \n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2010-05-15, presumably until 2010-05-16\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2010-05-15, presumably until 2010-05-16\n- iron succinyl milk protein complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron-dextran complex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- teferrol, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-16\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-05-16, presumably until 2011-05-17, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- ferrous asparto glycinate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous cacodylate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-05-15, presumably until 2010-05-16\n- iron, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous oxalate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2010-05-17, presumably until 2010-05-17\n- iron sucrose, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous sulfate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- iron carbonyl, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous lactate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous chloride, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-16\n- 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-05-16, presumably until 2010-05-18\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-11-13, with quantity of 90.0, with intended 0 refill(s). Instructions: take 2-4 Tabs by mouth every 4 hours as needed \n- iron sorbitex, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- ferrous phosphate, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2013-06-11. Instructions: take by mouth 2 times a day. \n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-05-18\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-05-15, presumably until 2010-05-15\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2010-05-18 09:50:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "4046b932a0f3fd61d809cd0071a8264222ae24ffa8bae32169b430e8f7a7e626", "prompt_hash": "30c535e4798e700a526ef0b95e6f77258cb84f4f4aadb027cc19b91d9c62d59b", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 0.0, "f1_gu_yn": [0, 1], "recall_gu_yn": [0, 1]}
{"doc_id": 5, "doc": {"person_id": 115967924, "visit_occurrence_id": 85358796, "death_date": null, "visit_concept_name": "Hospital", "visit_start_datetime": "2016-04-24 00:00:00", "visit_end_datetime": "2016-04-24 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Hospital, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-04-24, presumably until 2016-04-24\n\n", "approximate_token_count": 99, "patient_first_visit_date": "2014-10-03 14:30:00", "patient_last_visit_date": "2018-07-08 11:13:00", "end_obs_date": "2017-04-24", "readmission_30d": 0, "visit_sequence_number": 17, "cumulated_visit_num": 17, "cumulated_approximate_token_count": 4295, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-03 14:30:00, ended at 2014-10-03 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 12:12:00, ended at 2014-10-13 14:02:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n- Pure hypercholesterolemia\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 150 mg by mouth 2 times a day.\n- sucralfate 1000 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 1 g by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 14:03:00, ended at 2014-10-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-02 13:32:00, ended at 2014-11-02 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-11-03 00:00:00, ended at 2014-11-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-17 00:00:00, ended at 2015-01-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 12:36:00, ended at 2015-02-02 14:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Neoplasm defined only by topography: Rectum, NOS\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-02-02, presumably until 2015-02-03, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 14:30:00, ended at 2015-02-02 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Digestive symptom\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-07 10:30:00, ended at 2015-03-07 13:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- esomeprazole 40 MG Delayed Release Oral Capsule, through Oral route, presumably until 2015-03-30, with intended 0 refill(s). Instructions: take 40 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-13 00:00:00, ended at 2015-03-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-03-13, presumably until 2015-03-15, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- ertapenem 1000 MG Injection, started on 2015-03-15, presumably until 2015-03-15\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- midazolam 1 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 07:36:00, ended at 2015-03-17 13:47:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.49 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.9 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 149 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- Glucose [Mass/volume] in Blood: 131 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.2 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Other anterior resection of rectum\n- Anastomosis of large intestine to large intestine\n\n### Condition\n- Pure hypercholesterolemia\n- Primary malignant neoplasm of rectum\n- Gastroesophageal reflux disease\n- Intestinal disaccharidase deficiency\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-16\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2015-03-16, presumably until 2015-03-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-03-16, presumably until 2015-03-17\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-03-16, presumably until 2015-03-16\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-03-15, presumably until 2015-03-15\n- alvimopan 12 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2015-03-16, presumably until 2015-09-13, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-30 13:08:00, ended at 2015-03-30 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-21 11:06:42, ended at 2015-09-21 11:41:05\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.37\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-09-21, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n- prochlorperazine 10 MG Oral Tablet, started on 2015-06-14, presumably until 2015-06-14, with intended 0 refill(s)\n- psyllium 6000 MG Powder for Oral Suspension, through Oral route, started on 2015-09-21, presumably until 2015-09-21. Instructions: take 1 Packet by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-11 00:00:00, ended at 2016-03-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2016-03-11, presumably until 2016-03-11, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-04-24, presumably until 2016-04-24\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-03 14:30:00, ended at 2014-10-03 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 12:12:00, ended at 2014-10-13 14:02:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n- Pure hypercholesterolemia\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 150 mg by mouth 2 times a day.\n- sucralfate 1000 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 1 g by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 14:03:00, ended at 2014-10-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-02 13:32:00, ended at 2014-11-02 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-11-03 00:00:00, ended at 2014-11-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-17 00:00:00, ended at 2015-01-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 12:36:00, ended at 2015-02-02 14:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Neoplasm defined only by topography: Rectum, NOS\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-02-02, presumably until 2015-02-03, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 14:30:00, ended at 2015-02-02 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Digestive symptom\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-07 10:30:00, ended at 2015-03-07 13:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- esomeprazole 40 MG Delayed Release Oral Capsule, through Oral route, presumably until 2015-03-30, with intended 0 refill(s). Instructions: take 40 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-13 00:00:00, ended at 2015-03-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-03-13, presumably until 2015-03-15, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- ertapenem 1000 MG Injection, started on 2015-03-15, presumably until 2015-03-15\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- midazolam 1 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 07:36:00, ended at 2015-03-17 13:47:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.49 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.9 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 149 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- Glucose [Mass/volume] in Blood: 131 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.2 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Other anterior resection of rectum\n- Anastomosis of large intestine to large intestine\n\n### Condition\n- Pure hypercholesterolemia\n- Primary malignant neoplasm of rectum\n- Gastroesophageal reflux disease\n- Intestinal disaccharidase deficiency\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-16\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2015-03-16, presumably until 2015-03-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-03-16, presumably until 2015-03-17\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-03-16, presumably until 2015-03-16\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-03-15, presumably until 2015-03-15\n- alvimopan 12 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2015-03-16, presumably until 2015-09-13, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-30 13:08:00, ended at 2015-03-30 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-21 11:06:42, ended at 2015-09-21 11:41:05\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.37\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-09-21, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n- prochlorperazine 10 MG Oral Tablet, started on 2015-06-14, presumably until 2015-06-14, with intended 0 refill(s)\n- psyllium 6000 MG Powder for Oral Suspension, through Oral route, started on 2015-09-21, presumably until 2015-09-21. Instructions: take 1 Packet by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-11 00:00:00, ended at 2016-03-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2016-03-11, presumably until 2016-03-11, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-04-24, presumably until 2016-04-24\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2016-04-24 00:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "bbaaa5cf577dba9d179f61e3499690a78cbe4a630c8cc0e8d0b915a40e982b06", "prompt_hash": "ed3b94fc98e7b6038fcead1f0d21becaedc2865b67973971d1ad3ccb5ecc5b8e", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 0.0, "f1_gu_yn": [0, 1], "recall_gu_yn": [0, 1]}
{"doc_id": 6, "doc": {"person_id": 115968081, "visit_occurrence_id": 158570190, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2020-05-01 00:00:00", "visit_end_datetime": "2020-05-01 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Liver cell carcinoma\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- cefazolin 1000 MG Injection, started on 2020-05-01, presumably until 2020-05-01\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n\n", "approximate_token_count": 402, "patient_first_visit_date": "2011-01-09 10:37:00", "patient_last_visit_date": "2023-02-04 11:16:39", "end_obs_date": "2021-05-01", "readmission_30d": 0, "visit_sequence_number": 22, "cumulated_visit_num": 22, "cumulated_approximate_token_count": 7766, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-01-09 10:37:00, ended at 2011-01-29 15:45:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 52.7 (millimeter mercury column)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 415 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.03 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.47 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 55 (percent)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Prothrombin time (PT): 27.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.51 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 32.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 96 (millimeter mercury column)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.73 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 32.2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 61.8 (second)\n- Base excess in Blood by calculation: 8.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 13.2 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.8 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 1.4 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Base deficit in Blood: 9.0 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.4 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 15 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 20.9 (microgram per milliliter)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Aortocoronary bypass of two coronary arteries\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Catheterization of both left and right heart\n- Operative external blood circulation\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Collection of venous blood by venipuncture\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Coronary angiography\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Insertion of intra-aortic balloon counterpulsation\n- Single internal mammary-coronary artery bypass\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Controlled ventilation procedure and therapy, initiation and management\n- Occupational therapy evaluation\n\n### Condition\n- Congestive heart failure\n- Obesity\n- Obstructive sleep apnea syndrome\n- Postprocedural state finding\n- Acute respiratory failure\n- Peripheral vascular disease\n- Pulmonary congestion and hypostasis\n- Brachial radiculitis\n- Coronary arteriosclerosis\n- Essential hypertension\n- Glaucoma\n- Leukocytosis\n- Primary diagnosis: Acute myocardial infarction\n- Aortocoronary bypass graft present\n- Cardiomegaly\n- Hyperlipidemia\n- Acute combined systolic and diastolic heart failure\n- Cardiac arrhythmia\n- Chronic systolic heart failure\n- Hemorrhoids\n- Nuclear senile cataract\n- Sequelae of cardiovascular disorders\n- Type 2 diabetes mellitus without complication\n- Acute myocardial infarction of anterolateral wall\n- Chronic ischemic heart disease\n- Pleural effusion\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-02-15, with quantity of 15.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours. \n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-01-20, presumably until 2011-01-20\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2011-01-18, presumably until 2011-01-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-01-28\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-01-11, presumably until 2011-01-11\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-26\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-04-19. Instructions: take 25 mg by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-01-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-20\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2011-01-19, presumably until 2011-01-23\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2011-01-12, presumably until 2011-01-28\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2011-01-27, presumably until 2011-04-19, with quantity of 1.0, with intended 0 refill(s). Instructions: insert into the rectum as needed for Anorectal itching/discomfort. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2012-01-29, with quantity of 120.0, with intended 0 refill(s). Instructions: take 4 Tabs by mouth 2 times a day. \n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-01-09, presumably until 2011-01-09\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-01-12, presumably until 2011-01-28\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-01-14, presumably until 2012-01-29, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed \n- furosemide 40 MG Oral Tablet, through Oral route, started on 2011-01-27, presumably until 2012-01-29, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-13, presumably until 2020-04-28. Instructions: inject subcutaneous (under the skin). \n- citalopram 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-29. Instructions: take by mouth.\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2011-01-17, presumably until 2011-01-29\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- 10 ML furosemide 10 MG/ML Injection, started on 2011-01-13, presumably until 2011-01-26\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-01-09, presumably until 2011-01-13\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28. Instructions: take 20 mg by mouth daily.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-01-11, presumably until 2011-01-14\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-09, presumably until 2022-08-20. Instructions: inject subcutaneous (under the skin) 4 times a day before meals and bedtime. \n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-26\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-13\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-11\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2011-01-14, presumably until 2011-01-14\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2011-01-13, presumably until 2011-01-13\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2011-01-29, presumably until 2011-01-29, with quantity of 90.0, with intended 0 refill(s). Instructions: take 3 Tabs by mouth daily. Please have INR levels checked on Monday 02/01/2011 \n- pravastatin sodium 10 MG Oral Tablet, through Oral route, presumably until 2011-02-15. Instructions: take 20 mg by mouth daily. \n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2011-01-25, presumably until 2011-01-25\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2011-01-13, presumably until 2011-04-19, with quantity of 60.0, with intended 2 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed \n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2011-01-11, presumably until 2011-01-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2011-02-15, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast. \n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-01-12, presumably until 2011-01-12\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-23, presumably until 2011-04-19, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain. \n- 500 ML heparin sodium, porcine 2 UNT/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-10 14:38:57, ended at 2011-01-10 15:15:45\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Precordial pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-18 09:29:44, ended at 2011-01-18 10:42:10\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-29 10:00:00, ended at 2011-01-29 23:59:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-29 00:00:00, ended at 2020-01-29 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cancer Ag 19-9 [Units/volume] in Serum or Plasma: 2 (unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-01 08:29:50, ended at 2020-02-01 10:34:41\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2020-01-28, presumably until 2020-01-28, with intended 0 refill(s). Instructions: take 1 Tablet (300 mg total) by mouth daily\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2019-10-23, presumably until 2019-10-23, with intended 0 refill(s). Instructions: take 1 Tablet (20 mg total) by mouth AM\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2019-04-12, presumably until 2022-11-09, with intended 0 refill(s). Instructions: take 250 mg by mouth 2 times a day\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, started on 2019-10-25, presumably until 2022-03-01, with intended 0 refill(s). Instructions: take 40 mg by mouth daily\n- vitamin B complex, through Oral route, started on 2012-07-25, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Capsule by mouth daily\n- 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet, through Oral route, started on 2019-07-23, presumably until 2019-07-23, with intended 0 refill(s). Instructions: take 1 Tablet (150 mg total) by mouth AM\n- dorzolamide 20 MG/ML Ophthalmic Solution, through Intraocular route, started on 2019-08-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes 2 times a day\n- spironolactone 25 MG Oral Tablet, started on 2017-08-15, presumably until 2017-08-15, with intended 0 refill(s). Instructions: Take one tablet by mouth one time daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2017-08-19, presumably until 2017-08-19, with intended 0 refill(s). Instructions: inject 60 Units subcutaneous (under the skin) 2 times a day\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, through Oral route, started on 2019-12-30, presumably until 2019-12-30, with intended 0 refill(s). Instructions: take 500 mg by mouth 2 times a day\n- 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-01-07, presumably until 2020-01-07, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) every 7 days Every Mondays\n- rosuvastatin calcium 20 MG Oral Tablet, started on 2019-08-24, presumably until 2019-08-24, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2019-11-15, presumably until 2019-11-15, with intended 0 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-01 10:33:00, ended at 2020-02-01 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 13 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.43 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 46 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.67 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.21 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 69.0 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 72 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Prothrombin time (PT): 13.9 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-18 00:00:00, ended at 2020-02-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 07:12:00, ended at 2020-03-31 08:24:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Liver cell carcinoma\n- Lumbar spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 08:25:00, ended at 2020-03-31 10:25:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 13:22:00, ended at 2020-03-31 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cirrhosis of liver\n- Nonalcoholic steatohepatitis\n- Portal vein thrombosis\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-18 00:00:00, ended at 2020-04-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-18 10:04:44, ended at 2020-04-18 10:16:59\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-22 07:47:00, ended at 2020-04-22 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Postoperative state\n- Steatosis of liver\n- Disorder of digestive system\n- Hepatosplenomegaly\n- Liver cell carcinoma\n- Acquired absence of organ\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-28 09:33:22, ended at 2020-04-28 10:35:04\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Malignant neoplasm of liver\n- Traumatic or non-traumatic injury\n- Obstructive sleep apnea syndrome\n- Generalized ischemic myocardial dysfunction\n- Hyperlipidemia\n- Primary diagnosis: COVID-19\n- Liver cell carcinoma\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, presumably until 2020-11-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 Tablet (81 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Liver cell carcinoma\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- cefazolin 1000 MG Injection, started on 2020-05-01, presumably until 2020-05-01\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-01-09 10:37:00, ended at 2011-01-29 15:45:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 52.7 (millimeter mercury column)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 415 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.03 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.47 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 55 (percent)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Prothrombin time (PT): 27.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.51 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 32.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 96 (millimeter mercury column)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.73 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 32.2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 61.8 (second)\n- Base excess in Blood by calculation: 8.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 13.2 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.8 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 1.4 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Base deficit in Blood: 9.0 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.4 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 15 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 20.9 (microgram per milliliter)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Aortocoronary bypass of two coronary arteries\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Catheterization of both left and right heart\n- Operative external blood circulation\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Collection of venous blood by venipuncture\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Coronary angiography\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Insertion of intra-aortic balloon counterpulsation\n- Single internal mammary-coronary artery bypass\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Controlled ventilation procedure and therapy, initiation and management\n- Occupational therapy evaluation\n\n### Condition\n- Congestive heart failure\n- Obesity\n- Obstructive sleep apnea syndrome\n- Postprocedural state finding\n- Acute respiratory failure\n- Peripheral vascular disease\n- Pulmonary congestion and hypostasis\n- Brachial radiculitis\n- Coronary arteriosclerosis\n- Essential hypertension\n- Glaucoma\n- Leukocytosis\n- Primary diagnosis: Acute myocardial infarction\n- Aortocoronary bypass graft present\n- Cardiomegaly\n- Hyperlipidemia\n- Acute combined systolic and diastolic heart failure\n- Cardiac arrhythmia\n- Chronic systolic heart failure\n- Hemorrhoids\n- Nuclear senile cataract\n- Sequelae of cardiovascular disorders\n- Type 2 diabetes mellitus without complication\n- Acute myocardial infarction of anterolateral wall\n- Chronic ischemic heart disease\n- Pleural effusion\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-02-15, with quantity of 15.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours. \n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-01-20, presumably until 2011-01-20\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2011-01-18, presumably until 2011-01-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-01-28\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-01-11, presumably until 2011-01-11\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-26\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-04-19. Instructions: take 25 mg by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-01-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-20\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2011-01-19, presumably until 2011-01-23\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2011-01-12, presumably until 2011-01-28\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2011-01-27, presumably until 2011-04-19, with quantity of 1.0, with intended 0 refill(s). Instructions: insert into the rectum as needed for Anorectal itching/discomfort. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2012-01-29, with quantity of 120.0, with intended 0 refill(s). Instructions: take 4 Tabs by mouth 2 times a day. \n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-01-09, presumably until 2011-01-09\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-01-12, presumably until 2011-01-28\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-01-14, presumably until 2012-01-29, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed \n- furosemide 40 MG Oral Tablet, through Oral route, started on 2011-01-27, presumably until 2012-01-29, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-13, presumably until 2020-04-28. Instructions: inject subcutaneous (under the skin). \n- citalopram 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-29. Instructions: take by mouth.\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2011-01-17, presumably until 2011-01-29\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- 10 ML furosemide 10 MG/ML Injection, started on 2011-01-13, presumably until 2011-01-26\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-01-09, presumably until 2011-01-13\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28. Instructions: take 20 mg by mouth daily.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-01-11, presumably until 2011-01-14\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-09, presumably until 2022-08-20. Instructions: inject subcutaneous (under the skin) 4 times a day before meals and bedtime. \n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-26\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-13\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-11\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2011-01-14, presumably until 2011-01-14\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2011-01-13, presumably until 2011-01-13\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2011-01-29, presumably until 2011-01-29, with quantity of 90.0, with intended 0 refill(s). Instructions: take 3 Tabs by mouth daily. Please have INR levels checked on Monday 02/01/2011 \n- pravastatin sodium 10 MG Oral Tablet, through Oral route, presumably until 2011-02-15. Instructions: take 20 mg by mouth daily. \n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2011-01-25, presumably until 2011-01-25\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2011-01-13, presumably until 2011-04-19, with quantity of 60.0, with intended 2 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed \n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2011-01-11, presumably until 2011-01-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2011-02-15, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast. \n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-01-12, presumably until 2011-01-12\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-23, presumably until 2011-04-19, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain. \n- 500 ML heparin sodium, porcine 2 UNT/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-10 14:38:57, ended at 2011-01-10 15:15:45\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Precordial pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-18 09:29:44, ended at 2011-01-18 10:42:10\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-29 10:00:00, ended at 2011-01-29 23:59:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-29 00:00:00, ended at 2020-01-29 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cancer Ag 19-9 [Units/volume] in Serum or Plasma: 2 (unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-01 08:29:50, ended at 2020-02-01 10:34:41\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2020-01-28, presumably until 2020-01-28, with intended 0 refill(s). Instructions: take 1 Tablet (300 mg total) by mouth daily\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2019-10-23, presumably until 2019-10-23, with intended 0 refill(s). Instructions: take 1 Tablet (20 mg total) by mouth AM\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2019-04-12, presumably until 2022-11-09, with intended 0 refill(s). Instructions: take 250 mg by mouth 2 times a day\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, started on 2019-10-25, presumably until 2022-03-01, with intended 0 refill(s). Instructions: take 40 mg by mouth daily\n- vitamin B complex, through Oral route, started on 2012-07-25, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Capsule by mouth daily\n- 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet, through Oral route, started on 2019-07-23, presumably until 2019-07-23, with intended 0 refill(s). Instructions: take 1 Tablet (150 mg total) by mouth AM\n- dorzolamide 20 MG/ML Ophthalmic Solution, through Intraocular route, started on 2019-08-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes 2 times a day\n- spironolactone 25 MG Oral Tablet, started on 2017-08-15, presumably until 2017-08-15, with intended 0 refill(s). Instructions: Take one tablet by mouth one time daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2017-08-19, presumably until 2017-08-19, with intended 0 refill(s). Instructions: inject 60 Units subcutaneous (under the skin) 2 times a day\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, through Oral route, started on 2019-12-30, presumably until 2019-12-30, with intended 0 refill(s). Instructions: take 500 mg by mouth 2 times a day\n- 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-01-07, presumably until 2020-01-07, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) every 7 days Every Mondays\n- rosuvastatin calcium 20 MG Oral Tablet, started on 2019-08-24, presumably until 2019-08-24, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2019-11-15, presumably until 2019-11-15, with intended 0 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-01 10:33:00, ended at 2020-02-01 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 13 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.43 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 46 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.67 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.21 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 69.0 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 72 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Prothrombin time (PT): 13.9 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-18 00:00:00, ended at 2020-02-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 07:12:00, ended at 2020-03-31 08:24:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Liver cell carcinoma\n- Lumbar spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 08:25:00, ended at 2020-03-31 10:25:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 13:22:00, ended at 2020-03-31 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cirrhosis of liver\n- Nonalcoholic steatohepatitis\n- Portal vein thrombosis\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-18 00:00:00, ended at 2020-04-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-18 10:04:44, ended at 2020-04-18 10:16:59\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-22 07:47:00, ended at 2020-04-22 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Postoperative state\n- Steatosis of liver\n- Disorder of digestive system\n- Hepatosplenomegaly\n- Liver cell carcinoma\n- Acquired absence of organ\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-28 09:33:22, ended at 2020-04-28 10:35:04\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Malignant neoplasm of liver\n- Traumatic or non-traumatic injury\n- Obstructive sleep apnea syndrome\n- Generalized ischemic myocardial dysfunction\n- Hyperlipidemia\n- Primary diagnosis: COVID-19\n- Liver cell carcinoma\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, presumably until 2020-11-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 Tablet (81 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Liver cell carcinoma\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- cefazolin 1000 MG Injection, started on 2020-05-01, presumably until 2020-05-01\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2020-05-01 00:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "de4ca3071bf8594a47a02dc4f09259c5ccf71f0518ba1ec8249b22e48176a9df", "prompt_hash": "c21a3fb9d32a95dc992cba72a06056c3eaab152c63a8143b09e722694ebc3518", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 0.0, "f1_gu_yn": [0, 1], "recall_gu_yn": [0, 1]}
{"doc_id": 7, "doc": {"person_id": 115968162, "visit_occurrence_id": 45847265, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2011-12-06 15:05:29", "visit_end_datetime": "2011-12-06 15:35:19", "visit_length_in_hours": 0.49722222222222223, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2011-12-06 15:05:29, ended at 2011-12-06 15:35:19\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 131, "patient_first_visit_date": "2009-02-16 00:00:00", "patient_last_visit_date": "2015-11-10 00:00:00", "end_obs_date": "2012-12-05", "readmission_30d": 1, "visit_sequence_number": 9, "cumulated_visit_num": 9, "cumulated_approximate_token_count": 7448, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-16 00:00:00, ended at 2009-02-16 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 81 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 156 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.30 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.7 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.88 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Valproate [Mass/volume] in Serum or Plasma: 110.1 (microgram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.4 (femtoliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-11-02 23:01:00, ended at 2011-11-08 16:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 35 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 30 (microgram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 481 (unit per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 13.8 (microgram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 21.5 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Erythrocyte sedimentation rate: 134 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 159 (microgram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 45 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 149 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.08 (milli-international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 946 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 19 (percent)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 2.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 9.0 (gram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: Result checked (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.8 (nanogram per deciliter)\n- Valproate [Mass/volume] in Serum or Plasma: 33.1 (microgram per milliliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 19 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 4.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 16.5 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n\n### Procedure\n- Prophylactic administration of vaccine against other diseases\n- Echocardiography\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences\n- Molecular diagnostics; reverse transcription\n- Molecular diagnostics; interpretation and report\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent\n- Radiologic examination, chest; single view, frontal\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure)\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation\n- Radiologic examination, chest, special views (eg, lateral decubitus, Bucky studies)\n- Collection of venous blood by venipuncture\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Essential hypertension\n- Seizure disorder\n- Disorder of pericardium\n- Cardiomegaly\n- Fever\n- Acute renal failure syndrome\n- Leukocytosis\n- Physiological development failure\n- Pleural effusion\n- Atelectasis\n- Acquired hypothyroidism\n- Disorder of magnesium metabolism\n- Iron deficiency anemia\n- Cerebral palsy\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2011-11-05, presumably until 2011-11-08\n- divalproex sodium 250 MG Delayed Release Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- atenolol 50 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-07\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- sodium chloride 100 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-05, presumably until 2011-11-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-07\n- miconazole nitrate 0.02 MG/MG Topical Ointment, through Topical route, started on 2011-11-06, presumably until 2011-11-08\n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-11-03, presumably until 2011-11-05\n- gabapentin 400 MG Oral Capsule, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-11-03, presumably until 2011-11-08\n- lacosamide 100 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-12 13:34:00, ended at 2011-11-12 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-11-15 00:00:00, ended at 2011-11-15 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-11-16 07:24:00, ended at 2011-12-08 10:30:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.54 (million per microliter)\n- Globulin [Mass/volume] in Serum: 6.2 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 299 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 2.27 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 678 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Valproate [Mass/volume] in Serum or Plasma: 50.6 (microgram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 0.99 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.92 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 3.9 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 22.6 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Body height: 5' 2\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 3.13 (thousand per microliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 1.1 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 21 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 308 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Eosinophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.6 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 17.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 67 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Prothrombin time (PT): 15.4 (second)\n- Reticulocytes [#/volume] in Blood by Automated count: 47.9 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 134 (millimeter per hour)\n- Lymphocytes [#/volume] in Blood by Manual count: 4.3 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: <1 (nanogram per milliliter)\n- MCV [Entitic volume] by Automated count: 95.8 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.02 (thousand per microliter)\n\n### Procedure\n- Counseling\n- Pericardiocentesis\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Other incision of pleura\n- Molecular diagnostics; enzymatic digestion, each enzyme treatment\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Echocardiography\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation\n- Tube thoracostomy, includes connection to drainage system (eg, water seal), when performed, open (separate procedure)\n- Pericardiocentesis; initial\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Replacement of gastrostomy or cecostomy (or other colonic) tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, swallowing function, with cineradiography/videoradiography, including scout neck radiograph(s) and delayed image(s), when performed, contrast (eg, barium) study\n- Motion fluoroscopic evaluation of swallowing function by cine or video recording\n- Molecular diagnostics; mutation identification by sequencing, single segment, each segment\n- Biopsy of blood vessel\n- Collection of venous blood by venipuncture\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Occupational therapy evaluation\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Evaluation of oral and pharyngeal swallowing function\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; single anteroposterior view\n- Arterial puncture, withdrawal of blood for diagnosis\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n- Radiologic examination, chest; single view, frontal\n- Packed blood cell transfusion\n\n### Condition\n- Cerebral palsy\n- Disorder of magnesium metabolism\n- Primary malignant neoplasm of colon\n- Disorder of lung\n- Familial Mediterranean fever\n- Temporal arteritis\n- Lung field abnormal\n- Physiological development failure\n- Cardiac arrhythmia\n- Disorder of pericardium\n- Osteoporosis\n- Anemia\n- Leukocytosis\n- Acute renal failure syndrome\n- Hypoxemia\n- Pleural effusion\n- Acquired hypothyroidism\n- Atelectasis\n- Atherosclerosis of aorta\n- Dysphagia\n- Dyspnea\n- Fever\n- Pneumonitis due to inhaled substance\n- Prostatitis\n- Second degree atrioventricular block\n- Acute idiopathic pericarditis\n- Epilepsy\n\n### Drug\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2011-11-19, presumably until 2011-12-06\n- atenolol 50 MG Oral Tablet, through Oral route, started on 2011-12-07, presumably until 2012-01-08, with intended 0 refill(s). Instructions: take 50 mg by mouth daily. Hold for systolic BP below 100, and if heartrate is below 60 BPM \n- methylprednisolone 40 MG Injection, started on 2011-11-27, presumably until 2011-11-30\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-12-07. Instructions: 10 mg by Other route every bedtime. Given Via G-J Tube.\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-11-25, presumably until 2011-12-08\n- potassium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- tribasic potassium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-11-21, presumably until 2011-12-01\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-11-19, presumably until 2011-11-29\n- lacosamide 200 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2012-04-01. Instructions: 200 mg by Other route 2 times a day. Given via G-J tube\n- alendronic acid 70 MG Oral Tablet, presumably until 2012-06-05. Instructions: 70 mg by Other route once a week. Every Friday Given via G-J tube\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2011-11-25, presumably until 2011-12-08\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-12-08. Instructions: take by mouth 2 times a day.\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-11-17, presumably until 2011-11-17\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2011-12-03, presumably until 2011-12-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-11-30\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-11-17, presumably until 2011-12-08\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2011-11-19, presumably until 2011-11-19\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-11-19, presumably until 2011-11-30\n- tribasic sodium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-22, presumably until 2011-11-22\n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-26. Instructions: take by mouth daily.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2012-04-01. Instructions: 250 mg by Other route daily. Given via G-J tube.\n- gabapentin 400 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2012-04-01, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-12-08. Instructions: take by mouth daily.\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-12-08. Instructions: take by mouth daily.\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-30\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-11-29, presumably until 2012-01-08, with intended 5 refill(s). Instructions: take 1 Tab by mouth daily.\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2011-12-03, presumably until 2011-12-08, with intended 0 refill(s). Instructions: take 3 Tabs by mouth daily.\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2011-11-20, presumably until 2011-11-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-29\n- lacosamide 100 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-17\n- valproic acid 50 MG/ML Oral Solution, through Oral route, started on 2011-11-30, presumably until 2012-01-08, with intended 5 refill(s). Instructions: take 15 mL by mouth every morning.\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-11-16, presumably until 2011-11-16\n- sodium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- sodium phosphate, monobasic, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-11-17, presumably until 2011-11-19\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-11-16, presumably until 2011-11-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-21\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2011-11-30, presumably until 2011-11-30\n- sodium phosphate, dibasic, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- lamotrigine 25 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-22. Instructions: take 25 mg by mouth every other day.\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-12-08\n- 2 ML diazepam 5 MG/ML Auto-Injector, started on 2011-11-24, presumably until 2011-12-01\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-17. Instructions: take 500 mg by mouth 2 times a day.\n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2011-12-05, presumably until 2011-12-05\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-23, presumably until 2011-11-29\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2011-12-01, presumably until 2011-12-02\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2012-02-25. Instructions: take 1 Tab by mouth daily. 500 mg 3 times a day \n- dibasic sodium phosphate heptahydrate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-12-03, presumably until 2012-01-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-11-21, presumably until 2011-12-02\n- dibasic potassium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-29, presumably until 2011-12-04\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-11-16, presumably until 2011-11-16\n- 300 ML linezolid 2 MG/ML Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-11-16 08:39:08, ended at 2011-11-16 12:45:17\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-20 10:20:21, ended at 2011-11-20 16:50:18\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-11-30 08:06:54, ended at 2011-11-30 14:56:55\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-12-06 15:05:29, ended at 2011-12-06 15:35:19\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-16 00:00:00, ended at 2009-02-16 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 81 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 156 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.30 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.7 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.88 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Valproate [Mass/volume] in Serum or Plasma: 110.1 (microgram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.4 (femtoliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-11-02 23:01:00, ended at 2011-11-08 16:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 35 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 30 (microgram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 481 (unit per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 13.8 (microgram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 21.5 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Erythrocyte sedimentation rate: 134 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 159 (microgram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 45 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 149 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.08 (milli-international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 946 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 19 (percent)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 2.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 9.0 (gram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: Result checked (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.8 (nanogram per deciliter)\n- Valproate [Mass/volume] in Serum or Plasma: 33.1 (microgram per milliliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 19 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 4.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 16.5 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n\n### Procedure\n- Prophylactic administration of vaccine against other diseases\n- Echocardiography\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences\n- Molecular diagnostics; reverse transcription\n- Molecular diagnostics; interpretation and report\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent\n- Radiologic examination, chest; single view, frontal\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure)\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation\n- Radiologic examination, chest, special views (eg, lateral decubitus, Bucky studies)\n- Collection of venous blood by venipuncture\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Essential hypertension\n- Seizure disorder\n- Disorder of pericardium\n- Cardiomegaly\n- Fever\n- Acute renal failure syndrome\n- Leukocytosis\n- Physiological development failure\n- Pleural effusion\n- Atelectasis\n- Acquired hypothyroidism\n- Disorder of magnesium metabolism\n- Iron deficiency anemia\n- Cerebral palsy\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2011-11-05, presumably until 2011-11-08\n- divalproex sodium 250 MG Delayed Release Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- atenolol 50 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-07\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- sodium chloride 100 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-05, presumably until 2011-11-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-07\n- miconazole nitrate 0.02 MG/MG Topical Ointment, through Topical route, started on 2011-11-06, presumably until 2011-11-08\n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-11-03, presumably until 2011-11-05\n- gabapentin 400 MG Oral Capsule, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-11-03, presumably until 2011-11-08\n- lacosamide 100 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, started on 2011-11-03, presumably until 2011-11-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-12 13:34:00, ended at 2011-11-12 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-11-15 00:00:00, ended at 2011-11-15 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-11-16 07:24:00, ended at 2011-12-08 10:30:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.54 (million per microliter)\n- Globulin [Mass/volume] in Serum: 6.2 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 299 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 2.27 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 678 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Valproate [Mass/volume] in Serum or Plasma: 50.6 (microgram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 0.99 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.92 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 3.9 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 22.6 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Body height: 5' 2\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 3.13 (thousand per microliter)\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 1.1 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 21 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 308 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Eosinophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.6 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 17.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 67 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Prothrombin time (PT): 15.4 (second)\n- Reticulocytes [#/volume] in Blood by Automated count: 47.9 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 134 (millimeter per hour)\n- Lymphocytes [#/volume] in Blood by Manual count: 4.3 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: <1 (nanogram per milliliter)\n- MCV [Entitic volume] by Automated count: 95.8 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.02 (thousand per microliter)\n\n### Procedure\n- Counseling\n- Pericardiocentesis\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Other incision of pleura\n- Molecular diagnostics; enzymatic digestion, each enzyme treatment\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Echocardiography\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation\n- Tube thoracostomy, includes connection to drainage system (eg, water seal), when performed, open (separate procedure)\n- Pericardiocentesis; initial\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Replacement of gastrostomy or cecostomy (or other colonic) tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, swallowing function, with cineradiography/videoradiography, including scout neck radiograph(s) and delayed image(s), when performed, contrast (eg, barium) study\n- Motion fluoroscopic evaluation of swallowing function by cine or video recording\n- Molecular diagnostics; mutation identification by sequencing, single segment, each segment\n- Biopsy of blood vessel\n- Collection of venous blood by venipuncture\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Occupational therapy evaluation\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Evaluation of oral and pharyngeal swallowing function\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; single anteroposterior view\n- Arterial puncture, withdrawal of blood for diagnosis\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n- Radiologic examination, chest; single view, frontal\n- Packed blood cell transfusion\n\n### Condition\n- Cerebral palsy\n- Disorder of magnesium metabolism\n- Primary malignant neoplasm of colon\n- Disorder of lung\n- Familial Mediterranean fever\n- Temporal arteritis\n- Lung field abnormal\n- Physiological development failure\n- Cardiac arrhythmia\n- Disorder of pericardium\n- Osteoporosis\n- Anemia\n- Leukocytosis\n- Acute renal failure syndrome\n- Hypoxemia\n- Pleural effusion\n- Acquired hypothyroidism\n- Atelectasis\n- Atherosclerosis of aorta\n- Dysphagia\n- Dyspnea\n- Fever\n- Pneumonitis due to inhaled substance\n- Prostatitis\n- Second degree atrioventricular block\n- Acute idiopathic pericarditis\n- Epilepsy\n\n### Drug\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2011-11-19, presumably until 2011-12-06\n- atenolol 50 MG Oral Tablet, through Oral route, started on 2011-12-07, presumably until 2012-01-08, with intended 0 refill(s). Instructions: take 50 mg by mouth daily. Hold for systolic BP below 100, and if heartrate is below 60 BPM \n- methylprednisolone 40 MG Injection, started on 2011-11-27, presumably until 2011-11-30\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-12-07. Instructions: 10 mg by Other route every bedtime. Given Via G-J Tube.\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-11-25, presumably until 2011-12-08\n- potassium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- tribasic potassium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-11-21, presumably until 2011-12-01\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-11-19, presumably until 2011-11-29\n- lacosamide 200 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2012-04-01. Instructions: 200 mg by Other route 2 times a day. Given via G-J tube\n- alendronic acid 70 MG Oral Tablet, presumably until 2012-06-05. Instructions: 70 mg by Other route once a week. Every Friday Given via G-J tube\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2011-11-25, presumably until 2011-12-08\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-12-08. Instructions: take by mouth 2 times a day.\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-11-17, presumably until 2011-11-17\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2011-12-03, presumably until 2011-12-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-11-30\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-11-17, presumably until 2011-12-08\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2011-11-19, presumably until 2011-11-19\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-11-19, presumably until 2011-11-30\n- tribasic sodium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-22, presumably until 2011-11-22\n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-26. Instructions: take by mouth daily.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2012-04-01. Instructions: 250 mg by Other route daily. Given via G-J tube.\n- gabapentin 400 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2012-04-01, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-12-08. Instructions: take by mouth daily.\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-12-08. Instructions: take by mouth daily.\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-30\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-11-29, presumably until 2012-01-08, with intended 5 refill(s). Instructions: take 1 Tab by mouth daily.\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2011-12-03, presumably until 2011-12-08, with intended 0 refill(s). Instructions: take 3 Tabs by mouth daily.\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2011-11-20, presumably until 2011-11-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-29\n- lacosamide 100 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-17\n- valproic acid 50 MG/ML Oral Solution, through Oral route, started on 2011-11-30, presumably until 2012-01-08, with intended 5 refill(s). Instructions: take 15 mL by mouth every morning.\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-11-16, presumably until 2011-11-16\n- sodium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- sodium phosphate, monobasic, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-11-17, presumably until 2011-11-19\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-11-16, presumably until 2011-11-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-21\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2011-11-30, presumably until 2011-11-30\n- sodium phosphate, dibasic, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- lamotrigine 25 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-22. Instructions: take 25 mg by mouth every other day.\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2011-11-30, presumably until 2011-12-08\n- 2 ML diazepam 5 MG/ML Auto-Injector, started on 2011-11-24, presumably until 2011-12-01\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-17. Instructions: take 500 mg by mouth 2 times a day.\n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2011-12-05, presumably until 2011-12-05\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-23, presumably until 2011-11-29\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2011-12-01, presumably until 2011-12-02\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2012-02-25. Instructions: take 1 Tab by mouth daily. 500 mg 3 times a day \n- dibasic sodium phosphate heptahydrate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-12-03, presumably until 2012-01-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-11-21, presumably until 2011-12-02\n- dibasic potassium phosphate, through Oral route, started on 2011-11-25, presumably until 2011-11-25\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2011-11-29, presumably until 2011-12-04\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-11-16, presumably until 2011-11-16\n- 300 ML linezolid 2 MG/ML Injection, through Intravenous route, started on 2011-11-17, presumably until 2011-11-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-11-16 08:39:08, ended at 2011-11-16 12:45:17\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-20 10:20:21, ended at 2011-11-20 16:50:18\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-11-30 08:06:54, ended at 2011-11-30 14:56:55\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-12-06 15:05:29, ended at 2011-12-06 15:35:19\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of pericardium\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2011-12-06 15:35:19)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "6f1a6160c2b9d8bfe9f529fd619aafa19a7f929a60f9faeaa846ee86168155b5", "prompt_hash": "9552fd9e3b74f1fa671f5afe3b82ef357de302f04bcbd67ecc249853b302b1e3", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 8, "doc": {"person_id": 115968332, "visit_occurrence_id": 108277905, "death_date": null, "visit_concept_name": "Hospital", "visit_start_datetime": "2017-10-03 00:00:00", "visit_end_datetime": "2017-10-03 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Hospital, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-03, presumably until 2017-10-03\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-10-03, presumably until 2017-10-03\n\n", "approximate_token_count": 129, "patient_first_visit_date": "2013-01-21 00:00:00", "patient_last_visit_date": "2021-07-01 00:00:00", "end_obs_date": "2018-10-03", "readmission_30d": 1, "visit_sequence_number": 50, "cumulated_visit_num": 50, "cumulated_approximate_token_count": 15311, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2013-01-21 00:00:00, ended at 2013-01-21 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-21 13:35:00, ended at 2013-01-21 17:02:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n- Ultrasonography of digestive system\n- Morphometric analysis, tumor\n\n### Condition\n- Disorder of pancreas\n- Acquired hypothyroidism\n- Benign carcinoid tumor\n- Essential hypertension\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2013-01-21, presumably until 2013-01-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-21, presumably until 2013-01-21\n- midazolam 1 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 08:15:00, ended at 2013-02-05 10:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-01-20. Instructions: take  by mouth Every Day.  \n- 24 HR felodipine 10 MG Extended Release Oral Tablet, through Oral route. Instructions: take 10 mg by mouth daily at noon \n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, presumably until 2017-09-03. Instructions: take 112 mcg by mouth every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 10:01:00, ended at 2013-02-05 10:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.59 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 11:00:00, ended at 2013-02-05 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Disorder of pancreas\n- Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 08:09:00, ended at 2013-02-12 11:13:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 11:14:00, ended at 2013-02-12 13:05:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-17 14:32:00, ended at 2013-03-17 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; pancreatectomy, partial or total (eg, Whipple procedure)\n\n### Condition\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 08:17:00, ended at 2013-03-26 10:15:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.7 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 7.008\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Prothrombin time (PT): 15.3 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n\n### Procedure\n- Cholecystectomy\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; single anteroposterior view\n- Morphometric analysis, tumor\n- Radical pancreaticoduodenectomy\n- Collection of venous blood by venipuncture\n\n### Condition\n- Low blood pressure\n- Malignant carcinoid tumor\n- Nausea\n- Essential hypertension\n- Primary malignant neoplasm of gastrointestinal tract\n- Chronic cholecystitis\n- Postprocedural state finding\n- Acquired hypothyroidism\n- Hyperlipidemia\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-03-25, presumably until 2013-03-25\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-22\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-22\n- 1 ML octreotide 0.05 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-03-22, presumably until 2013-09-22, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-03-24, presumably until 2013-03-24\n- sodium chloride 9 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-21\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-26\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2013-03-24, presumably until 2013-03-26\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-03-22, presumably until 2013-03-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-02 13:51:00, ended at 2013-04-02 17:44:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-04-02 17:45:00, ended at 2013-04-04 09:48:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 694 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 186 (unit per liter)\n- Body height: 5' 7\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.2 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.3 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Prothrombin time (PT): 13.2 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired hypothyroidism\n- Abdominal pain\n- Essential hypertension\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Postprocedural state finding\n- Urinary tract infectious disease\n- Hyperlipidemia\n- Malignant carcinoid tumor\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-04-02, presumably until 2013-04-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-04\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-02\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-03\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-04-02, presumably until 2013-04-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-04-03, presumably until 2013-04-03\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2013-04-03, presumably until 2013-04-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2013-04-04\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2014-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 13:11:00, ended at 2013-04-23 16:16:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-04-23, presumably until 2014-04-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 16:17:00, ended at 2013-04-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 404 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.75 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 59 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 228 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.06 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-23 13:20:00, ended at 2013-07-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 10:22:00, ended at 2014-01-21 12:38:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 12:39:00, ended at 2014-01-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant carcinoid tumor\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 10:11:00, ended at 2014-07-21 12:54:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Diverticular disease of colon\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 12:55:00, ended at 2014-07-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-22 00:00:00, ended at 2014-07-22 00:00:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 09:59:00, ended at 2015-01-20 13:29:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 13:30:00, ended at 2015-01-20 23:59:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.362\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ibuprofen 600 MG Oral Tablet, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 600 mg by mouth every 6 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-02 12:02:00, ended at 2016-02-02 23:59:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Postoperative state\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-02 14:52:50, ended at 2016-02-02 16:41:03\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- temazepam 30 MG Oral Capsule, through Oral route, presumably until 2017-01-31, with intended 0 refill(s). Instructions: take 30 mg by mouth every bedtime as needed for Insomnia\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-13 00:00:00, ended at 2016-02-13 00:00:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-31 10:31:00, ended at 2017-01-31 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-31 12:48:55, ended at 2017-01-31 15:51:30\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-03 00:00:00, ended at 2017-02-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-01 00:00:00, ended at 2017-08-01 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-01 10:19:00, ended at 2017-08-01 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Disease of liver\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2017-08-01, presumably until 2017-08-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-04 00:00:00, ended at 2017-08-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-08-20, presumably until 2017-10-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-03 09:15:44, ended at 2017-09-03 10:00:07\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 112 mcg by mouth every morning before breakfast\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2017-09-03, with intended 0 refill(s). Instructions: take 100 mcg by mouth every morning before breakfast\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 20 mg by mouth as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-03 10:20:00, ended at 2017-09-03 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.65 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Prothrombin time (PT): 13.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 230 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-04 00:00:00, ended at 2017-09-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- lidocaine hydrochloride 40 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2017-09-04, presumably until 2017-09-04\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-04 11:10:00, ended at 2017-09-09 09:30:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prothrombin time (PT): 15.8 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 265 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 462 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 21 - 50 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 101 - 200 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Supplement Abdominal Wall with Autologous Tissue Substitute, Open Approach\n- Excision of Aortic Lymphatic, Open Approach\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Release Peritoneum, Open Approach\n- Morphometric analysis, tumor\n- Excision of Right Lobe Liver, Open Approach\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n\n### Condition\n- Malignant neuroendocrine tumor\n- Neuroendocrine tumor\n- Primary diagnosis: Benign neuroendocrine tumor\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Peritoneal adhesion\n- Benign neoplasm of peripheral nerves of abdomen\n- Metastatic carcinoid tumor\n- Abnormal findings on diagnostic imaging of lung\n- Essential hypertension\n- Postoperative hypothyroidism\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2017-09-08, presumably until 2017-09-08\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-07, presumably until 2017-09-07\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-07\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2017-09-09\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-09-04, presumably until 2017-09-09\n- cefazolin 1000 MG Injection, started on 2017-09-04, presumably until 2017-09-04\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-05, presumably until 2017-09-08\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-08\n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2017-09-06, presumably until 2018-09-09, with intended 1 refill(s). Instructions: take 20.3 mL by mouth every 6 hours\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-09\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2017-09-05, presumably until 2017-09-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2017-09-09, presumably until 2017-11-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-16 00:00:00, ended at 2017-09-16 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 15:42:00, ended at 2017-09-16 16:46:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of kidney and/or ureter\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 16:47:00, ended at 2017-09-16 18:29:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 457 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucagon [Mass/volume] in Serum or Plasma: 71 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 22.35 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.3 (percent)\n- Pancreatic polypeptide [Mass/volume] in Serum or Plasma: 62 (picogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.69 (million per microliter)\n- Gastrin [Mass/volume] in Serum or Plasma: 28 (picogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Proinsulin [Moles/volume] in Serum or Plasma: 72 (picomole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.25 (thousand per microliter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 74 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 24.8 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 587 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Enolase.neuron specific [Mass/volume] in Serum or Plasma by Immunoassay: 2.2 (microgram per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign neuroendocrine tumor\n- Postprocedural fever\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-16 18:30:00, ended at 2017-09-20 12:16:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 188 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 346 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.74 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 599 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.1 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 1.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Body height: 5' 7.52\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Prothrombin time (PT): 15.1 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.23 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach\n\n### Condition\n- Acquired absence of organ\n- Leukocytosis\n- Streptococcal infectious disease\n- Infection due to enterococcus\n- Late effect of complications of procedure\n- Primary diagnosis: Ascites\n- Benign neuroendocrine tumor\n- Hyperlipidemia\n- Hypothyroidism\n- Postprocedural infection\n- Bacterial infectious disease\n- Essential hypertension\n- Abscess of peritoneum\n- Disorder of digestive system\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-17, presumably until 2017-09-19\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2017-09-18\n- Lacticaseibacillus rhamnosus GG 15000000000 UNT Oral Capsule, through Oral route, started on 2017-09-20, presumably until 2017-11-21, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-09-18\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-10-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-16, presumably until 2017-09-19\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-09-16, presumably until 2017-09-16\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, through Oral route, started on 2017-09-19, presumably until 2017-09-22, with intended 0 refill(s). Instructions: take 10.94 mL by mouth 2 times a day for 2 days\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-19, presumably until 2017-09-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-17 00:00:00, ended at 2017-09-17 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n\n### Condition\n- Abscess of peritoneum\n- Benign neuroendocrine tumor\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-17, presumably until 2017-09-17\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-17, presumably until 2017-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-26 00:00:00, ended at 2017-09-26 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-30 00:00:00, ended at 2017-09-30 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, started on 2017-10-02, presumably until 2017-10-02, with intended 0 refill(s). Instructions: take 10.94 milliliter twice a day for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-02 00:00:00, ended at 2017-10-02 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cystocele\n- Primary diagnosis: Benign neuroendocrine tumor\n- Hydronephrosis\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:10:00, ended at 2017-10-02 16:52:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Benign neuroendocrine tumor\n- Hydronephrosis\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:53:00, ended at 2017-10-02 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.94 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 93 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 455 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.55 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 243 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-03, presumably until 2017-10-03\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-10-03, presumably until 2017-10-03\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-01-21 00:00:00, ended at 2013-01-21 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-21 13:35:00, ended at 2013-01-21 17:02:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n- Ultrasonography of digestive system\n- Morphometric analysis, tumor\n\n### Condition\n- Disorder of pancreas\n- Acquired hypothyroidism\n- Benign carcinoid tumor\n- Essential hypertension\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2013-01-21, presumably until 2013-01-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-21, presumably until 2013-01-21\n- midazolam 1 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 08:15:00, ended at 2013-02-05 10:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-01-20. Instructions: take  by mouth Every Day.  \n- 24 HR felodipine 10 MG Extended Release Oral Tablet, through Oral route. Instructions: take 10 mg by mouth daily at noon \n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, presumably until 2017-09-03. Instructions: take 112 mcg by mouth every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 10:01:00, ended at 2013-02-05 10:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.59 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 11:00:00, ended at 2013-02-05 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Disorder of pancreas\n- Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 08:09:00, ended at 2013-02-12 11:13:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 11:14:00, ended at 2013-02-12 13:05:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-17 14:32:00, ended at 2013-03-17 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; pancreatectomy, partial or total (eg, Whipple procedure)\n\n### Condition\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 08:17:00, ended at 2013-03-26 10:15:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.7 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 7.008\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Prothrombin time (PT): 15.3 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n\n### Procedure\n- Cholecystectomy\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; single anteroposterior view\n- Morphometric analysis, tumor\n- Radical pancreaticoduodenectomy\n- Collection of venous blood by venipuncture\n\n### Condition\n- Low blood pressure\n- Malignant carcinoid tumor\n- Nausea\n- Essential hypertension\n- Primary malignant neoplasm of gastrointestinal tract\n- Chronic cholecystitis\n- Postprocedural state finding\n- Acquired hypothyroidism\n- Hyperlipidemia\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-03-25, presumably until 2013-03-25\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-22\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-22\n- 1 ML octreotide 0.05 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-03-22, presumably until 2013-09-22, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-03-24, presumably until 2013-03-24\n- sodium chloride 9 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-21\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-26\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2013-03-24, presumably until 2013-03-26\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-03-22, presumably until 2013-03-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-02 13:51:00, ended at 2013-04-02 17:44:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-04-02 17:45:00, ended at 2013-04-04 09:48:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 694 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 186 (unit per liter)\n- Body height: 5' 7\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.2 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.3 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Prothrombin time (PT): 13.2 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired hypothyroidism\n- Abdominal pain\n- Essential hypertension\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Postprocedural state finding\n- Urinary tract infectious disease\n- Hyperlipidemia\n- Malignant carcinoid tumor\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-04-02, presumably until 2013-04-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-04\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-02\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-03\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-04-02, presumably until 2013-04-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-04-03, presumably until 2013-04-03\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2013-04-03, presumably until 2013-04-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2013-04-04\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2014-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 13:11:00, ended at 2013-04-23 16:16:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-04-23, presumably until 2014-04-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 16:17:00, ended at 2013-04-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 404 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.75 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 59 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 228 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.06 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-23 13:20:00, ended at 2013-07-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 10:22:00, ended at 2014-01-21 12:38:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 12:39:00, ended at 2014-01-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant carcinoid tumor\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 10:11:00, ended at 2014-07-21 12:54:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Diverticular disease of colon\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 12:55:00, ended at 2014-07-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-22 00:00:00, ended at 2014-07-22 00:00:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 09:59:00, ended at 2015-01-20 13:29:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 13:30:00, ended at 2015-01-20 23:59:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.362\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ibuprofen 600 MG Oral Tablet, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 600 mg by mouth every 6 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-02 12:02:00, ended at 2016-02-02 23:59:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Postoperative state\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-02 14:52:50, ended at 2016-02-02 16:41:03\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- temazepam 30 MG Oral Capsule, through Oral route, presumably until 2017-01-31, with intended 0 refill(s). Instructions: take 30 mg by mouth every bedtime as needed for Insomnia\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-13 00:00:00, ended at 2016-02-13 00:00:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-31 10:31:00, ended at 2017-01-31 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-31 12:48:55, ended at 2017-01-31 15:51:30\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-03 00:00:00, ended at 2017-02-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-01 00:00:00, ended at 2017-08-01 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-01 10:19:00, ended at 2017-08-01 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Disease of liver\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2017-08-01, presumably until 2017-08-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-04 00:00:00, ended at 2017-08-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-08-20, presumably until 2017-10-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-03 09:15:44, ended at 2017-09-03 10:00:07\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 112 mcg by mouth every morning before breakfast\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2017-09-03, with intended 0 refill(s). Instructions: take 100 mcg by mouth every morning before breakfast\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 20 mg by mouth as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-03 10:20:00, ended at 2017-09-03 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.65 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Prothrombin time (PT): 13.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 230 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-04 00:00:00, ended at 2017-09-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- lidocaine hydrochloride 40 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2017-09-04, presumably until 2017-09-04\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-04 11:10:00, ended at 2017-09-09 09:30:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prothrombin time (PT): 15.8 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 265 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 462 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 21 - 50 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 101 - 200 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Supplement Abdominal Wall with Autologous Tissue Substitute, Open Approach\n- Excision of Aortic Lymphatic, Open Approach\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Release Peritoneum, Open Approach\n- Morphometric analysis, tumor\n- Excision of Right Lobe Liver, Open Approach\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n\n### Condition\n- Malignant neuroendocrine tumor\n- Neuroendocrine tumor\n- Primary diagnosis: Benign neuroendocrine tumor\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Peritoneal adhesion\n- Benign neoplasm of peripheral nerves of abdomen\n- Metastatic carcinoid tumor\n- Abnormal findings on diagnostic imaging of lung\n- Essential hypertension\n- Postoperative hypothyroidism\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2017-09-08, presumably until 2017-09-08\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-07, presumably until 2017-09-07\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-07\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2017-09-09\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-09-04, presumably until 2017-09-09\n- cefazolin 1000 MG Injection, started on 2017-09-04, presumably until 2017-09-04\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-05, presumably until 2017-09-08\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-08\n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2017-09-06, presumably until 2018-09-09, with intended 1 refill(s). Instructions: take 20.3 mL by mouth every 6 hours\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-09\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2017-09-05, presumably until 2017-09-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2017-09-09, presumably until 2017-11-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-16 00:00:00, ended at 2017-09-16 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 15:42:00, ended at 2017-09-16 16:46:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of kidney and/or ureter\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 16:47:00, ended at 2017-09-16 18:29:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 457 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucagon [Mass/volume] in Serum or Plasma: 71 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 22.35 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.3 (percent)\n- Pancreatic polypeptide [Mass/volume] in Serum or Plasma: 62 (picogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.69 (million per microliter)\n- Gastrin [Mass/volume] in Serum or Plasma: 28 (picogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Proinsulin [Moles/volume] in Serum or Plasma: 72 (picomole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.25 (thousand per microliter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 74 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 24.8 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 587 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Enolase.neuron specific [Mass/volume] in Serum or Plasma by Immunoassay: 2.2 (microgram per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign neuroendocrine tumor\n- Postprocedural fever\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-16 18:30:00, ended at 2017-09-20 12:16:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 188 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 346 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.74 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 599 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.1 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 1.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Body height: 5' 7.52\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Prothrombin time (PT): 15.1 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.23 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach\n\n### Condition\n- Acquired absence of organ\n- Leukocytosis\n- Streptococcal infectious disease\n- Infection due to enterococcus\n- Late effect of complications of procedure\n- Primary diagnosis: Ascites\n- Benign neuroendocrine tumor\n- Hyperlipidemia\n- Hypothyroidism\n- Postprocedural infection\n- Bacterial infectious disease\n- Essential hypertension\n- Abscess of peritoneum\n- Disorder of digestive system\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-17, presumably until 2017-09-19\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2017-09-18\n- Lacticaseibacillus rhamnosus GG 15000000000 UNT Oral Capsule, through Oral route, started on 2017-09-20, presumably until 2017-11-21, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-09-18\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-10-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-16, presumably until 2017-09-19\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-09-16, presumably until 2017-09-16\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, through Oral route, started on 2017-09-19, presumably until 2017-09-22, with intended 0 refill(s). Instructions: take 10.94 mL by mouth 2 times a day for 2 days\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-19, presumably until 2017-09-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-17 00:00:00, ended at 2017-09-17 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n\n### Condition\n- Abscess of peritoneum\n- Benign neuroendocrine tumor\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-17, presumably until 2017-09-17\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-17, presumably until 2017-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-26 00:00:00, ended at 2017-09-26 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-30 00:00:00, ended at 2017-09-30 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, started on 2017-10-02, presumably until 2017-10-02, with intended 0 refill(s). Instructions: take 10.94 milliliter twice a day for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-02 00:00:00, ended at 2017-10-02 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cystocele\n- Primary diagnosis: Benign neuroendocrine tumor\n- Hydronephrosis\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:10:00, ended at 2017-10-02 16:52:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Benign neuroendocrine tumor\n- Hydronephrosis\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:53:00, ended at 2017-10-02 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.94 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 93 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 455 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.55 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 243 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-03, presumably until 2017-10-03\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-10-03, presumably until 2017-10-03\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2017-10-03 00:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "09323c2371abdbff4e3facc061f0b723fde177d05fd7fe1ab3f680e7dbd397a0", "prompt_hash": "0ee6b52571cb73d0b8848a984d863667d7b57e652cd09a5b0e000cee4fc99c58", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 1.0, "f1_gu_yn": [1, 1], "recall_gu_yn": [1, 1]}
{"doc_id": 9, "doc": {"person_id": 115968494, "visit_occurrence_id": 168450122, "death_date": null, "visit_concept_name": "Hospital", "visit_start_datetime": "2020-12-21 00:00:00", "visit_end_datetime": "2020-12-21 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Hospital, started at 2020-12-21 00:00:00, ended at 2020-12-21 00:00:00\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2020-12-21, presumably until 2020-12-21\n- triamcinolone acetonide 40 MG/ML Injectable Suspension, started on 2020-12-21, presumably until 2020-12-21\n\n", "approximate_token_count": 128, "patient_first_visit_date": "2017-09-03 00:00:00", "patient_last_visit_date": "2022-10-26 09:59:00", "end_obs_date": "2021-12-21", "readmission_30d": 0, "visit_sequence_number": 156, "cumulated_visit_num": 156, "cumulated_approximate_token_count": 58787, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-03 00:00:00, ended at 2017-09-03 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Mature T-cell AND/OR NK cell neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-10 00:00:00, ended at 2017-09-10 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-09-10, presumably until 2017-09-10, with intended 3 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-10 17:36:00, ended at 2017-09-17 16:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 91.4 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Anion gap in Serum or Plasma: <2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 39 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 4 (per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 241 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 413 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.25 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.3 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.8 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.24 (millimole per liter)\n- Prothrombin time (PT): 13.0 (second)\n- Thrombin time: 15.0 (second)\n- Urate [Mass/volume] in Serum or Plasma: <2.0 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.73 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 453 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Body height: 5' 4.764\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.67 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 1049 (microgram of fibrinogen equivalent unit per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: 1 (per microliter)\n\n### Procedure\n- Diagnostic bone marrow; biopsy(ies)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Extraction of Iliac Bone Marrow, Percutaneous Approach, Diagnostic\n- Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n- Ultrasound, scrotum and contents\n- Collection of venous blood by venipuncture\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n\n### Condition\n- Non-Hodgkin's lymphoma of extranodal site\n- Atrial fibrillation\n- Pleural effusion\n- Abnormal findings on diagnostic imaging of lung\n- Anemia in neoplastic disease\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Disorder of male genital organ\n- Abnormal cytological findings in CSF\n- Electrocardiogram abnormal\n- Anemia\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2017-09-15, presumably until 2017-09-15\n- sodium bicarbonate 650 MG Oral Tablet, started on 2017-09-16, presumably until 2017-09-19, with intended 0 refill(s). Instructions: Take 2 tabs the night before chemotherapy and the morning of chemotherapy.\n- metoclopramide 1 MG/ML Oral Solution, through Oral route, started on 2017-09-15, presumably until 2017-10-05, with intended 0 refill(s). Instructions: take 10 mL by mouth 3 times a day as needed (hiccups)\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-09-12, presumably until 2018-05-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2017-09-11, presumably until 2017-09-16\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-09-14, presumably until 2017-10-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (Mild to moderate nausea/vomiting.)\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-09-12, presumably until 2017-10-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-09-11, presumably until 2017-09-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-12, presumably until 2017-09-14\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-09-11, presumably until 2017-09-15\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-09-11, presumably until 2017-09-11\n- clotrimazole 10 MG Oral Lozenge, through Submucosal route, started on 2017-09-17, presumably until 2017-10-04, with intended 3 refill(s). Instructions: take 1 Lozenge by mouth 5 times a day\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-09-16\n- sodium chloride 9 MG/ML Injection, started on 2017-09-16, presumably until 2017-09-16\n- gadobenate, through Intravenous route, started on 2017-09-11, presumably until 2017-09-11\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-09-10, presumably until 2017-09-17\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-09-10, presumably until 2017-09-16\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-09-11, presumably until 2017-10-05, with intended 4 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2017-09-14, presumably until 2017-10-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (Mild to moderate nausea/vomiting)\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2017-09-15, presumably until 2017-09-15\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2018-02-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth every day Do not take 24 hours prior to chemotherapy\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-13, presumably until 2017-09-13\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-09-15, presumably until 2017-09-15\n- leucovorin 25 MG Oral Tablet, through Oral route, started on 2017-09-15, presumably until 2017-09-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-09-13, presumably until 2017-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-19 00:00:00, ended at 2017-09-19 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2017-09-19, presumably until 2018-02-07, with intended 2 refill(s). Instructions: take 4 Tabs by mouth every 4 hours Starting at 6 am on the day of hospital admission\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 12:00:00, ended at 2017-10-04 15:36:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 187 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.68 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 163 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 147 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 4.9 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 91 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.0 (second)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.98 (thousand per microliter)\n- Prothrombin time (PT): 15.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 418 (unit per liter)\n- Thrombin time: 21.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 475 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 821 (microgram of fibrinogen equivalent unit per milliliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 240 (unit per liter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-04 12:43:33, ended at 2017-10-04 14:51:18\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 4.8 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 334 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 15:37:00, ended at 2017-10-05 17:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 78 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 4.9 (gram per deciliter)\n- Thrombin time: 20.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.38 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Prothrombin time (PT): 16.0 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.7 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.9 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 439 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.71 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Body height: 5' 5.551\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 565 (microgram of fibrinogen equivalent unit per milliliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 86 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 136 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n\n### Procedure\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Transfusion, blood or blood components\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study\n- Ultrasound, abdominal, real time with image documentation; complete\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of bilirubin metabolism\n- Disease of liver\n- Fatigue\n- Headache\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Anemia of chronic disease\n- Atrial fibrillation\n- Nausea\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- gadobenate, through Intravenous route, started on 2017-10-04, presumably until 2017-10-04\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2018-04-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain (headache)\n- docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-10-05, presumably until 2018-04-20, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day as needed For constipation\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-07 07:40:00, ended at 2017-10-07 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.76 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 321 (unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.1 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 164 (unit per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Thrombin time: 18.6 (second)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 87.6 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 168 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 196 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 290 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.36 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.24 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 991 (microgram of fibrinogen equivalent unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 734 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.6 (percent)\n- Prothrombin time (PT): 13.1 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-11 12:12:00, ended at 2017-10-11 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 701 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- MCV [Entitic volume] by Automated count: 87.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 238 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.6 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.61 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 553 (microgram of fibrinogen equivalent unit per milliliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.8 (percent)\n- Prothrombin time (PT): 13.0 (second)\n- Thrombin time: 16.5 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 195 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.90 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 322 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-17 10:00:00, ended at 2017-10-17 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.51 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.3 (femtoliter)\n- Thrombin time: 14.9 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 311 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 489 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 42.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.2 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 383 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.02 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 20.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Prothrombin time (PT): 12.2 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 205 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 231 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 35.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 261 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-17 10:56:58, ended at 2017-10-17 13:31:27\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-18 00:00:00, ended at 2017-10-18 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-10-19 12:16:00, ended at 2017-10-23 15:30:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 1 (per microliter)\n- Thrombin time: 15.2 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 469 (microgram of fibrinogen equivalent unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.28 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 193 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 357 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 227 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: <1 (per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Prothrombin time (PT): 12.5 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 271 (unit per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 368 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.55 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach\n- Collection of blood specimen from a completely implantable venous access device\n- Hospital discharge day management; more than 30 minutes\n- Radiologic examination, chest; single view, frontal\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n\n### Condition\n- Pleural effusion\n- Disease of liver\n- Essential hypertension\n- Disorder of the central nervous system\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Anemia due to and following chemotherapy\n- Chronic atrial fibrillation\n- Headache\n- Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-10-23\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-10-21, presumably until 2018-04-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (Mild to moderate nausea/vomiting.)\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-11-29, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-10-21\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2017-10-21, presumably until 2017-10-21\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-10-19, presumably until 2017-10-22\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-10-19, presumably until 2017-10-23\n- baclofen 10 MG Oral Tablet, through Oral route, started on 2017-10-21, presumably until 2017-10-22\n- dexamethasone 2 MG Oral Tablet, through Oral route, started on 2017-10-21, presumably until 2017-11-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-10-23\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-10-24, presumably until 2017-11-15, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily For 10 days starting in the evening on 9/28\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-10-20, presumably until 2017-10-21\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-10-22, presumably until 2017-10-22\n- leucovorin 25 MG Oral Tablet, through Oral route, started on 2017-10-22, presumably until 2017-10-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-23 14:40:00, ended at 2017-10-23 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplastic disease of uncertain behavior\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-25 09:08:22, ended at 2017-10-25 10:28:31\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-01 00:00:00, ended at 2017-11-01 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-04 00:00:00, ended at 2017-11-04 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2017-11-04, presumably until 2017-11-14, with intended 1 refill(s). Instructions: take 30 mL by mouth 3 times a day as needed Titrate to 2 soft stools daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-04 07:46:00, ended at 2017-11-04 13:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 97 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-04 07:46:00, ended at 2017-11-04 13:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-04 13:01:06, ended at 2017-11-04 15:19:46\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.12\" (inch (US))\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm\n- Extranodal NK/T-cell lymphoma, nasal type\n- Primary diagnosis: Malignant tumor of lymphoid hemopoietic and related tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-04 14:00:00, ended at 2017-11-04 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Ammonia [Mass/volume] in Plasma: 52 (micromole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.30 (million per microliter)\n- Thrombin time: 16.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 612 (microgram of fibrinogen equivalent unit per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 45 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.4 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 355 (unit per liter)\n- Prothrombin time (PT): 13.2 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 2 (milli-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.41 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 41.2 (second)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 1.03 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 223 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.58 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 178 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant tumor of lymphoid hemopoietic and related tissue\n- Extranodal NK/T-cell lymphoma, nasal type\n- Blood coagulation disorder\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Disease of liver\n- Primary malignant neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Eruption\n- Localized infection of skin AND/OR subcutaneous tissue\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-07 10:19:00, ended at 2017-11-07 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16 (percent)\n- Prothrombin time (PT): 13.8 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13 (percent)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.19 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 185 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.56 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 307 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 43.8 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 259 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 703 (microgram of fibrinogen equivalent unit per milliliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Neutrophils/100 leukocytes in Blood by Manual count: 57 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Ammonia [Mass/volume] in Plasma: 67 (micromole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 1.92 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 241 (unit per liter)\n- Thrombin time: 16.9 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Localized infection of skin AND/OR subcutaneous tissue\n- Eruption\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-07 11:12:56, ended at 2017-11-07 13:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-07 15:24:05, ended at 2017-11-07 16:06:44\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of uncertain behavior of skin\n- Eruption\n- Localized infection of skin AND/OR subcutaneous tissue\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-11-07, presumably until 2017-11-12, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day for 5 days Please do not dispense generic form.\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2017-11-07, presumably until 2018-04-20, with intended 3 refill(s). Instructions: Apply topically as directed twice daily to affected area(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-11 00:00:00, ended at 2017-11-11 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-14 11:29:00, ended at 2017-11-14 17:58:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.56 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 358 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.20 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Neutrophils/100 leukocytes in Blood by Manual count: 59 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 381 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.36 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.1 (gram per deciliter)\n- Ammonia [Mass/volume] in Plasma: 55 (micromole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 537 (microgram of fibrinogen equivalent unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 282 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 201 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Prothrombin time (PT): 12.9 (second)\n- Thrombin time: 13.3 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n\n### Procedure\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-14 13:07:17, ended at 2017-11-14 14:23:18\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2018-04-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-11-14 17:59:00, ended at 2017-11-18 14:53:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.59 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Body height: 5' 4.961\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: 13 (per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 308 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- MCV [Entitic volume] by Automated count: 94.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.94 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 2 (per microliter)\n- Platelets [#/volume] in Blood by Automated count: 429 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Hyperlipidemia\n- Disease of liver\n- Herpesvirus infection\n- Prediabetes\n- Localized edema\n- Chronic atrial fibrillation\n- Essential hypertension\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Disorder of the central nervous system\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-14\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-18\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-17\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-18\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-11-16, presumably until 2017-11-17\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-11-18, presumably until 2017-11-18\n- dexamethasone 1 MG Oral Tablet, started on 2017-11-15, presumably until 2017-11-16, with intended 0 refill(s). Instructions: Take 2 mg in the morning for 2 days then 1 mg in the morning for 2 days then 0.5 mg in the morning for 2 days then stop.\n- dexamethasone 2 MG Oral Tablet, started on 2017-11-15, presumably until 2017-12-16, with intended 0 refill(s). Instructions: Take 2 mg in morning and evening for 2 days ( 10/24 and 10/25)  then 2 mg in the morning for 2 days ( 10/26 and 10/27)  then 1 mg ( 1/2 tablet)  in the morning for 2 days ( 10/28 and 10/29).\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-18\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-11-15, presumably until 2017-11-16\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-11-15, presumably until 2017-12-16, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-11-17, presumably until 2017-11-17\n- mupirocin 0.02 MG/MG Topical Ointment, through Topical route, started on 2017-11-16, presumably until 2017-11-18\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-11-17, presumably until 2017-11-18\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-11-16, presumably until 2017-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-25 00:00:00, ended at 2017-11-25 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-25 07:28:00, ended at 2017-11-25 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 8.4 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 212 (unit per liter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.58 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 822 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.60 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.2 (percent)\n- Prothrombin time (PT): 12.5 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Thrombin time: 13.8 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.1 (second)\n- Ammonia [Mass/volume] in Plasma: 31 (micromole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 107 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 213 (unit per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 523 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-29 00:00:00, ended at 2017-11-29 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea\n\n### Drug\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-11-29, presumably until 2017-12-18, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-12 10:50:00, ended at 2017-12-12 15:04:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.89 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 197 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.25 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 791 (microgram of fibrinogen equivalent unit per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.8 (percent)\n- Thrombin time: 17.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.85 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Ammonia [Mass/volume] in Plasma: 66 (micromole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 208 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 311 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.1 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 188 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.56 (milligram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Extranodal NK/T-cell lymphoma, nasal type\n- Atrial fibrillation\n- Localized edema\n- Disease of liver\n- Herpesvirus infection\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 12:14:34, ended at 2017-12-12 14:25:45\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-12-12 15:05:00, ended at 2017-12-16 17:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- MCV [Entitic volume] by Automated count: 97.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.38 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Thrombin time: 19.9 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Prothrombin time (PT): 14.5 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.6 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.70 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 950 (microgram of fibrinogen equivalent unit per milliliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 184 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 4 (per microliter)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.69 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: <1 (per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.3 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.7 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n\n### Procedure\n- Inspection of Lower Back, External Approach\n- Collection of venous blood by venipuncture\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n\n### Condition\n- Hypervolemia\n- Disorder of the central nervous system\n- Enteropathy-associated T-cell lymphoma\n- Acquired absence of organ\n- Atrial fibrillation\n- Disorder of digestive system\n- Disseminated intravascular coagulation\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hiccoughs\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-15\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-12-12, presumably until 2017-12-13\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-14\n- baclofen 10 MG Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-16\n- dexamethasone 2 MG Oral Tablet, started on 2017-12-16, presumably until 2018-02-07, with intended 0 refill(s). Instructions: Take 2 mg in morning and evening for 2 days (11/21 and 11/22)  then 2 mg in the morning for 2 days (11/24-11/25)  then 1 mg ( 1/2 tablet)  in the morning for 2 days (11/26-11/27).\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-12-15, presumably until 2017-12-16\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-12-16, presumably until 2018-02-07, with intended 0 refill(s). Instructions: Inject daily for 10 days starting 24-48h after completion of chemotherapy\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2017-12-12, presumably until 2017-12-15\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-12-15, presumably until 2017-12-16\n- leucovorin 25 MG Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-18 00:00:00, ended at 2017-12-18 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-12-18, presumably until 2017-12-29, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-23 00:00:00, ended at 2017-12-23 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-12-23, presumably until 2018-12-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-26 00:00:00, ended at 2017-12-26 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 07:38:00, ended at 2017-12-26 09:49:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Disorder of bone\n- Disorder of lower leg\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 07:38:00, ended at 2017-12-26 09:49:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 84 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 09:50:00, ended at 2017-12-26 10:50:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.8 (percent)\n- MCV [Entitic volume] by Automated count: 100.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 226 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 65 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 199 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.48 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.2 (gram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 8 (milli-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 22.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.4 (second)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 411 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 49 (thousand per microliter)\n- Prothrombin time (PT): 12.9 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.60 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.23 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 553 (microgram of fibrinogen equivalent unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.46 (thousand per microliter)\n- Thrombin time: 15.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Ammonia [Mass/volume] in Plasma: 51 (micromole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 10:51:00, ended at 2017-12-26 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- gadobenate, through Intravenous route, started on 2017-12-26, presumably until 2017-12-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-29 00:00:00, ended at 2017-12-29 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-12-30, presumably until 2018-05-12, with intended 0 refill(s). Instructions: TAKE 2 TABS BY MOUTH EVERY BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-02 12:42:56, ended at 2018-01-02 15:30:22\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Disease of liver\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hyperlipidemia\n- Localized edema\n- Herpesvirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-01-06 00:00:00, ended at 2018-01-06 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-14 14:00:00, ended at 2018-01-14 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Nutritional anemia\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n- Disorder of hematopoietic structure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 08:52:00, ended at 2018-01-15 12:24:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 68.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 12:25:00, ended at 2018-01-15 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.1 (gram per deciliter)\n- Ammonia [Mass/volume] in Plasma: 55 (micromole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.6 (picogram)\n- Thrombin time: 16.2 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 126 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 191 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 499 (microgram of fibrinogen equivalent unit per milliliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 313 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 234 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.6 (percent)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Prothrombin time (PT): 12.5 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.53 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 23.2 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Collection of venous blood by venipuncture\n- Diagnostic bone marrow; biopsy(ies)\n\n### Condition\n- Nutritional anemia\n- Neutropenia\n- Extranodal NK/T-cell lymphoma, nasal type\n- Thrombocytopenic disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-30 00:00:00, ended at 2018-01-30 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-Hodgkin's lymphoma (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-02-04 00:00:00, ended at 2018-02-04 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2018-02-04, presumably until 2018-02-04\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-02-04, presumably until 2018-02-04\n- midazolam 1 MG/ML Injectable Solution, started on 2018-02-04, presumably until 2018-02-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-04 06:38:00, ended at 2018-02-04 09:58:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Prediabetes\n- Secondary malignant neoplasm of bone\n- Essential hypertension\n- Paroxysmal atrial fibrillation\n- Hyperlipidemia\n- Mature T-cell AND/OR NK cell neoplasm\n- Secondary malignant neoplasm of small intestine\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-02-04, presumably until 2018-02-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-04 11:52:00, ended at 2018-02-04 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Herpesvirus infection\n- Localized edema\n- Disease of liver\n- Extranodal NK/T-cell lymphoma, nasal type\n- Non-Hodgkin's lymphoma (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-02-05 17:53:00, ended at 2018-02-07 16:22:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.21 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.81 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.4 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Base excess in Arterial blood by calculation: -9.6 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.95 (million per microliter)\n- Lactate [Moles/volume] in Blood: 8.3 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.5 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 360 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 182 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 215 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 35.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.58 (micro-international unit per milliliter)\n- Urate [Mass/volume] in Serum or Plasma: 7.3 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 5' 5.354\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 114 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- MCV [Entitic volume] by Automated count: 109.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 95 (thousand per microliter)\n- Prothrombin time (PT): 14.3 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 16.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.67 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Thrombin time: 15.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 3308 (microgram of fibrinogen equivalent unit per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n\n### Procedure\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; 1 view\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Atrial fibrillation\n- Heart failure\n- Hyperlipidemia\n- Prediabetes\n- Electrocardiogram abnormal\n- Abdominal distension, gaseous\n- Chronic pulmonary edema\n- Low blood pressure\n- Disorder of digestive system\n- Essential hypertension\n- Paroxysmal atrial fibrillation\n- Acquired absence of organ\n- Drug-induced hypotension\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hypovolemic shock\n- Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- 1000 ML potassium chloride 0.04 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-02-05, presumably until 2018-02-05\n- hydrocortisone 100 MG Injection, started on 2018-02-06, presumably until 2018-02-06\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2018-02-06, presumably until 2018-02-06\n- etoposide 20 MG/ML Injectable Solution, through Intravenous route, started on 2018-02-05, presumably until 2018-02-05\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2018-02-06, presumably until 2018-02-07\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2018-02-05, presumably until 2018-02-06\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-02-05, presumably until 2018-02-07\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-02-05, presumably until 2018-02-06\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-02-05, presumably until 2018-02-05\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-02-07, presumably until 2018-02-07\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-02-07, presumably until 2018-02-07\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2018-02-06, presumably until 2018-02-07\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2018-02-06, presumably until 2018-02-06\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2018-02-06, presumably until 2018-02-07\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-02-06, presumably until 2018-02-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-02-05, presumably until 2018-02-05\n- 100 ML amiodarone hydrochloride 1.5 MG/ML Injection, through Intravenous route, started on 2018-02-06, presumably until 2018-02-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 08:09:00, ended at 2018-02-06 08:42:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; single view\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 08:43:00, ended at 2018-02-06 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, abdomen; 1 view\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-08 11:00:00, ended at 2018-02-08 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 22.5 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 105.6 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 194 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 98.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- MCH [Entitic mass] by Automated count: 34.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 22.05 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 107 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 74 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.80 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Herpesvirus infection\n- Disease of liver\n- Paroxysmal atrial fibrillation\n- Localized edema\n\n### Drug\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-02-08, presumably until 2018-02-08\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-02-08, presumably until 2018-02-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-11 11:30:00, ended at 2018-02-11 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-12 11:45:00, ended at 2018-02-12 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-13 11:45:00, ended at 2018-02-13 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-14 11:30:00, ended at 2018-02-14 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-15 11:15:00, ended at 2018-02-15 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-16 11:30:00, ended at 2018-02-16 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-17 12:00:00, ended at 2018-02-17 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-18 12:00:00, ended at 2018-02-18 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-19 10:28:00, ended at 2018-02-19 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-20 11:58:00, ended at 2018-02-20 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-21 12:38:00, ended at 2018-02-21 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-03 00:00:00, ended at 2018-03-03 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-03 13:33:00, ended at 2018-03-03 13:43:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Pleural effusion\n- Atelectasis\n- Chronic pulmonary edema\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-03 13:44:00, ended at 2018-03-03 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 293 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 35.2 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 2.09 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.99 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 123 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.4 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-03, presumably until 2018-03-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-03 14:37:03, ended at 2018-03-03 15:56:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2018-02-25, presumably until 2018-03-31, with intended 0 refill(s). Instructions: take 200 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-12 16:54:00, ended at 2018-03-12 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2018-03-12, presumably until 2018-03-12\n- 1.2 ML plerixafor 20 MG/ML Injection, through Subcutaneous route, started on 2018-03-12, presumably until 2018-03-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-13 07:30:00, ended at 2018-03-13 17:58:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.0 (percent)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.22 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 16 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 14.74 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 156 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.92 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Body height: 5' 5.354\" (inch (US))\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 32 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Leukocytes [#/volume] in Blood by Automated count: 92100 (per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 92.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 7.37 (thousand per microliter)\n\n### Procedure\n- Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage\n- Collection of venous blood by venipuncture\n- Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- sodium citrate, through Intravenous route, started on 2018-03-13, presumably until 2018-03-13\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-03-13, presumably until 2018-03-13\n- citric acid, through Intravenous route, started on 2018-03-13, presumably until 2018-03-13\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-13, presumably until 2018-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-13 17:59:00, ended at 2018-03-13 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- 1.2 ML plerixafor 20 MG/ML Injection, through Subcutaneous route, started on 2018-03-13, presumably until 2018-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-14 07:30:00, ended at 2018-03-14 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.3 (percent)\n- Body height: 5' 5.354\" (inch (US))\n- MCV [Entitic volume] by Automated count: 95.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 80 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.58 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 92.3 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage\n- Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- sodium citrate, through Intravenous route, started on 2018-03-14, presumably until 2018-03-14\n- citric acid, through Intravenous route, started on 2018-03-14, presumably until 2018-03-14\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-14, presumably until 2018-03-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-21 00:00:00, ended at 2018-03-21 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-27, presumably until 2018-03-27, with intended 2 refill(s). Instructions: 3 mL by Intravenous route every day Flush each lumen of double lumen catheter daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-27 00:00:00, ended at 2018-03-27 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-31 13:50:00, ended at 2018-03-31 14:14:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 1483 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.33 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 39.5 (second)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Thrombin time: 37.3 (second)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 64 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.0 (percent)\n- Prothrombin time (PT): 12.7 (second)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 341 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Ammonia [Mass/volume] in Plasma: 13 (micromole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 197 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.9 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pancytopenia due to antineoplastic chemotherapy\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-31, presumably until 2018-03-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-31 14:15:00, ended at 2018-03-31 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-01 17:10:00, ended at 2018-04-20 12:14:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Lactate [Moles/volume] in Blood: 1.8 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.91 (thousand per microliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.5 (microgram per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 161 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.01 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.24 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 9 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 99.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Manual count: 0.39 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 68 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.31 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.050 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, chest; single view\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Radiologic examination, abdomen; 2 views\n- Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach\n- Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Hematopoietic progenitor cell (HPC); autologous transplantation\n- Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Sepsis\n- Tachycardia\n- Disorder of esophagus\n- Essential hypertension\n- Electrocardiogram abnormal\n- Fever\n- Low blood pressure\n- Neutropenia\n- Oral ulcerative mucositis due to antineoplastic therapy\n- Paroxysmal atrial fibrillation\n- Herpesvirus infection\n- Transplant present\n- Benign prostatic hyperplasia\n- Disorder of intestine\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Long QT syndrome\n- Pancytopenia due to antineoplastic chemotherapy\n- Abdominal distension, gaseous\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hyperlipidemia\n- Hypervolemia\n- Inflammatory disorder of digestive tract\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2018-04-07, presumably until 2018-04-07\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2018-04-13, presumably until 2018-04-19\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-20\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2018-04-03, presumably until 2018-04-20, with intended 3 refill(s). Instructions: take 2 Caps by mouth 4 times a day as needed\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-04-16, presumably until 2018-04-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2018-04-07, presumably until 2018-04-07\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-19\n- melphalan 50 MG Injection, through Intravenous route, started on 2018-04-06, presumably until 2018-04-06\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2019-04-19, with intended 11 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-03\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-12, presumably until 2018-04-13\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2018-04-03\n- diphenhydramine hydrochloride 2.5 MG/ML Oral Solution, through Oral route, started on 2018-04-08, presumably until 2018-04-12\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2018-04-10, presumably until 2018-04-11\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 6 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-07\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-18\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2018-04-04, presumably until 2018-04-06\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-04-09, presumably until 2018-04-12\n- 1 ML dexamethasone phosphate 10 MG/ML Injection, started on 2018-04-18, presumably until 2018-04-18\n- cholecalciferol 0.025 MG Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2019-04-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 10 ML furosemide 10 MG/ML Injection, started on 2018-04-07, presumably until 2018-04-19\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2018-04-20\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-04-20, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-17\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-18\n- atropine sulfate 0.025 MG / diphenoxylate hydrochloride 2.5 MG Oral Tablet, through Oral route, started on 2018-04-14, presumably until 2018-04-19\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-02, presumably until 2018-04-20\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-01, presumably until 2018-04-20\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2018-04-19, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day for 6 days\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-20\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2018-04-01, presumably until 2018-04-15\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2018-04-02, presumably until 2018-04-02\n- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2018-04-08, presumably until 2018-04-12\n- 250 ML heparin sodium, porcine 100 UNT/ML Injection, through Intravenous route, started on 2018-04-01, presumably until 2018-04-18\n- loratadine 10 MG Oral Tablet, through Oral route, started on 2018-04-15, presumably until 2018-04-20\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2018-04-15, presumably until 2018-04-16\n- opium tincture 100 MG/ML Oral Solution, through Oral route, started on 2018-04-15, presumably until 2018-04-15\n- 200 ML fluconazole 2 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-15\n- glucose 50 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-14\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2018-04-19, presumably until 2018-04-19\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2018-04-08, presumably until 2018-04-13\n- ondansetron 8 MG Disintegrating Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-04 00:00:00, ended at 2018-04-04 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, started on 2018-04-08, presumably until 2018-04-08, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-22 16:33:00, ended at 2018-04-22 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.33 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.0 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.31 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.64 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.26 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 68 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 5 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Transfusion, blood or blood components\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-04-22, presumably until 2018-04-22\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-22, presumably until 2018-04-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-23 13:59:00, ended at 2018-04-23 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.16 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.61 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 19 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-23, presumably until 2018-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-24 15:40:00, ended at 2018-04-24 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 0.34 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 35 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.15 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.62 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 9 (thousand per microliter)\n\n### Procedure\n- Transfusion, blood or blood components\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Pancytopenia due to antineoplastic chemotherapy\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-27 15:06:00, ended at 2018-04-27 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.42 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 10 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 27.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.57 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.05 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 54.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.6 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Transfusion, blood or blood components\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2018-04-27, presumably until 2018-04-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-30 14:59:00, ended at 2018-04-30 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 25.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.65 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 23 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 33.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.92 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.4 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Paroxysmal atrial fibrillation\n\n### Drug\n- dibasic potassium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- potassium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- tribasic potassium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- tribasic sodium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-30, presumably until 2018-04-30\n- sodium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- sodium phosphate, monobasic, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- sodium phosphate, dibasic, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2018-04-30, presumably until 2018-05-30, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day for 30 days\n- dibasic sodium phosphate heptahydrate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-05 14:04:00, ended at 2018-05-05 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 40 (nanogram per milliliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 24 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Prothrombin time (PT): 12.5 (second)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.58 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.75 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.73 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.3 (second)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 40 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.02 (thousand per microliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 1055 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 25.6 (percent)\n- Ammonia [Mass/volume] in Plasma: 19 (micromole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 13 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Thrombin time: 28.4 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Monocytes [#/volume] in Blood by Manual count: 0.48 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 441 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-05, presumably until 2018-05-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-05 14:28:59, ended at 2018-05-05 16:48:36\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.16\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-12 10:40:00, ended at 2018-05-12 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 102 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.76 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 39.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.41 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 25 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 21.0 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-12, presumably until 2018-05-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-12 11:32:31, ended at 2018-05-12 12:50:33\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- fluconazole 200 MG Oral Tablet, through Oral route, started on 2018-05-12, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-20 00:00:00, ended at 2018-05-20 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-21, presumably until 2018-07-18, with intended 6 refill(s). Instructions: 3 mL by Intravenous route every day Flush each lumen of double lumen catheter daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-26 10:20:00, ended at 2018-05-26 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 20.7 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 40 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.73 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 49.1 (percent)\n- MCV [Entitic volume] by Automated count: 95.3 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.16 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-26, presumably until 2018-05-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-25 00:00:00, ended at 2018-06-25 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-06-26, presumably until 2018-06-26, with intended 6 refill(s). Instructions: 3 mL by Intravenous route every day Flush each lumen of double lumen catheter daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-26 00:00:00, ended at 2018-06-26 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-06-26, presumably until 2018-07-07, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-07 08:44:00, ended at 2018-07-07 12:05:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 114 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-07 08:44:00, ended at 2018-07-07 12:05:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-07 12:06:00, ended at 2018-07-07 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 44 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.4 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 356 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 416 (microgram of fibrinogen equivalent unit per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n- MCV [Entitic volume] by Automated count: 106.3 (femtoliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Prothrombin time (PT): 12.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.96 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Thrombin time: 17.0 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-07 13:23:41, ended at 2018-07-07 14:11:17\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-07-07, presumably until 2018-08-11, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-18 12:18:00, ended at 2018-07-18 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 42 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.90 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 107.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.6 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.5 (percent)\n- MCH [Entitic mass] by Automated count: 36.8 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-18 12:54:41, ended at 2018-07-18 14:32:13\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, presumably until 2019-02-02, with intended 0 refill(s). Instructions: take by mouth\n- pregabalin 50 MG Oral Capsule, through Oral route, presumably until 2018-08-04, with intended 0 refill(s). Instructions: take by mouth daily Advised to titrate up to 100mg po daily starting 6/23   08/04/2018 150mg daily\n- celecoxib 200 MG Oral Capsule, through Oral route, presumably until 2020-09-14, with intended 0 refill(s). Instructions: take 400 mg by mouth every day\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2018-06-02, presumably until 2018-06-02, with intended 5 refill(s). Instructions: Take 1 capsule (0.4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-04 14:19:00, ended at 2018-08-04 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 107.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.46 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 36.5 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 46 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.08 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Polyneuropathy due to drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-11 00:00:00, ended at 2018-08-11 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-08-12, presumably until 2018-09-15, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-11 00:00:00, ended at 2018-08-11 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2018-08-11, presumably until 2019-02-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-15 00:00:00, ended at 2018-09-15 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-09-15, presumably until 2018-10-21, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-19 00:00:00, ended at 2018-09-19 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- famotidine 20 MG Oral Tablet, started on 2018-09-19, presumably until 2019-02-02, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-20 14:00:00, ended at 2018-10-20 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.81 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.18 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 43 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.5 (picogram)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.18 (million per microliter)\n- MCV [Entitic volume] by Automated count: 104.4 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-20 15:01:49, ended at 2018-10-20 16:09:07\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-21 00:00:00, ended at 2018-10-21 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-10-21, presumably until 2018-12-09, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-24 13:36:03, ended at 2018-10-24 14:56:06\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-04 10:26:00, ended at 2018-11-04 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.33 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 104.0 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.19 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 35.5 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 56.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.51 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 56 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Diagnostic bone marrow; biopsy(ies) and aspiration(s)\n\n### Condition\n- Thrombocytopenic disorder\n- Extranodal NK/T-cell lymphoma, nasal type\n- Nutritional anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-09 00:00:00, ended at 2018-12-09 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-12-15, presumably until 2020-01-14, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-07 11:05:00, ended at 2019-01-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-07 11:05:00, ended at 2019-01-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 117 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2019-01-15, presumably until 2019-04-16, with intended 6 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, started on 2019-01-15, presumably until 2019-01-15, with intended 3 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-02 13:58:00, ended at 2019-02-02 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.79 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.7 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 104.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.19 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 57 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 48.9 (percent)\n- MCH [Entitic mass] by Automated count: 34.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 38.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-26 00:00:00, ended at 2019-03-26 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-30 10:25:00, ended at 2019-03-30 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 113 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-16 08:00:00, ended at 2019-04-16 09:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 175 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.37 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 51 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Polyneuropathy due to drug\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-16 10:00:00, ended at 2019-04-16 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-04-16, presumably until 2019-04-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-08 14:46:59, ended at 2019-07-08 15:26:05\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-Hodgkin's lymphoma (clinical)\n- Extranodal NK/T-cell lymphoma, nasal type\n- Polyneuropathy due to drug\n- Anemia\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2019-07-08, presumably until 2020-07-07, with intended 11 refill(s). Instructions: take 1 Tab (500 mg total) by mouth 2 times a day Take 1000 mg (2 pills) three time a day for 10 days, then decrease to 500 mg (1 pill) twice a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-20 00:00:00, ended at 2019-07-20 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-23 11:46:00, ended at 2019-07-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 107.4 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 38.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.77 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 240 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 4.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 76 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 51.5 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.02 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-23 13:28:37, ended at 2019-07-23 14:43:38\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-25 00:00:00, ended at 2019-09-25 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, started on 2019-09-30, presumably until 2020-03-13, with intended 4 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH TWICE A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-20 11:06:00, ended at 2019-10-20 11:06:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 120 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Localized enlarged lymph nodes\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 10:45:00, ended at 2019-10-28 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.61 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 48.0 (percent)\n- MCV [Entitic volume] by Automated count: 109.8 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.48 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.08 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 36.8 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 70 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 40.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-28 12:30:16, ended at 2019-10-28 14:04:48\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Polyneuropathy due to drug\n- Primary diagnosis: Non-Hodgkin's lymphoma (clinical)\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-14 00:00:00, ended at 2020-01-14 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-14 13:16:00, ended at 2020-01-14 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.78 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 37.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 168 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 52.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.56 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 106.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 82 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.84 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 35.1 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-13 00:00:00, ended at 2020-03-13 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2020-03-15, presumably until 2020-05-15, with intended 1 refill(s). Instructions: take 1 Abdul (150 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-21 11:21:24, ended at 2020-04-21 11:32:43\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-herpetic neuritis\n- Primary diagnosis: Cough\n- Polyneuropathy due to drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-21 15:01:22, ended at 2020-04-21 15:15:22\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Post-herpetic neuritis\n- Primary diagnosis: Polyneuropathy due to drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-27 00:00:00, ended at 2020-04-27 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2020-04-27, presumably until 2020-04-27, with intended 1 refill(s). Instructions: take 1 Zarghami (150 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-15 00:00:00, ended at 2020-05-15 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2020-05-16, presumably until 2020-07-15, with intended 1 refill(s). Instructions: take 1 Thampy (150 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-23 09:25:00, ended at 2020-05-23 11:22:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 125 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-23 09:25:00, ended at 2020-05-23 11:22:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-23 11:23:00, ended at 2020-05-23 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 94 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 45.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.03 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 178 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 35.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-30 13:59:51, ended at 2020-05-30 14:11:28\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycosis fungoides (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-14 13:26:56, ended at 2020-07-14 14:07:23\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-15 08:54:12, ended at 2020-07-15 09:34:54\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- pregabalin 200 MG Oral Capsule, started on 2020-07-15, presumably until 2020-11-11, with intended 2 refill(s). Instructions: 1 cap 2 times a day and 3rd cap daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-19 00:00:00, ended at 2020-07-19 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ketamine, started on 2020-07-19, presumably until 2020-09-15, with intended 2 refill(s). Instructions: Ketamine 15% Diclofenac 3% Gabapentin 3% Cyclobenzaprine 3% Lidocaine 5%. Apply quarter size in total (2 grams) 2 times a day to painful areas as needed for pain as a part of a desensitization regimen\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-08 00:00:00, ended at 2020-09-08 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-13 11:20:45, ended at 2020-09-13 11:20:54\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-09-15 00:00:00, ended at 2020-09-15 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2020-09-15, presumably until 2020-09-15\n- methylprednisolone acetate 40 MG/ML Injectable Suspension, started on 2020-09-15, presumably until 2020-09-15\n- midazolam 1 MG/ML Injectable Solution, started on 2020-09-15, presumably until 2020-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-15 09:41:00, ended at 2020-09-15 12:18:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level (List separately in addition to code for primary procedure)\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level\n\n### Condition\n- Intercostal neuropathy\n- Atrial fibrillation\n- Essential hypertension\n- Mononeuropathy\n- Post-herpetic neuritis\n- Prediabetes\n- Polyneuropathy\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: sodium bicarbonate 650 mg tablet\n- metoclopramide 1 MG/ML Oral Solution, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: metoclopramide 5 mg/5 mL oral solution\n- famotidine 20 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: famotidine 20 mg tablet\n- pregabalin 150 MG Oral Capsule, presumably until 2020-09-14, with intended 0 refill(s). Instructions: pregabalin 150 mg capsule   Take 1 capsule twice a day by oral route for 90 days.\n- diclofenac sodium 0.01 MG/MG Topical Gel, presumably until 2022-04-04, with intended 0 refill(s). Instructions: diclofenac 1 % topical gel   APPLY 2 GRAMS TO THE AFFECTED AREA(S) BY TOPICAL ROUTE 4 TIMES PER DAY\n- hydrochlorothiazide 25 MG / metoprolol tartrate 50 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-14, with intended 0 refill(s). Instructions: metoprolol tartrate 50 mg-hydrochlorothiazide 25 mg tablet\n- acyclovir 400 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: acyclovir 400 mg tablet\n- lorazepam 0.5 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: lorazepam 0.5 mg tablet\n- olanzapine 2.5 MG Oral Tablet, started on 2018-03-28, presumably until 2020-09-15, with intended 0 refill(s). Instructions: olanzapine 2.5 mg tablet\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: fluticasone propionate 50 mcg/actuation nasal spray,suspension\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, presumably until 2020-09-15, with intended 0 refill(s). Instructions: hydrocodone 10 mg-acetaminophen 325 mg tablet\n- 1.6 ML filgrastim 0.3 MG/ML Injection, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: filgrastim 480 mcg/1.6 mL injection solution\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, presumably until 2020-09-14, with intended 0 refill(s). Instructions: Shingrix (PF) 50 mcg/0.5 mL intramuscular suspension, kit\n- ezetimibe 10 MG Oral Tablet, presumably until 2020-09-15, with intended 0 refill(s). Instructions: ezetimibe 10 mg tablet   TAKE 1 TABLET BY MOUTH EVERY DAY\n- simvastatin 20 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: simvastatin 20 mg tablet   TAKE 1 TABLET BY MOUTH EVERY DAY\n- sodium chloride 9 MG/ML Injectable Solution, started on 2018-08-12, presumably until 2020-09-15, with intended 0 refill(s). Instructions: sodium chloride 0.9 % (flush) injection syringe\n- clotrimazole 10 MG Oral Lozenge, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: clotrimazole 10 mg troche\n- vitamin B12 1 MG/ML Injectable Solution, presumably until 2020-11-16, with intended 0 refill(s). Instructions: 1 mL\n- trimethobenzamide hydrochloride 300 MG Oral Capsule, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: trimethobenzamide 300 mg capsule\n- 0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection, presumably until 2020-09-14, with intended 0 refill(s). Instructions: Zostavax (PF) 19,400 unit/0.65 mL subcutaneous suspension\n- tobramycin 3 MG/ML Ophthalmic Solution, presumably until 2020-09-15, with intended 0 refill(s). Instructions: tobramycin 0.3 % eye drops\n- sennosides, USP 8.6 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: sennosides 8.6 mg tablet\n- valacyclovir 500 MG Oral Tablet, with intended 0 refill(s). Instructions: valacyclovir 500 mg tablet   Take 1 tablet twice a day by oral route for 90 days.\n- azithromycin 500 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: azithromycin 500 mg tablet\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, presumably until 2020-09-15, with intended 0 refill(s). Instructions: polyethylene glycol 3350 17 gram oral powder packet\n- prochlorperazine 10 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: prochlorperazine maleate 10 mg tablet\n- levofloxacin 500 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: levofloxacin 500 mg tablet\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, presumably until 2020-09-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- celecoxib 200 MG Oral Capsule, started on 2020-07-03, presumably until 2020-09-14, with intended 0 refill(s)\n- diphenhydramine hydrochloride 25 MG Oral Capsule, started on 2020-08-25, presumably until 2020-09-15, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY 12 HOURS FOR 90 DAYS (NC OTC )\n- valacyclovir 1000 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: valacyclovir 1 gram tablet\n- dexamethasone 1 MG/ML / tobramycin 3 MG/ML Ophthalmic Suspension, presumably until 2020-09-14, with intended 0 refill(s). Instructions: tobramycin 0.3 %-dexamethasone 0.1 % eye drops,suspension\n- lidocaine 50 MG/ML Topical Cream, presumably until 2020-09-15, with intended 0 refill(s). Instructions: 3 times a day\n- leucovorin 25 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: leucovorin calcium 25 mg tablet\n- ondansetron 8 MG Disintegrating Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: ondansetron 8 mg disintegrating tablet\n- azelastine hydrochloride 0.137 MG/ACTUAT / fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, presumably until 2020-09-15, with intended 0 refill(s). Instructions: azelastine-fluticasone 137 mcg-50 mcg/spray nasal spray\n- triamcinolone acetonide 1 MG/ML Topical Cream, presumably until 2020-09-15, with intended 0 refill(s). Instructions: triamcinolone acetonide 0.1 %-emollient comb.no.45 topical cream\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-11 00:00:00, ended at 2020-11-11 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pregabalin 200 MG Oral Capsule, started on 2020-11-11, presumably until 2020-11-16, with intended 2 refill(s). Instructions: 1 CAP 2 TIMES A DAY AND 3RD CAP DAILY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-14 11:01:00, ended at 2020-11-14 13:07:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 114 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-14 13:08:00, ended at 2020-11-14 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.35 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.73 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.8 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 366 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.03 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 100 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 39.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 48.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 105.2 (femtoliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 11:26:18, ended at 2020-11-16 11:57:53\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- pregabalin 200 MG Oral Capsule, through Oral route, started on 2020-11-16, presumably until 2020-11-16, with intended 2 refill(s). Instructions: take 1 Biles (200 mg total) by mouth 3 times a day\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2020-11-16, presumably until 2021-05-19, with intended 11 refill(s). Instructions: 20 mg orally daily for 3 days, then 40 mg daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-17 13:25:03, ended at 2020-11-17 13:56:15\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-25 00:00:00, ended at 2020-11-25 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-15 00:00:00, ended at 2020-12-15 00:00:00\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-19 12:35:17, ended at 2020-12-19 12:35:21\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-21 00:00:00, ended at 2020-12-21 00:00:00\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2020-12-21, presumably until 2020-12-21\n- triamcinolone acetonide 40 MG/ML Injectable Suspension, started on 2020-12-21, presumably until 2020-12-21\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit based on their EHR visit data:\n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-03 00:00:00, ended at 2017-09-03 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Mature T-cell AND/OR NK cell neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-10 00:00:00, ended at 2017-09-10 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-09-10, presumably until 2017-09-10, with intended 3 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-10 17:36:00, ended at 2017-09-17 16:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 91.4 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Anion gap in Serum or Plasma: <2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 39 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 4 (per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 241 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 413 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.25 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.3 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.8 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.24 (millimole per liter)\n- Prothrombin time (PT): 13.0 (second)\n- Thrombin time: 15.0 (second)\n- Urate [Mass/volume] in Serum or Plasma: <2.0 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.73 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 453 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Body height: 5' 4.764\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.67 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 1049 (microgram of fibrinogen equivalent unit per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: 1 (per microliter)\n\n### Procedure\n- Diagnostic bone marrow; biopsy(ies)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Extraction of Iliac Bone Marrow, Percutaneous Approach, Diagnostic\n- Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n- Ultrasound, scrotum and contents\n- Collection of venous blood by venipuncture\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n\n### Condition\n- Non-Hodgkin's lymphoma of extranodal site\n- Atrial fibrillation\n- Pleural effusion\n- Abnormal findings on diagnostic imaging of lung\n- Anemia in neoplastic disease\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Disorder of male genital organ\n- Abnormal cytological findings in CSF\n- Electrocardiogram abnormal\n- Anemia\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2017-09-15, presumably until 2017-09-15\n- sodium bicarbonate 650 MG Oral Tablet, started on 2017-09-16, presumably until 2017-09-19, with intended 0 refill(s). Instructions: Take 2 tabs the night before chemotherapy and the morning of chemotherapy.\n- metoclopramide 1 MG/ML Oral Solution, through Oral route, started on 2017-09-15, presumably until 2017-10-05, with intended 0 refill(s). Instructions: take 10 mL by mouth 3 times a day as needed (hiccups)\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-09-12, presumably until 2018-05-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2017-09-11, presumably until 2017-09-16\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-09-14, presumably until 2017-10-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (Mild to moderate nausea/vomiting.)\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-09-12, presumably until 2017-10-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-09-11, presumably until 2017-09-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-12, presumably until 2017-09-14\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-09-11, presumably until 2017-09-15\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-09-11, presumably until 2017-09-11\n- clotrimazole 10 MG Oral Lozenge, through Submucosal route, started on 2017-09-17, presumably until 2017-10-04, with intended 3 refill(s). Instructions: take 1 Lozenge by mouth 5 times a day\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-09-13, presumably until 2017-09-16\n- sodium chloride 9 MG/ML Injection, started on 2017-09-16, presumably until 2017-09-16\n- gadobenate, through Intravenous route, started on 2017-09-11, presumably until 2017-09-11\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-09-10, presumably until 2017-09-17\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-09-10, presumably until 2017-09-16\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-09-11, presumably until 2017-10-05, with intended 4 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2017-09-14, presumably until 2017-10-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (Mild to moderate nausea/vomiting)\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2017-09-15, presumably until 2017-09-15\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2018-02-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth every day Do not take 24 hours prior to chemotherapy\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-13, presumably until 2017-09-13\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-09-15, presumably until 2017-09-15\n- leucovorin 25 MG Oral Tablet, through Oral route, started on 2017-09-15, presumably until 2017-09-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-09-13, presumably until 2017-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-19 00:00:00, ended at 2017-09-19 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2017-09-19, presumably until 2018-02-07, with intended 2 refill(s). Instructions: take 4 Tabs by mouth every 4 hours Starting at 6 am on the day of hospital admission\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 12:00:00, ended at 2017-10-04 15:36:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 187 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.68 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 163 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 147 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 4.9 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 91 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.0 (second)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.98 (thousand per microliter)\n- Prothrombin time (PT): 15.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 418 (unit per liter)\n- Thrombin time: 21.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 475 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 821 (microgram of fibrinogen equivalent unit per milliliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 240 (unit per liter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-04 12:43:33, ended at 2017-10-04 14:51:18\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 4.8 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 334 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 15:37:00, ended at 2017-10-05 17:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 78 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 4.9 (gram per deciliter)\n- Thrombin time: 20.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.38 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Prothrombin time (PT): 16.0 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.7 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.9 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 439 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.71 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Body height: 5' 5.551\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 565 (microgram of fibrinogen equivalent unit per milliliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 86 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 136 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n\n### Procedure\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Transfusion, blood or blood components\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study\n- Ultrasound, abdominal, real time with image documentation; complete\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of bilirubin metabolism\n- Disease of liver\n- Fatigue\n- Headache\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Anemia of chronic disease\n- Atrial fibrillation\n- Nausea\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- gadobenate, through Intravenous route, started on 2017-10-04, presumably until 2017-10-04\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2017-10-05\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-10-04, presumably until 2018-04-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain (headache)\n- docusate sodium 50 MG / sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-10-05, presumably until 2018-04-20, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day as needed For constipation\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-07 07:40:00, ended at 2017-10-07 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.76 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 321 (unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.1 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 164 (unit per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Thrombin time: 18.6 (second)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 87.6 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 168 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 196 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 290 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.36 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.24 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 991 (microgram of fibrinogen equivalent unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 734 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.6 (percent)\n- Prothrombin time (PT): 13.1 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-11 12:12:00, ended at 2017-10-11 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 701 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- MCV [Entitic volume] by Automated count: 87.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 238 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.6 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.61 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 553 (microgram of fibrinogen equivalent unit per milliliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.8 (percent)\n- Prothrombin time (PT): 13.0 (second)\n- Thrombin time: 16.5 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 195 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.90 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 322 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-17 10:00:00, ended at 2017-10-17 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.51 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.3 (femtoliter)\n- Thrombin time: 14.9 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 311 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 489 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 42.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.2 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 383 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.02 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 20.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Prothrombin time (PT): 12.2 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 205 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 231 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 35.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 261 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-17 10:56:58, ended at 2017-10-17 13:31:27\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-18 00:00:00, ended at 2017-10-18 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-10-19 12:16:00, ended at 2017-10-23 15:30:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 1 (per microliter)\n- Thrombin time: 15.2 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 469 (microgram of fibrinogen equivalent unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.28 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 193 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 357 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 227 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: <1 (per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Prothrombin time (PT): 12.5 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 271 (unit per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 368 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.55 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach\n- Collection of blood specimen from a completely implantable venous access device\n- Hospital discharge day management; more than 30 minutes\n- Radiologic examination, chest; single view, frontal\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n\n### Condition\n- Pleural effusion\n- Disease of liver\n- Essential hypertension\n- Disorder of the central nervous system\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Anemia due to and following chemotherapy\n- Chronic atrial fibrillation\n- Headache\n- Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-10-23\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-10-21, presumably until 2018-04-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (Mild to moderate nausea/vomiting.)\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-11-29, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-10-21\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2017-10-21, presumably until 2017-10-21\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-10-19, presumably until 2017-10-22\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-10-19, presumably until 2017-10-23\n- baclofen 10 MG Oral Tablet, through Oral route, started on 2017-10-21, presumably until 2017-10-22\n- dexamethasone 2 MG Oral Tablet, through Oral route, started on 2017-10-21, presumably until 2017-11-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-10-19, presumably until 2017-10-23\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-10-24, presumably until 2017-11-15, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily For 10 days starting in the evening on 9/28\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-10-20, presumably until 2017-10-21\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-10-22, presumably until 2017-10-22\n- leucovorin 25 MG Oral Tablet, through Oral route, started on 2017-10-22, presumably until 2017-10-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-23 14:40:00, ended at 2017-10-23 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplastic disease of uncertain behavior\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-25 09:08:22, ended at 2017-10-25 10:28:31\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-01 00:00:00, ended at 2017-11-01 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-04 00:00:00, ended at 2017-11-04 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2017-11-04, presumably until 2017-11-14, with intended 1 refill(s). Instructions: take 30 mL by mouth 3 times a day as needed Titrate to 2 soft stools daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-04 07:46:00, ended at 2017-11-04 13:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 97 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-04 07:46:00, ended at 2017-11-04 13:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-04 13:01:06, ended at 2017-11-04 15:19:46\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.12\" (inch (US))\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm\n- Extranodal NK/T-cell lymphoma, nasal type\n- Primary diagnosis: Malignant tumor of lymphoid hemopoietic and related tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-04 14:00:00, ended at 2017-11-04 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Ammonia [Mass/volume] in Plasma: 52 (micromole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.30 (million per microliter)\n- Thrombin time: 16.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 612 (microgram of fibrinogen equivalent unit per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 45 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.4 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 355 (unit per liter)\n- Prothrombin time (PT): 13.2 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 2 (milli-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.41 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 41.2 (second)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 1.03 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 223 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.58 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 178 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant tumor of lymphoid hemopoietic and related tissue\n- Extranodal NK/T-cell lymphoma, nasal type\n- Blood coagulation disorder\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Disease of liver\n- Primary malignant neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Eruption\n- Localized infection of skin AND/OR subcutaneous tissue\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-07 10:19:00, ended at 2017-11-07 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16 (percent)\n- Prothrombin time (PT): 13.8 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13 (percent)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.19 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 185 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.56 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 307 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 43.8 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 259 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 703 (microgram of fibrinogen equivalent unit per milliliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Neutrophils/100 leukocytes in Blood by Manual count: 57 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Ammonia [Mass/volume] in Plasma: 67 (micromole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 1.92 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 241 (unit per liter)\n- Thrombin time: 16.9 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Localized infection of skin AND/OR subcutaneous tissue\n- Eruption\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-07 11:12:56, ended at 2017-11-07 13:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-07 15:24:05, ended at 2017-11-07 16:06:44\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of uncertain behavior of skin\n- Eruption\n- Localized infection of skin AND/OR subcutaneous tissue\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-11-07, presumably until 2017-11-12, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day for 5 days Please do not dispense generic form.\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2017-11-07, presumably until 2018-04-20, with intended 3 refill(s). Instructions: Apply topically as directed twice daily to affected area(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-11 00:00:00, ended at 2017-11-11 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-14 11:29:00, ended at 2017-11-14 17:58:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.56 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 358 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.20 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Neutrophils/100 leukocytes in Blood by Manual count: 59 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 381 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.36 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.1 (gram per deciliter)\n- Ammonia [Mass/volume] in Plasma: 55 (micromole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 537 (microgram of fibrinogen equivalent unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.3 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 282 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 201 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Prothrombin time (PT): 12.9 (second)\n- Thrombin time: 13.3 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n\n### Procedure\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-14 13:07:17, ended at 2017-11-14 14:23:18\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2018-04-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-11-14 17:59:00, ended at 2017-11-18 14:53:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.59 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Body height: 5' 4.961\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: 13 (per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 308 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- MCV [Entitic volume] by Automated count: 94.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.94 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 2 (per microliter)\n- Platelets [#/volume] in Blood by Automated count: 429 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Hyperlipidemia\n- Disease of liver\n- Herpesvirus infection\n- Prediabetes\n- Localized edema\n- Chronic atrial fibrillation\n- Essential hypertension\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Disorder of the central nervous system\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-14\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-18\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-17\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-18\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-11-16, presumably until 2017-11-17\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-11-18, presumably until 2017-11-18\n- dexamethasone 1 MG Oral Tablet, started on 2017-11-15, presumably until 2017-11-16, with intended 0 refill(s). Instructions: Take 2 mg in the morning for 2 days then 1 mg in the morning for 2 days then 0.5 mg in the morning for 2 days then stop.\n- dexamethasone 2 MG Oral Tablet, started on 2017-11-15, presumably until 2017-12-16, with intended 0 refill(s). Instructions: Take 2 mg in morning and evening for 2 days ( 10/24 and 10/25)  then 2 mg in the morning for 2 days ( 10/26 and 10/27)  then 1 mg ( 1/2 tablet)  in the morning for 2 days ( 10/28 and 10/29).\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-11-18\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-11-15, presumably until 2017-11-16\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-11-15, presumably until 2017-12-16, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-11-17, presumably until 2017-11-17\n- mupirocin 0.02 MG/MG Topical Ointment, through Topical route, started on 2017-11-16, presumably until 2017-11-18\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-11-17, presumably until 2017-11-18\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-11-16, presumably until 2017-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-25 00:00:00, ended at 2017-11-25 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-25 07:28:00, ended at 2017-11-25 23:59:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 8.4 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 212 (unit per liter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.58 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 822 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.60 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.2 (percent)\n- Prothrombin time (PT): 12.5 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Thrombin time: 13.8 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.1 (second)\n- Ammonia [Mass/volume] in Plasma: 31 (micromole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 107 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 213 (unit per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 523 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-29 00:00:00, ended at 2017-11-29 00:00:00\nThe patient in this visit was 65 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea\n\n### Drug\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-11-29, presumably until 2017-12-18, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-12 10:50:00, ended at 2017-12-12 15:04:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.89 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 197 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.25 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 791 (microgram of fibrinogen equivalent unit per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.8 (percent)\n- Thrombin time: 17.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.85 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Ammonia [Mass/volume] in Plasma: 66 (micromole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 208 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 311 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.1 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 188 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.56 (milligram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Extranodal NK/T-cell lymphoma, nasal type\n- Atrial fibrillation\n- Localized edema\n- Disease of liver\n- Herpesvirus infection\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 12:14:34, ended at 2017-12-12 14:25:45\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-12-12 15:05:00, ended at 2017-12-16 17:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- MCV [Entitic volume] by Automated count: 97.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.38 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Thrombin time: 19.9 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Prothrombin time (PT): 14.5 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.6 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.70 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 950 (microgram of fibrinogen equivalent unit per milliliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 184 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- Leukocytes [#/volume] in Cerebral spinal fluid: 4 (per microliter)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.69 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Erythrocytes [#/volume] in Cerebral spinal fluid: <1 (per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.3 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.7 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n\n### Procedure\n- Inspection of Lower Back, External Approach\n- Collection of venous blood by venipuncture\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture\n\n### Condition\n- Hypervolemia\n- Disorder of the central nervous system\n- Enteropathy-associated T-cell lymphoma\n- Acquired absence of organ\n- Atrial fibrillation\n- Disorder of digestive system\n- Disseminated intravascular coagulation\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hiccoughs\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-15\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-12-12, presumably until 2017-12-13\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-14\n- baclofen 10 MG Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-16\n- dexamethasone 2 MG Oral Tablet, started on 2017-12-16, presumably until 2018-02-07, with intended 0 refill(s). Instructions: Take 2 mg in morning and evening for 2 days (11/21 and 11/22)  then 2 mg in the morning for 2 days (11/24-11/25)  then 1 mg ( 1/2 tablet)  in the morning for 2 days (11/26-11/27).\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-12-15, presumably until 2017-12-16\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-12-16, presumably until 2018-02-07, with intended 0 refill(s). Instructions: Inject daily for 10 days starting 24-48h after completion of chemotherapy\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-12-12, presumably until 2017-12-16\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2017-12-12, presumably until 2017-12-15\n- mesna 400 MG Oral Tablet, through Oral route, started on 2017-12-15, presumably until 2017-12-16\n- leucovorin 25 MG Oral Tablet, through Oral route, started on 2017-12-14, presumably until 2017-12-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-18 00:00:00, ended at 2017-12-18 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-12-18, presumably until 2017-12-29, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-23 00:00:00, ended at 2017-12-23 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2017-12-23, presumably until 2018-12-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-26 00:00:00, ended at 2017-12-26 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 07:38:00, ended at 2017-12-26 09:49:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Disorder of bone\n- Disorder of lower leg\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 07:38:00, ended at 2017-12-26 09:49:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 84 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 09:50:00, ended at 2017-12-26 10:50:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.8 (percent)\n- MCV [Entitic volume] by Automated count: 100.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 226 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 65 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 199 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.48 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.2 (gram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 8 (milli-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 22.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.4 (second)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 411 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 49 (thousand per microliter)\n- Prothrombin time (PT): 12.9 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.60 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.23 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 553 (microgram of fibrinogen equivalent unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.46 (thousand per microliter)\n- Thrombin time: 15.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Ammonia [Mass/volume] in Plasma: 51 (micromole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 10:51:00, ended at 2017-12-26 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- gadobenate, through Intravenous route, started on 2017-12-26, presumably until 2017-12-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-29 00:00:00, ended at 2017-12-29 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n\n### Drug\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2017-12-30, presumably until 2018-05-12, with intended 0 refill(s). Instructions: TAKE 2 TABS BY MOUTH EVERY BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-02 12:42:56, ended at 2018-01-02 15:30:22\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Disease of liver\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hyperlipidemia\n- Localized edema\n- Herpesvirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-01-06 00:00:00, ended at 2018-01-06 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-14 14:00:00, ended at 2018-01-14 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Nutritional anemia\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n- Disorder of hematopoietic structure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 08:52:00, ended at 2018-01-15 12:24:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 68.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 12:25:00, ended at 2018-01-15 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.1 (gram per deciliter)\n- Ammonia [Mass/volume] in Plasma: 55 (micromole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.6 (picogram)\n- Thrombin time: 16.2 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 126 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 191 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 499 (microgram of fibrinogen equivalent unit per milliliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 313 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 234 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.6 (percent)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Prothrombin time (PT): 12.5 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.53 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 23.2 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Collection of venous blood by venipuncture\n- Diagnostic bone marrow; biopsy(ies)\n\n### Condition\n- Nutritional anemia\n- Neutropenia\n- Extranodal NK/T-cell lymphoma, nasal type\n- Thrombocytopenic disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-30 00:00:00, ended at 2018-01-30 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-Hodgkin's lymphoma (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-02-04 00:00:00, ended at 2018-02-04 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2018-02-04, presumably until 2018-02-04\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-02-04, presumably until 2018-02-04\n- midazolam 1 MG/ML Injectable Solution, started on 2018-02-04, presumably until 2018-02-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-04 06:38:00, ended at 2018-02-04 09:58:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Prediabetes\n- Secondary malignant neoplasm of bone\n- Essential hypertension\n- Paroxysmal atrial fibrillation\n- Hyperlipidemia\n- Mature T-cell AND/OR NK cell neoplasm\n- Secondary malignant neoplasm of small intestine\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-02-04, presumably until 2018-02-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-04 11:52:00, ended at 2018-02-04 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Herpesvirus infection\n- Localized edema\n- Disease of liver\n- Extranodal NK/T-cell lymphoma, nasal type\n- Non-Hodgkin's lymphoma (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-02-05 17:53:00, ended at 2018-02-07 16:22:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.21 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.81 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.4 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Base excess in Arterial blood by calculation: -9.6 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.95 (million per microliter)\n- Lactate [Moles/volume] in Blood: 8.3 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.5 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 360 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 182 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 215 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 35.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.58 (micro-international unit per milliliter)\n- Urate [Mass/volume] in Serum or Plasma: 7.3 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 5' 5.354\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 114 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- MCV [Entitic volume] by Automated count: 109.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 95 (thousand per microliter)\n- Prothrombin time (PT): 14.3 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 16.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.67 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Thrombin time: 15.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 3308 (microgram of fibrinogen equivalent unit per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n\n### Procedure\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; 1 view\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Atrial fibrillation\n- Heart failure\n- Hyperlipidemia\n- Prediabetes\n- Electrocardiogram abnormal\n- Abdominal distension, gaseous\n- Chronic pulmonary edema\n- Low blood pressure\n- Disorder of digestive system\n- Essential hypertension\n- Paroxysmal atrial fibrillation\n- Acquired absence of organ\n- Drug-induced hypotension\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hypovolemic shock\n- Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- 1000 ML potassium chloride 0.04 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-02-05, presumably until 2018-02-05\n- hydrocortisone 100 MG Injection, started on 2018-02-06, presumably until 2018-02-06\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2018-02-06, presumably until 2018-02-06\n- etoposide 20 MG/ML Injectable Solution, through Intravenous route, started on 2018-02-05, presumably until 2018-02-05\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2018-02-06, presumably until 2018-02-07\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2018-02-05, presumably until 2018-02-06\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-02-05, presumably until 2018-02-07\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-02-05, presumably until 2018-02-06\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-02-05, presumably until 2018-02-05\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-02-07, presumably until 2018-02-07\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-02-07, presumably until 2018-02-07\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2018-02-06, presumably until 2018-02-07\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2018-02-06, presumably until 2018-02-06\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2018-02-06, presumably until 2018-02-07\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-02-06, presumably until 2018-02-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-02-05, presumably until 2018-02-05\n- 100 ML amiodarone hydrochloride 1.5 MG/ML Injection, through Intravenous route, started on 2018-02-06, presumably until 2018-02-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 08:09:00, ended at 2018-02-06 08:42:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; single view\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 08:43:00, ended at 2018-02-06 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, abdomen; 1 view\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-08 11:00:00, ended at 2018-02-08 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 22.5 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 105.6 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 194 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 98.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- MCH [Entitic mass] by Automated count: 34.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 22.05 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 107 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 74 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.80 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Herpesvirus infection\n- Disease of liver\n- Paroxysmal atrial fibrillation\n- Localized edema\n\n### Drug\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-02-08, presumably until 2018-02-08\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-02-08, presumably until 2018-02-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-11 11:30:00, ended at 2018-02-11 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-12 11:45:00, ended at 2018-02-12 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-13 11:45:00, ended at 2018-02-13 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-14 11:30:00, ended at 2018-02-14 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-15 11:15:00, ended at 2018-02-15 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-16 11:30:00, ended at 2018-02-16 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-17 12:00:00, ended at 2018-02-17 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-18 12:00:00, ended at 2018-02-18 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-19 10:28:00, ended at 2018-02-19 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-20 11:58:00, ended at 2018-02-20 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-21 12:38:00, ended at 2018-02-21 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-03 00:00:00, ended at 2018-03-03 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-03 13:33:00, ended at 2018-03-03 13:43:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Pleural effusion\n- Atelectasis\n- Chronic pulmonary edema\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-03 13:44:00, ended at 2018-03-03 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 293 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 35.2 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 2.09 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.99 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 123 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.4 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-03, presumably until 2018-03-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-03 14:37:03, ended at 2018-03-03 15:56:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2018-02-25, presumably until 2018-03-31, with intended 0 refill(s). Instructions: take 200 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-12 16:54:00, ended at 2018-03-12 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2018-03-12, presumably until 2018-03-12\n- 1.2 ML plerixafor 20 MG/ML Injection, through Subcutaneous route, started on 2018-03-12, presumably until 2018-03-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-13 07:30:00, ended at 2018-03-13 17:58:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.0 (percent)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.22 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 16 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 14.74 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 156 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.92 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Body height: 5' 5.354\" (inch (US))\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 32 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Leukocytes [#/volume] in Blood by Automated count: 92100 (per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 92.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 7.37 (thousand per microliter)\n\n### Procedure\n- Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage\n- Collection of venous blood by venipuncture\n- Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- sodium citrate, through Intravenous route, started on 2018-03-13, presumably until 2018-03-13\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-03-13, presumably until 2018-03-13\n- citric acid, through Intravenous route, started on 2018-03-13, presumably until 2018-03-13\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-13, presumably until 2018-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-13 17:59:00, ended at 2018-03-13 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- 1.2 ML plerixafor 20 MG/ML Injection, through Subcutaneous route, started on 2018-03-13, presumably until 2018-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-14 07:30:00, ended at 2018-03-14 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.3 (percent)\n- Body height: 5' 5.354\" (inch (US))\n- MCV [Entitic volume] by Automated count: 95.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 80 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.58 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 92.3 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage\n- Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- sodium citrate, through Intravenous route, started on 2018-03-14, presumably until 2018-03-14\n- citric acid, through Intravenous route, started on 2018-03-14, presumably until 2018-03-14\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-14, presumably until 2018-03-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-21 00:00:00, ended at 2018-03-21 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-27, presumably until 2018-03-27, with intended 2 refill(s). Instructions: 3 mL by Intravenous route every day Flush each lumen of double lumen catheter daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-27 00:00:00, ended at 2018-03-27 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-31 13:50:00, ended at 2018-03-31 14:14:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 1483 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.33 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 39.5 (second)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Thrombin time: 37.3 (second)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 64 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.0 (percent)\n- Prothrombin time (PT): 12.7 (second)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 341 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Ammonia [Mass/volume] in Plasma: 13 (micromole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 197 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.9 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pancytopenia due to antineoplastic chemotherapy\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-31, presumably until 2018-03-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-31 14:15:00, ended at 2018-03-31 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-01 17:10:00, ended at 2018-04-20 12:14:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Lactate [Moles/volume] in Blood: 1.8 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.91 (thousand per microliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.5 (microgram per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 161 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.01 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.24 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 9 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 99.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Manual count: 0.39 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 68 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.31 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.050 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, chest; single view\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Radiologic examination, abdomen; 2 views\n- Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach\n- Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Hematopoietic progenitor cell (HPC); autologous transplantation\n- Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Sepsis\n- Tachycardia\n- Disorder of esophagus\n- Essential hypertension\n- Electrocardiogram abnormal\n- Fever\n- Low blood pressure\n- Neutropenia\n- Oral ulcerative mucositis due to antineoplastic therapy\n- Paroxysmal atrial fibrillation\n- Herpesvirus infection\n- Transplant present\n- Benign prostatic hyperplasia\n- Disorder of intestine\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Long QT syndrome\n- Pancytopenia due to antineoplastic chemotherapy\n- Abdominal distension, gaseous\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n- Hyperlipidemia\n- Hypervolemia\n- Inflammatory disorder of digestive tract\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2018-04-07, presumably until 2018-04-07\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2018-04-13, presumably until 2018-04-19\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-20\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2018-04-03, presumably until 2018-04-20, with intended 3 refill(s). Instructions: take 2 Caps by mouth 4 times a day as needed\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-04-16, presumably until 2018-04-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2018-04-07, presumably until 2018-04-07\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-19\n- melphalan 50 MG Injection, through Intravenous route, started on 2018-04-06, presumably until 2018-04-06\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2019-04-19, with intended 11 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-03\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-12, presumably until 2018-04-13\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2018-04-03\n- diphenhydramine hydrochloride 2.5 MG/ML Oral Solution, through Oral route, started on 2018-04-08, presumably until 2018-04-12\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2018-04-10, presumably until 2018-04-11\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 6 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-07\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-18\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2018-04-04, presumably until 2018-04-06\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-04-09, presumably until 2018-04-12\n- 1 ML dexamethasone phosphate 10 MG/ML Injection, started on 2018-04-18, presumably until 2018-04-18\n- cholecalciferol 0.025 MG Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2019-04-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 10 ML furosemide 10 MG/ML Injection, started on 2018-04-07, presumably until 2018-04-19\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2018-04-20\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-04-20, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-17\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-18\n- atropine sulfate 0.025 MG / diphenoxylate hydrochloride 2.5 MG Oral Tablet, through Oral route, started on 2018-04-14, presumably until 2018-04-19\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-02, presumably until 2018-04-20\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-01, presumably until 2018-04-20\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2018-04-19, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day for 6 days\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-20\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2018-04-01, presumably until 2018-04-15\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2018-04-02, presumably until 2018-04-02\n- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2018-04-08, presumably until 2018-04-12\n- 250 ML heparin sodium, porcine 100 UNT/ML Injection, through Intravenous route, started on 2018-04-01, presumably until 2018-04-18\n- loratadine 10 MG Oral Tablet, through Oral route, started on 2018-04-15, presumably until 2018-04-20\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2018-04-15, presumably until 2018-04-16\n- opium tincture 100 MG/ML Oral Solution, through Oral route, started on 2018-04-15, presumably until 2018-04-15\n- 200 ML fluconazole 2 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-15\n- glucose 50 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-14\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2018-04-19, presumably until 2018-04-19\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2018-04-08, presumably until 2018-04-13\n- ondansetron 8 MG Disintegrating Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-04 00:00:00, ended at 2018-04-04 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, started on 2018-04-08, presumably until 2018-04-08, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-22 16:33:00, ended at 2018-04-22 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.33 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.0 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.31 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.64 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.26 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 68 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 5 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Transfusion, blood or blood components\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-04-22, presumably until 2018-04-22\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-22, presumably until 2018-04-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-23 13:59:00, ended at 2018-04-23 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.16 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.61 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 19 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-23, presumably until 2018-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-24 15:40:00, ended at 2018-04-24 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 0.34 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 35 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.15 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.62 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 9 (thousand per microliter)\n\n### Procedure\n- Transfusion, blood or blood components\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Pancytopenia due to antineoplastic chemotherapy\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-27 15:06:00, ended at 2018-04-27 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.42 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 10 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 27.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.57 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.05 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 54.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.6 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Transfusion, blood or blood components\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2018-04-27, presumably until 2018-04-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-30 14:59:00, ended at 2018-04-30 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 25.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.65 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 23 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 33.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.92 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.4 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Paroxysmal atrial fibrillation\n\n### Drug\n- dibasic potassium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- potassium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- tribasic potassium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- tribasic sodium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-30, presumably until 2018-04-30\n- sodium phosphate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- sodium phosphate, monobasic, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- sodium phosphate, dibasic, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2018-04-30, presumably until 2018-05-30, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day for 30 days\n- dibasic sodium phosphate heptahydrate, through Oral route, started on 2018-04-30, presumably until 2018-04-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-05 14:04:00, ended at 2018-05-05 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 40 (nanogram per milliliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 24 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Prothrombin time (PT): 12.5 (second)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.58 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.75 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.73 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.3 (second)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 40 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.02 (thousand per microliter)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 1055 (microgram of fibrinogen equivalent unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 25.6 (percent)\n- Ammonia [Mass/volume] in Plasma: 19 (micromole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 13 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Thrombin time: 28.4 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Monocytes [#/volume] in Blood by Manual count: 0.48 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 441 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-05, presumably until 2018-05-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-05 14:28:59, ended at 2018-05-05 16:48:36\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.16\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-12 10:40:00, ended at 2018-05-12 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 102 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.76 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 39.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.41 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 25 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 21.0 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-12, presumably until 2018-05-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-12 11:32:31, ended at 2018-05-12 12:50:33\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- fluconazole 200 MG Oral Tablet, through Oral route, started on 2018-05-12, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-20 00:00:00, ended at 2018-05-20 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-21, presumably until 2018-07-18, with intended 6 refill(s). Instructions: 3 mL by Intravenous route every day Flush each lumen of double lumen catheter daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-26 10:20:00, ended at 2018-05-26 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 20.7 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 40 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.73 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 49.1 (percent)\n- MCV [Entitic volume] by Automated count: 95.3 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.16 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-05-26, presumably until 2018-05-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-25 00:00:00, ended at 2018-06-25 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-06-26, presumably until 2018-06-26, with intended 6 refill(s). Instructions: 3 mL by Intravenous route every day Flush each lumen of double lumen catheter daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-26 00:00:00, ended at 2018-06-26 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-06-26, presumably until 2018-07-07, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-07 08:44:00, ended at 2018-07-07 12:05:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 114 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-07 08:44:00, ended at 2018-07-07 12:05:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-07 12:06:00, ended at 2018-07-07 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 44 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 28.4 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 356 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 416 (microgram of fibrinogen equivalent unit per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n- MCV [Entitic volume] by Automated count: 106.3 (femtoliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Prothrombin time (PT): 12.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.96 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Thrombin time: 17.0 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-07 13:23:41, ended at 2018-07-07 14:11:17\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-07-07, presumably until 2018-08-11, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-18 12:18:00, ended at 2018-07-18 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 42 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.90 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 107.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.6 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.5 (percent)\n- MCH [Entitic mass] by Automated count: 36.8 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-18 12:54:41, ended at 2018-07-18 14:32:13\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, presumably until 2019-02-02, with intended 0 refill(s). Instructions: take by mouth\n- pregabalin 50 MG Oral Capsule, through Oral route, presumably until 2018-08-04, with intended 0 refill(s). Instructions: take by mouth daily Advised to titrate up to 100mg po daily starting 6/23   08/04/2018 150mg daily\n- celecoxib 200 MG Oral Capsule, through Oral route, presumably until 2020-09-14, with intended 0 refill(s). Instructions: take 400 mg by mouth every day\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2018-06-02, presumably until 2018-06-02, with intended 5 refill(s). Instructions: Take 1 capsule (0.4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-04 14:19:00, ended at 2018-08-04 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 107.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.46 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 36.5 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 46 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.08 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Polyneuropathy due to drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-11 00:00:00, ended at 2018-08-11 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-08-12, presumably until 2018-09-15, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-11 00:00:00, ended at 2018-08-11 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2018-08-11, presumably until 2019-02-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-15 00:00:00, ended at 2018-09-15 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-09-15, presumably until 2018-10-21, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-19 00:00:00, ended at 2018-09-19 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- famotidine 20 MG Oral Tablet, started on 2018-09-19, presumably until 2019-02-02, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-20 14:00:00, ended at 2018-10-20 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.81 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.18 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n- MCHC [Mass/volume] by Automated count: 35.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 43 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.5 (picogram)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.18 (million per microliter)\n- MCV [Entitic volume] by Automated count: 104.4 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-20 15:01:49, ended at 2018-10-20 16:09:07\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-21 00:00:00, ended at 2018-10-21 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-10-21, presumably until 2018-12-09, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-24 13:36:03, ended at 2018-10-24 14:56:06\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-04 10:26:00, ended at 2018-11-04 23:59:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.33 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 104.0 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.19 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 35.5 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 56.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.51 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 56 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Diagnostic bone marrow; biopsy(ies) and aspiration(s)\n\n### Condition\n- Thrombocytopenic disorder\n- Extranodal NK/T-cell lymphoma, nasal type\n- Nutritional anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-09 00:00:00, ended at 2018-12-09 00:00:00\nThe patient in this visit was 66 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2018-12-15, presumably until 2020-01-14, with intended 3 refill(s). Instructions: 10 ml prefilled syringes. Flush each lumen with 10 ml daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-07 11:05:00, ended at 2019-01-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-07 11:05:00, ended at 2019-01-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 117 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2019-01-15, presumably until 2019-04-16, with intended 6 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, started on 2019-01-15, presumably until 2019-01-15, with intended 3 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-02 13:58:00, ended at 2019-02-02 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.79 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.7 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 104.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.19 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 57 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 48.9 (percent)\n- MCH [Entitic mass] by Automated count: 34.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 38.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-26 00:00:00, ended at 2019-03-26 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-30 10:25:00, ended at 2019-03-30 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 113 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-16 08:00:00, ended at 2019-04-16 09:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 175 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.37 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 51 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Polyneuropathy due to drug\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-16 10:00:00, ended at 2019-04-16 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-04-16, presumably until 2019-04-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-08 14:46:59, ended at 2019-07-08 15:26:05\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.118\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-Hodgkin's lymphoma (clinical)\n- Extranodal NK/T-cell lymphoma, nasal type\n- Polyneuropathy due to drug\n- Anemia\n\n### Drug\n- valacyclovir 500 MG Oral Tablet, through Oral route, started on 2019-07-08, presumably until 2020-07-07, with intended 11 refill(s). Instructions: take 1 Tab (500 mg total) by mouth 2 times a day Take 1000 mg (2 pills) three time a day for 10 days, then decrease to 500 mg (1 pill) twice a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-20 00:00:00, ended at 2019-07-20 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-23 11:46:00, ended at 2019-07-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 107.4 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 38.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.77 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 240 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 4.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 76 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 51.5 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.02 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-23 13:28:37, ended at 2019-07-23 14:43:38\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-25 00:00:00, ended at 2019-09-25 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, started on 2019-09-30, presumably until 2020-03-13, with intended 4 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH TWICE A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-20 11:06:00, ended at 2019-10-20 11:06:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 120 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Localized enlarged lymph nodes\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 10:45:00, ended at 2019-10-28 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.61 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 48.0 (percent)\n- MCV [Entitic volume] by Automated count: 109.8 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.48 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.08 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 36.8 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 70 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 40.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-28 12:30:16, ended at 2019-10-28 14:04:48\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Polyneuropathy due to drug\n- Primary diagnosis: Non-Hodgkin's lymphoma (clinical)\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-14 00:00:00, ended at 2020-01-14 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-14 13:16:00, ended at 2020-01-14 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.78 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 37.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 168 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 52.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.56 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 106.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 82 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.84 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 35.1 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-13 00:00:00, ended at 2020-03-13 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2020-03-15, presumably until 2020-05-15, with intended 1 refill(s). Instructions: take 1 Abdul (150 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-21 11:21:24, ended at 2020-04-21 11:32:43\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-herpetic neuritis\n- Primary diagnosis: Cough\n- Polyneuropathy due to drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-21 15:01:22, ended at 2020-04-21 15:15:22\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n- Post-herpetic neuritis\n- Primary diagnosis: Polyneuropathy due to drug\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-27 00:00:00, ended at 2020-04-27 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2020-04-27, presumably until 2020-04-27, with intended 1 refill(s). Instructions: take 1 Zarghami (150 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-15 00:00:00, ended at 2020-05-15 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Polyneuropathy due to drug\n\n### Drug\n- pregabalin 150 MG Oral Capsule, through Oral route, started on 2020-05-16, presumably until 2020-07-15, with intended 1 refill(s). Instructions: take 1 Thampy (150 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-23 09:25:00, ended at 2020-05-23 11:22:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 125 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-23 09:25:00, ended at 2020-05-23 11:22:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-23 11:23:00, ended at 2020-05-23 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 94 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 45.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.03 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 178 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 35.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-30 13:59:51, ended at 2020-05-30 14:11:28\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycosis fungoides (clinical)\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-14 13:26:56, ended at 2020-07-14 14:07:23\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-15 08:54:12, ended at 2020-07-15 09:34:54\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- pregabalin 200 MG Oral Capsule, started on 2020-07-15, presumably until 2020-11-11, with intended 2 refill(s). Instructions: 1 cap 2 times a day and 3rd cap daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-19 00:00:00, ended at 2020-07-19 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ketamine, started on 2020-07-19, presumably until 2020-09-15, with intended 2 refill(s). Instructions: Ketamine 15% Diclofenac 3% Gabapentin 3% Cyclobenzaprine 3% Lidocaine 5%. Apply quarter size in total (2 grams) 2 times a day to painful areas as needed for pain as a part of a desensitization regimen\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-08 00:00:00, ended at 2020-09-08 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-13 11:20:45, ended at 2020-09-13 11:20:54\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-09-15 00:00:00, ended at 2020-09-15 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2020-09-15, presumably until 2020-09-15\n- methylprednisolone acetate 40 MG/ML Injectable Suspension, started on 2020-09-15, presumably until 2020-09-15\n- midazolam 1 MG/ML Injectable Solution, started on 2020-09-15, presumably until 2020-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-15 09:41:00, ended at 2020-09-15 12:18:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level (List separately in addition to code for primary procedure)\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level\n\n### Condition\n- Intercostal neuropathy\n- Atrial fibrillation\n- Essential hypertension\n- Mononeuropathy\n- Post-herpetic neuritis\n- Prediabetes\n- Polyneuropathy\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: sodium bicarbonate 650 mg tablet\n- metoclopramide 1 MG/ML Oral Solution, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: metoclopramide 5 mg/5 mL oral solution\n- famotidine 20 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: famotidine 20 mg tablet\n- pregabalin 150 MG Oral Capsule, presumably until 2020-09-14, with intended 0 refill(s). Instructions: pregabalin 150 mg capsule   Take 1 capsule twice a day by oral route for 90 days.\n- diclofenac sodium 0.01 MG/MG Topical Gel, presumably until 2022-04-04, with intended 0 refill(s). Instructions: diclofenac 1 % topical gel   APPLY 2 GRAMS TO THE AFFECTED AREA(S) BY TOPICAL ROUTE 4 TIMES PER DAY\n- hydrochlorothiazide 25 MG / metoprolol tartrate 50 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-14, with intended 0 refill(s). Instructions: metoprolol tartrate 50 mg-hydrochlorothiazide 25 mg tablet\n- acyclovir 400 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: acyclovir 400 mg tablet\n- lorazepam 0.5 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: lorazepam 0.5 mg tablet\n- olanzapine 2.5 MG Oral Tablet, started on 2018-03-28, presumably until 2020-09-15, with intended 0 refill(s). Instructions: olanzapine 2.5 mg tablet\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: fluticasone propionate 50 mcg/actuation nasal spray,suspension\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, presumably until 2020-09-15, with intended 0 refill(s). Instructions: hydrocodone 10 mg-acetaminophen 325 mg tablet\n- 1.6 ML filgrastim 0.3 MG/ML Injection, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: filgrastim 480 mcg/1.6 mL injection solution\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, presumably until 2020-09-14, with intended 0 refill(s). Instructions: Shingrix (PF) 50 mcg/0.5 mL intramuscular suspension, kit\n- ezetimibe 10 MG Oral Tablet, presumably until 2020-09-15, with intended 0 refill(s). Instructions: ezetimibe 10 mg tablet   TAKE 1 TABLET BY MOUTH EVERY DAY\n- simvastatin 20 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: simvastatin 20 mg tablet   TAKE 1 TABLET BY MOUTH EVERY DAY\n- sodium chloride 9 MG/ML Injectable Solution, started on 2018-08-12, presumably until 2020-09-15, with intended 0 refill(s). Instructions: sodium chloride 0.9 % (flush) injection syringe\n- clotrimazole 10 MG Oral Lozenge, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: clotrimazole 10 mg troche\n- vitamin B12 1 MG/ML Injectable Solution, presumably until 2020-11-16, with intended 0 refill(s). Instructions: 1 mL\n- trimethobenzamide hydrochloride 300 MG Oral Capsule, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: trimethobenzamide 300 mg capsule\n- 0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection, presumably until 2020-09-14, with intended 0 refill(s). Instructions: Zostavax (PF) 19,400 unit/0.65 mL subcutaneous suspension\n- tobramycin 3 MG/ML Ophthalmic Solution, presumably until 2020-09-15, with intended 0 refill(s). Instructions: tobramycin 0.3 % eye drops\n- sennosides, USP 8.6 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: sennosides 8.6 mg tablet\n- valacyclovir 500 MG Oral Tablet, with intended 0 refill(s). Instructions: valacyclovir 500 mg tablet   Take 1 tablet twice a day by oral route for 90 days.\n- azithromycin 500 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: azithromycin 500 mg tablet\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, presumably until 2020-09-15, with intended 0 refill(s). Instructions: polyethylene glycol 3350 17 gram oral powder packet\n- prochlorperazine 10 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: prochlorperazine maleate 10 mg tablet\n- levofloxacin 500 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: levofloxacin 500 mg tablet\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, presumably until 2020-09-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- celecoxib 200 MG Oral Capsule, started on 2020-07-03, presumably until 2020-09-14, with intended 0 refill(s)\n- diphenhydramine hydrochloride 25 MG Oral Capsule, started on 2020-08-25, presumably until 2020-09-15, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY 12 HOURS FOR 90 DAYS (NC OTC )\n- valacyclovir 1000 MG Oral Tablet, presumably until 2020-09-14, with intended 0 refill(s). Instructions: valacyclovir 1 gram tablet\n- dexamethasone 1 MG/ML / tobramycin 3 MG/ML Ophthalmic Suspension, presumably until 2020-09-14, with intended 0 refill(s). Instructions: tobramycin 0.3 %-dexamethasone 0.1 % eye drops,suspension\n- lidocaine 50 MG/ML Topical Cream, presumably until 2020-09-15, with intended 0 refill(s). Instructions: 3 times a day\n- leucovorin 25 MG Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: leucovorin calcium 25 mg tablet\n- ondansetron 8 MG Disintegrating Oral Tablet, started on 2017-09-27, presumably until 2020-09-15, with intended 0 refill(s). Instructions: ondansetron 8 mg disintegrating tablet\n- azelastine hydrochloride 0.137 MG/ACTUAT / fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, presumably until 2020-09-15, with intended 0 refill(s). Instructions: azelastine-fluticasone 137 mcg-50 mcg/spray nasal spray\n- triamcinolone acetonide 1 MG/ML Topical Cream, presumably until 2020-09-15, with intended 0 refill(s). Instructions: triamcinolone acetonide 0.1 %-emollient comb.no.45 topical cream\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-11 00:00:00, ended at 2020-11-11 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pregabalin 200 MG Oral Capsule, started on 2020-11-11, presumably until 2020-11-16, with intended 2 refill(s). Instructions: 1 CAP 2 TIMES A DAY AND 3RD CAP DAILY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-14 11:01:00, ended at 2020-11-14 13:07:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 114 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-14 13:08:00, ended at 2020-11-14 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.35 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.73 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.8 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 366 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.03 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 100 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 39.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 48.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- MCV [Entitic volume] by Automated count: 105.2 (femtoliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 11:26:18, ended at 2020-11-16 11:57:53\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- pregabalin 200 MG Oral Capsule, through Oral route, started on 2020-11-16, presumably until 2020-11-16, with intended 2 refill(s). Instructions: take 1 Biles (200 mg total) by mouth 3 times a day\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2020-11-16, presumably until 2021-05-19, with intended 11 refill(s). Instructions: 20 mg orally daily for 3 days, then 40 mg daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-17 13:25:03, ended at 2020-11-17 13:56:15\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Extranodal NK/T-cell lymphoma, nasal type\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-25 00:00:00, ended at 2020-11-25 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-15 00:00:00, ended at 2020-12-15 00:00:00\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-19 12:35:17, ended at 2020-12-19 12:35:21\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-herpetic neuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-21 00:00:00, ended at 2020-12-21 00:00:00\nThe patient in this visit was 69 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2020-12-21, presumably until 2020-12-21\n- triamcinolone acetonide 40 MG/ML Injectable Suspension, started on 2020-12-21, presumably until 2020-12-21\n\n\n\nAbove are the patient's EHR visit records (including the current inpatient visit) in chronological order.\n\n\n\nYou are a medical AI assistant analyzing patient data to predict if the patient will be readmitted to the hospital within 30 days after discharge from their current inpatient visit given the patient's EHR visit records and current visit information provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will be readmitted to the hospital within 30 days after the current inpatient visit end datetime (2020-12-21 00:00:00)\n- Do not provide any explanation, reasoning, or additional text\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "c5567af816f9b8ea7b51642feae1158f9251d15df3c39bf15e3366433ec1fd66", "prompt_hash": "280315b3903609b145d40b80ddc8c7f943eb3268ee3e388109a88f32c84cb0cd", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
